0DUFK  
6LUL *OLPVWDG //3
$DURQ 6LUL (VT
 3DUN $YH
WK )ORRU
1HZ <RUN 1< 
,Q UHSO\ UHIHU WR ILOH 
'HDU 0U 6LUL
7KLV LV LQ UHSO\ WR \RXU )UHHGRP RI ,QIRUPDWLRQ $FW )2,$ UHTXHVW GDWHG $XJXVW   LQ
ZKLFK \RX UHTXHVWHG Â³D FRS\ RI WKH UHSRUW IRU HDFK FOLQLFDO WULDO UHOLHG XSRQ E\ WKH )'$ ZKHQ
DSSURYLQJ 005 ,, LQ Â´ <RXU UHTXHVW ZDV UHFHLYHG LQ WKH &HQWHU IRU %LRORJLFV (YDOXDWLRQ
DQG 5HVHDUFK &%(5 RQ $XJXVW  
(QFORVHG DUH WKH GRFXPHQWV UHVSRQVLYH WR \RXU UHTXHVW
:H KDYH ZLWKKHOG SRUWLRQV RI SDJHV XQGHU ([HPSWLRQ E    86& Â†  E   7KDW
H[HPSWLRQ SHUPLWV WKH ZLWKKROGLQJ RI WUDGH VHFUHWV DQG FRPPHUFLDO RU ILQDQFLDO LQIRUPDWLRQ WKDW
ZDV REWDLQHG IURP D SHUVRQ RXWVLGH WKH JRYHUQPHQW DQG WKDW LV SULYLOHJHG RU FRQILGHQWLDO 7KH
ZLWKKROGLQJ RI VXFK LQIRUPDWLRQ LV SHUPLWWHG LI GLVFORVXUH LV OLNHO\ WR FDXVH VXEVWDQWLDO
FRPSHWLWLYH KDUP WR WKH SHUVRQ ZKR VXEPLWWHG WKH LQIRUPDWLRQ
,Q DGGLWLRQ ZH KDYH ZLWKKHOG SRUWLRQV RI SDJHV XQGHU ([HPSWLRQ E    86& Â†  E  
7KDW H[HPSWLRQ SURWHFWV LQIRUPDWLRQ IURP GLVFORVXUH ZKHQ LWV UHOHDVH ZRXOG FDXVH D FOHDUO\
XQZDUUDQWHG LQYDVLRQ RI SHUVRQDO SULYDF\ )2,$ ([HPSWLRQ  LV DYDLODEOH WR SURWHFW
LQIRUPDWLRQ LQ SHUVRQQHO RU PHGLFDO ILOHV DQG VLPLODU ILOHV 7KLV UHTXLUHV D EDODQFLQJ RI WKH
SXEOLFÂ¶V ULJKW WR GLVFORVXUH DJDLQVW WKH LQGLYLGXDOÂ¶V ULJKW WR SULYDF\
<RX KDYH WKH ULJKW WR DSSHDO WKLV GHWHUPLQDWLRQ %\ ILOLQJ DQ DSSHDO \RX SUHVHUYH \RXU ULJKWV
XQGHU )2,$ DQG JLYH WKH DJHQF\ D FKDQFH WR UHYLHZ DQG UHFRQVLGHU \RXU UHTXHVW DQG WKH
DJHQF\Â¶V GHFLVLRQ
<RXU DSSHDO PXVW EH PDLOHG ZLWKLQ  GD\V IURP WKH GDWH RI WKLV UHVSRQVH WR
0V &DWKHULQH 7HWL
'HSXW\ $JHQF\ &KLHI )2,$ 2IILFHU
86 'HSDUWPHQW RI +HDOWK DQG +XPDQ 6HUYLFHV
2IILFH RI WKH $VVLVWDQW 6HFUHWDU\ IRU 3XEOLF $IIDLUV
5RRP +
 ,QGHSHQGHQFH $YHQXH 6:
:DVKLQJWRQ '& 
3OHDVH FOHDUO\ PDUN ERWK WKH HQYHORSH DQG \RXU OHWWHU Â³)'$ )UHHGRP RI ,QIRUPDWLRQ $FW
$SSHDOÂ´

,I \RX ZRXOG OLNH WR GLVFXVV RXU UHVSRQVH EHIRUH ILOLQJ DQ DSSHDO WR DWWHPSW WR UHVROYH \RXU
GLVSXWH ZLWKRXW JRLQJ WKURXJK WKH DSSHDOV SURFHVV SOHDVH FRQWDFW
%HWK %URFNQHU5\DQ %UDQFK &KLHI
&HQWHU IRU %LRORJLFV (YDOXDWLRQ DQG 5HVHDUFK &%(5
$FFHVV /LWLJDWLRQ DQG )UHHGRP RI ,QIRUPDWLRQ %UDQFK
86 )RRG DQG 'UXJ $GPLQLVWUDWLRQ
 1HZ +DPSVKLUH $YHQXH
%XLOGLQJ  5RRP 
6LOYHU 6SULQJ 0' 
(PDLOEHWKEURFNQHUU\DQ#IGDKKVJRY
0DLQ /LQH 
)2, /LQH 
<RX DOVR KDYH WKH ULJKW WR FRQWDFW
)'$ )2,$ 3XEOLF /LDLVRQ
2IILFH RI WKH ([HFXWLYH 6HFUHWDULDW
 )LVKHUV /DQH
5RRP
5RFNYLOOH 0' 
(PDLO )'$)2,$#IGDKKVJRY
,I \RX DUH XQDEOH WR UHVROYH \RXU )2,$ GLVSXWH WKURXJK RXU )2,$ 3XEOLF /LDLVRQ WKH 2IILFH RI
*RYHUQPHQW ,QIRUPDWLRQ 6HUYLFHV 2*,6  WKH )HGHUDO )2,$ 2PEXGVPDQÂ¶V RIILFH RIIHUV
PHGLDWLRQ VHUYLFHV WR KHOS UHVROYH GLVSXWHV EHWZHHQ )2,$ UHTXHVWHUV DQG )HGHUDO DJHQFLHV
7KH FRQWDFW LQIRUPDWLRQ IRU 2*,6 LV
2IILFH RI *RYHUQPHQW ,QIRUPDWLRQ 6HUYLFHV
1DWLRQDO $UFKLYHV DQG 5HFRUGV $GPLQLVWUDWLRQ
 $GHOSKL 5RDGÂ±2*,6
&ROOHJH 3DUN 0' 
7HOHSKRQH 
7ROO)UHH 
(PDLO RJLV#QDUDJRY
)D[ 
,I \RX KDYH DQ\ TXHVWLRQV RU LI ZH FDQ EH RI IXUWKHU DVVLVWDQFH SOHDVH OHW XV NQRZ E\
UHIHUHQFLQJ WKH DERYH ILOH QXPEHU <RX FDQ FRQWDFW -RKQ +\GHU E\ SKRQH DW  RU
E\ HPDLO DW -RKQ+\GHU#IGDKKVJRY

6LQFHUHO\

Beth A. Brockner
Ryan -S

Digitally signed by Beth A. Brockner Ryan -S
DN: c=US, o=U.S. Government, ou=HHS,
ou=FDA, ou=People,
0.9.2342.19200300.100.1.1=1300052489,
cn=Beth A. Brockner Ryan -S
Date: 2019.03.27 10:26:33 -04'00'

%HWK %URFNQHU 5\DQ
&KLHI $FFHVV /LWLJDWLRQ DQG )UHHGRP RI ,QIRUPDWLRQ %UDQFK

86 )RRG 'UXJ $GPLQLVWUDWLRQ
 1HZ +DPSVKLUH $YHQXH
6LOYHU 6SULQJ 0' 
Z ZZIGDJRY

\

DEPARTME:: NT OF HEAL TH, EDUCATION,
PUBLIC
FOOD

AND

AND WELFARE

HEAL TH SC:RVICE
DRUG

flETHESDA.

ADMINISTRATION

MARYLAND

20014

SEP1 5 ig7B
Our Reference

Nos. 76-316,

77-303 and 77-304

Alan Gray, Ph.D.
Merck Sharp & Dohme
Division of Merck and Co., Inc.
West Point, Pennsylvania
19486
Dear Dr. Gray:
This is to inform you that the amendments to your product license
applications
to include the use of the RA27/3 strain
rubella
virus
gro~m in human diploid
cells have been accepted for manufacture
of
the following products:
Rubella Virus Vaccine, Live
Measles, Mumps and Rubella Virus Vaccine,
Measles and Rubella Virus Vaccine, Live

Liv~

Â·-Â·
We agree that the results
of stability
testing
of vacctnes
prepared
with the buffered
sorbitol-gelatin
diluent
support your request Â· for a
longer dating period.
Accordingly,
your license
applications
for the
three products are also amended to include the use of the diluent
and
0
a dating period of two years at 2Â°-a c from date of issue.
Please

continue

to submit

stability

data

as they become available.

Sincerely

yours,

- ~Q~

t

Harry M. Meyer, Jr.,
Director
Bureau of Biologics

M.D.

I

I,

F

Summary No. 1
of
Investigative
Studies
of

Clinical

Combined Live Measle s Virus Vaccine (Moraten Line-ATTENUVAX)
Jeryl Lynn Mumps Virus Vaccine (MUMPSVAX)
RA 27/3 Rubella Virus Vaccine
for Purpose of Support for
a License to Manufacture and Sell.

?

I

,.

A,

...
;

-:

M. R. Hilleman,

Ph.D .

Prepared:
April 27, 1978
Merck Institute
for Therapeutic
West Point, Pennsylvania

Research

;

Clinical
Investigative
Measles-Mumps-Rubella
1.

Studies of Combined Live
(RA 27/3) Virus Vaccine

Background
On January 11, 1978, we submitted "Summary No. 2 of Clinical
Investigative
Studies of RA 27/3 Strain Live Rubella Virus Vaccine for Support for
a License to Manufacture and Sell" to the Bureau.
That summary showed
the RA 27 /3 rubella
virus vaccine to be safe and highly effective
in
inducing rubella
hemagglutination-inhibition
(HI) antibodies
in persons
of various ages.
In extension
of clinical
tests with RA 27/3 strain
rubella
virus vaccine,
studies
were conducted to evaluate
its immunizing capability
when combined with live attenuated
Moraten line measles virus vaccine (ATTENUVAX)
and Jeryl Lynn mumps virus vaccine (MUMPSVAX). The present submission
relates
to clinical
investigative
studies
of combined live measle smumps-rubella
(RA 27/3) virus vaccine.
All clinical

2.

studies

were conducted

Lot Numbers of Vaccine

under

BB-UID-1016.

and Cell

Biology

Tested

Experimental
lot prepared by Virus
and Dahme Research Laboratories:

Research,

Nerck Sharp

by Merck Sharp and Dahme Biologics

Manufacturing:

621/C-D763
Consistency

lots

prepared

60664/C-E810
60665/C-E811
60666/C-E812
3,

Serologic

Testing

Serologic
determinations
were made in the laboratories
Biology Research, Merck Institute,
and in the Control
the Merck Sharp and Dahme Division of Merck & Co.

of Virus and Cell
Laboratories
of

The hemagglutination-inhibition
(HI) test was used to determine both
measles antibody response and rubella
antibody response.
Starting
dilutions
in these two tests were 1:5 and 1:8, respectively
. The serum
neutralization
test was used to measure mumps antibody response with
a starting
dilution
of 1:2.

Page 2

4.

Clinical

Studies

The clinical
studies were conducted under the overall
responsibility
of Dr. Maurice R. Hilleman, Vice President,
Virus and Cell Biology
Research, Merck Institute
for Therapeutic
Research,
West Point,
Pennsylvania.
The clinical

tests

were carried

out by five

groups

of workers:

a.

Dr . Robert E. Weibel, Director,
Division of Preventive
Medicine, Joseph Stokes, Jr. Research Institute,
Children's
Hospital
of Philadelphia,
Philadelphia,
Pennsylvania

b.

Dr. Victor M. Villarejos,
Director,
Louisiana
University
- International
Center for Medical
and Training,
San Jose, Costa Rica

c.

Dr. Stephen J. Lennan, Director,
Pediatric
Infectious
Disease Unit, Department of Pediatrics,
The University
of Nebraska Medical Center, Omaha, Nebraska

d.

Dr. Anne A. Gershon, Associate
Pediatrics,
New York University
New York

e.

Dr. Robert
Department
University

Clinical

studies

fall

State
Research

Professor,
Department of
Medical Center, New York,

W. McCollum and Dr. Dorothy M. Borstmann,
of Epidemiology and Public Health, Yale
School of Medicine,
New Haven, Connecticut
into

two main categories:
Reference.

a.

Comparison of M-M-R (RA 27/3) and
M-M-R (HPV-77) vaccines
in children

3, 4, 5, 6

b.

Serologic
and clinical
measles - mumps- rubella

1, 2, 7, 8

responses
to
(RA 27/3) vaccine

The clinical
studies
were carried
out by the physicians
at the locations
in the individual
study summaries to follow.
The populations
employed
were defined with respect
to age, location
and other pertinent
parameters
necessary
to permit analysis
by statistical
sampling procedures.
Subjects
in the sampled groups were bled initially
later.
The sera were tested
to define the initial
subsequent
antibody response.

and again
serostatus

6 to 8 weeks
and the

Page 3
Clinical
surveillance
was by two procedures.
In studies
by Drs. Weibel,
Lerman, Gershon, and McCollurn, the observations
were recorded dail y
by the mother.
The parent was asked to contact
the physician
should
any significant
or bothersome reaction
occur.
In the studies
by
Dr. Villarejos,
observations
were made on a routine basis by medical
or paramedical
personnel;
physicians
were notified
of an y significant
illness
which occurred subsequent to vaccination.
The data presented
in the following
sections
are self explanatory.
detailed
background r eco rds are on file in Virus and Cell Biology
Research, Merck Institute
for Therapeutic
Research, West Point,
Pennsylvania.
These records are available
for review at any tim e.
5.

Clinical

The

Study Summaries

Reference 1 - Study 442 - Dr. Victor Villarejos
Details
of the study plan are given in the clinical
test protocol.
The
study was designed to measure antibody and clinical
responses
to the
RA 27/3 rub ella component when given alone or combined with mumps and/or
measles vaccine.
Findings presented
in the summary tables indicate
excellent
antibody response to all components among children
receivinf
live measles-mumps-rubella
(RA 27/3) virus vaccine.
No untoward clinical
reactions
were noted following vaccination.
Reference 2 - Study 443 - Dr. Robert Weibel
Details
of the study plan are presented
in the clinical
protocol.
The
purpose of the study was to measure antibody and clinical
responses
to
the RA 27/3 rubella
component when given alone or combined with measles
and mumps virus components.
Findings are presented
in the summary tables.
Each of the three viruses produced excellent
antibody responses
when
administered
in combined form.
Both vaccines were well tolerated.
Reference 3 - Study 459 - Dr. Stephen Lerman
Study 459 is being conducted in children
to compare responses
to HPV-77
and RA 27/3 rubella
vaccines when given alone or combined with measles
and mumps vaccines.
Details
of the study plan are given in the clinical
test protocol.
Preliminary
findings
presented
in the summary tables
show excellent
antibody response to measles, mumps, and rubella
components
and lack of suppression
when the three viruses
are combined.
Reaction rates
were as expected.
Reference 4 - Study 467 - Dr. Robert Weibel
Study 467 was conducted among children
to compare responses
to combined
measles-mumps-rubella
vaccines
containing
either
the HPV-77 or RA 27/3
rubella
component.
Details
of the study plan are given in the clinical
test protocol,
and study results
are presented
in the summary tables.
Antibody responses
to both vaccines were excellent,
indicating
no
reduced affect
on any component in combined form.
Reaction rates were
as expected for both vaccines.

Page 4
Reference 5 - Study 473 - Dr. Robert Mccollum
Study 473 is being conducted among children
to compare responses
to
combined measles-mumps - rubella
virus vaccines
containing
either
th e
HPV- 77 or RA 27/3 rubella
component.
Details
of the study plan are
given in the clinical
test protocol . No results
are available
at
this time .
Reference 6 - Study 484 - Dr. Anne Gershon
Study 484 is bein g conducted among children
to compare responses
to
combined measles-mumps - rubella virus vaccines
containing
either
the
HPV- 77 or RA 27 /3 rubella
component.
Preliminary
findings
are prese n ted
in the report from Dr. Gershon.
The study continues
in progress.
Reference 7 - Study 511 - Dr . Victor Villarejos
Study 511 was conducted to measure antibody and clinical
responses
to
three consecutive
lots of combined measles-mumps-rubella
vaccine
containing
the RA 27/3 rubella
component.
Details
of the study plan
are given in the clinical
test protocol,
and study results
are presented
in the summary tables.
Responses to the rubella
component were excellent
Seroconversion
rates
for measles and mumps were somewhat lower than
expected,
and the decreased
seroconversion
rates were attributed
to
some overheating
of the vaccine during transport
in the field.
Reaction
rates were comparable among the lots.
Reference 8 - Study 513 - Dr. Robert Weibel
Study 513 is being conducted
to measure antibody and clinical
responses
to three consecutive
lots of combined measles-mumps-ruhella
vaccine
containing
the RA 27/3 rubella
component.
Study details
are given in
the clinical
protocol,
and preliminary
findings
are given in the summary
tables.
To date, all three lots of vaccine have produced good antibody
responses
and have been well tolerated .
6,

Overall

Summary

The total numbers of vaccinations
given are as follows:

for which supporting

No. Seroconverting/No.

Triple

Lot ti

No.
Vacc.

621
60664
60665
60666

480
144
104
106

143/150
50/55
37 /39
34/35

(95)
(91)
(95)
(97)

145/150
52/55
37 /39
34/35

(97)
(95)
(95)

Total

834

264/279

(95)

268/279

Measles

Mumps

data

have been

Negatives

(%)

RA 27 / 3 Rubella
(100)
(100)

(97)

150/150
55/55
38/39
34/35

(96)

277/279

(99)

The data show that combined live measles-mumps-rubella
vaccine
the RA 27/3 rubel l a virus component is safe and effective.

(97)

(97)

containing

.

Summary of Clinica l Tests of Combined Live
Measles - Mumps- Rubella (RA 27/3) Virus Vaccine

Age

Study
No.

Investi~ato

442

Lot
No.

Range

Villarejos

621

443

Wei bel

459

Mean

Antibody Responses among Triple Seron e~at i ves
Measles
Mumps
RA 27 /3 Rubella
No. Conv./
No. Conv./
No. Conv ./
No. Seroneg.
No. Seroneg.
No. Seroneg.
( %)
GM
T
( %)
GMT
(%)
GMT Re.

(Yrs.)

No.
Va cc.

lOm- 7y

3 .7

199

23/23

(100)

99

22/23

(96)

7

23/23

(100)

621

149

Um- 8y

l

1.7

105

65/69

(94)

56

66/69

(96)

8

69/69

(100)

Lennan

133

2

60664

14m- 4y

1. 6

41

13/14

(93)

62

13/14

(93)

17

46 7

14/14

Weibel

(100)

269

621

3

llm-

1. 9

137

55/58

(95)

71

57/58

(98)

7

58/58

473

McCol lum

(100)

621

146

4

484

Gershon

621

13m-15y

60664

8m- lly

3.3

50

9/11

(82)

20

10/11

(91)

5

11/11

(100)

226

60665

llm - 7y

3.3

50

4/5

(80)

25

4/5

(80)

11

5/5

(100)

169

60666

llm -ll y

4.2

50

2/2

(100 )

28

2/2

(100)

8

2/2

(100)

256

60664

12m- 7y

1. 7

53

28/30

(93)

70

29/30

(97)

19

30/30

(100)

256

60665

12m- 4y

1.5

54

33/34

(97)

70

33/34

(97)

23

33/34

(97)

200

60666

llm - 4y

1.4

56

32/33

(97)

66

32/33

(97)

26

32/33

(97)

251

834

264/279

(95)

63

268/279

(96)

11

277 /279

(99)

178

511

513

Villar

ejos

Weibel

r

Totals

7y

5
39

6
7

~

4/24/78

Reference

Program:

Study !/442

Vaccine:

Combined Live Measles-Numps - Rubella
Lot No. 621/C-D763
Combined Live Xeasles-Rubella
Lot No. 622/C-D764
Ltve Attenuated
Rubella
Lot No. 579/C-D418

Responsible

Clin i cal

(RA 27/3)

(RA 27/3)

(RA 27/3)

Virus

Virus

Virus

No. 1

Vaccine

Vaccine

Vaccine

Investigator:

Victor M. Villarejos,
M.D.
Director
Louisiana
State University
International
Center for Medical
Research and Training
Apartado 10.155
San Jose, Costa Rica
Study Location:

Rivas,

Nicaragua

Date Study Initiated;

January

Date Study Completed:

April

19, 1976
28, 1976

Study Procedure:
A total

of 589 children,
10 months to 7 years .of age,
from the open population
were included in the study .
Each participant
received
a 0.5 ml subcutaneous
dose
of one of the three vaccines.
Blood samples were obtained
prior to and six weeks after vaccination
.

Clinical

Protocol

- Study #442

Combin~d Live iÂ·!easles-Nurnps-Rubella
(RA 27 /3) Virus Vaccine
Combined Live Heasles-Rubella
(RA 27/3) Virus Vaccine
Li ve Attenuated
Rubella (RA 27/3) Virus Vaccine

Purpose:

To determine antibod y and clinical
response s to combined live
measles-mu mps-rubella
(RA 27/3) virus vaccine,
to combined live
measles-rubella
(RA 27/3) virus
vaccine,
and to live attenuated
rubella
(RA 27/3) virus vaccine.

Vaccines :

a)

Combined liv e measles-mumps-rubella
Lot No. 621
Vaccine

dose is 0.5 ml given

(RA 27/3)

virus

vaccine

subcutaneously.

The vaccine is supplied
in two-dose vials.
Each vial
vaccine should be rehydrated
with 1.2 ml of sterile,
pyrogen-free
distilled
water.
b)

Combined liv e measles-rubella
Lot No. 622
Vaccine

dose

(RA 27/3)

virus

vaccin e

is 0.5 ml givery subcutaneously.

The vaccine is supplied
in two-dose vials.
Each vial
vaccine should be rehydrated
with 1.2 ml of sterile,
pyrogen-free
distilled
water.
c)

Live attenuated
Lot No. 579
Vaccine

o::

rubella

(RA 27/3)

dose is 0 . 5 ml given

virus

of

vaccine

subcutaneously.

The vaccine is supplied
in single
of vaccine should be reconstituted
pyrogen-free
distilled
water.

dose vials.
Each vial
with 0.7 ~l of st eri le,

CAUTION; The combined vaccines
contain egg protein
and should not
be given to persons with known sensitivity
to egg, chicken,
or
chicken feathers.
All three vaccines
contain neomycin and should
not be given to persons with sensitivity
to neomycin.
Persons
with leukemia or other immunologic disorders
and persons receiving
immunosupprcssive
drugs should not be vaccinated.
Also, the
vaccines should not be given to persons with any febrile
respiratory
illness
or other active febrile
in fection.
keep dried

vaccines

stored

Keep dried

vaccines

at 4Â°C in tran sport .

Keep reconstituted
after rehydration.

vaccines

at -20Â°C until

on i ce.

used .

Discard

unused

vaccine

4 hours

Clinical
Protocol
Study 11442

Pr ocedure:

-2-

-

The study

population

will

consist

of children

1 to 6 years

of a ge.

Children receiving
a given vaccine will have a negative
histor y for
vaccination
with and illness
caused by viruses
represented
in t hat
vaccine.
Children will be assign e d to receive one of the three
vaccines as follows:
Vaccine

Vaccine

measles-mu mps-rubella
measles-rubella
rubella
Informed
guardian

Lot

No. Children

621
622

150-200
150-200
150-200

579

consent will be obtained
prior to his participation

from each child's
in the study.

Each child t-rill be bled (10-15 ml) immediately
and 6 weeks following
vaccination.
Vaccine

dose is 0.5 ml given

Days 0-42
Week 6

to vac.:: .~nation

for 42 day$ following
complaints
will be recorded

Time
Day 0

or

subcutaneously.

Each child will be followed clinically
vaccination . All local and systemic
on the case report form.
Schedule:

prior

parent

Action
Bleed 10-15 ml.
Vaccinate
0.5 ml, subcutaneously.
Clinical
systemic

follow-up
reacttons.

Bleed 10-lS

for

local

and

ml.

Laboratory:

Remove sera from clot aseptically
and store frozen at -20Â°C until
shipped.
It is imperative
that sera are sterile
to avoid interference with the serologic
assay.

Serology:

Circulating
levels
of antibody
to each vaccine component will be
determined
for samples drawn before and after vaccination.
Measles
and rubella
antibody levels will be determined by hemagglutinationinhibition
test.
Mumps antibody levels will be determined by serum
neutralization
test.

Clinical
Forms:

Attached.

Clinical
Pr ctocol
Study /1442

- 3-

-

Any serious

Adverse
Reactions:

or alarming
reaction,
including
death due to any cause
during the investigation
, whether related
or not related
to the
test material,
must be report ed im~ediately
to Merck 6 Co., I nc . ,
through Dr. ~faurice R. Hille man, telephone
(215) 699-5311, Ext .
5532 , or i n his ab s ence, Dr. Al l en F . Woodhour, telephone
(215)
699-5311, Ext. 5588.

Unused
Vaccine:

All un used vaccine should be returned
immediately
to Merck Sharp
Dohme Research Laboratories,
West Poin t, Pa. 19486.

Shipping
of Sera &
Records:

a)

Send sera

b)

Send sera and records
to Dr. Maurice R. Hilleman,
Virus and Cell
Biology Research,
Merck Sharp & Dohme Research Laboratories,
West Point,
Pa. 19486.

c)

Alert Dr. Hilleman by cable as soon as possible
number, air bill,
and date of arrival.

frozen

within

insulated

containers

6

which are supplied.

as to f.:.._:."sht

.'

,
VACUNACION

\ __

,
SARAMPl()N

CONTRA

Estudio No. ___

PAPERAS

\., ) __

.,.

RUBEOLA

_

NO. DEL C/\SQ_,,,âœ“.:_'__
(4-91

(1-J)

No n1hre Complclo

CT
2
o uoa

er

Olrecclon

2

I

F

.l

CT G

Fe cha de nac l mlen to (.36-41 I

(35)

del Nlii'o

comp leta de PJdres

o Guardl.m:

,

d i.ii

~

mes

a nu

(141)Â· (5,1-59)

IJ

INOIOUE

S â€¢ Saramp ion
P â€¢ Paper.is
R â€¢ Rubcola
S C70J
P (71J
RC721

IIA:

S I INOIVIOUO

1
2

1
2

1
2

Fer.ha de ex-pt11",";

I
I

I
I

3
IOura11Lâ€¢Â·Ul t imas Cuat ro Se m;in.isl

3

3

Fccha de expuesto

I

I

1. 1 <â€¢nidn Enlcr111f'dad
2. Siil n V;,c1111Jdo

:J. C.st.ioJn E ~1:11â€¢â€¢
<10

Fccha de eXPll "\ln

PERIODO DE VACUNACION O CONTROL

D

('181

0 Co ntrol

V:v.:ur>Jr!O

I

Neâ€¢. rf c Lo tn

----

(4%1 1

--- ---- ....,-

SA RA MP ION

HI
Pre

I

-- - -- senOLOG(A
P/\l'ERAS

- Nr?ut- -Neut
--Â·-PrA
-- - Port
--- --- Pre-- - ---Post---- Â·- - - ---

Post

- ---

I

Feclia de vacunacion

Fccha de rr i111er s,,n!lrado (011trs de v,1c1111adol

152fil l
I

I

(SZ-571

l'ccha de se,_1111ic
lo s.,ngrado (dcsrmcs de vacunado )

I

I

1siÂµ;JI

------ HI RUOEOLA
-- -- Neut
---Â·
- Pre
Pre
Post
Port
.

]]

l ndioue si el niâ„¢>con1rajo Sarampion ctir,ico:

1 = Si

2 ~No

lnd iuuc si cl ni110contrajo Paperas clinica :

1 = Si

2 = No

lnclique si el nitoo contrajo

1 C Si

2 = No

Rullco la cli~ica:

Fcr:ha de comic11zo:

I

I

Ouirn hi10 d ia11nostico?

Otra~ qu cj,1\ u ollscrvJciunes

clinic.i s:

Dc11Jues de co mplr tnd:is, dcvm:/v ;, fo rm,ual:

M. n. HILLEMAN,
MEn C K SHAnP
Pl957-0075(SP/\NISH

Firm;, de/ Med ico:

( Rer en9;, copia rosa pa ra sus ;,rchivo s}

Fecha:

PhD. DSc

& OOHME R ESEAnCH
II, ENGLISH!

L/\BS . , WES T POINT, PENNSYLVANIA

l!M0G

Nom brc de/ M,; tic o (en /err., de mol<lc):

(â€¢3957Â·01751

__

_

I

(4<">471

,
,
,
VAGU,~ACION CONTRA SA ?.AMPION PAPE i .,-,.S RUBEOLA
NO. O E CASQ ___

HOJA CLI N ICA

FECHA DE VACUNAC ION-~-"---d ia

\.

I

I
I

I

I

~

I

.,

FECHA

I

.;

t;;

I

..

~

I
I

'

24
0

I
I

1

I

'I

2 1

I

I
I

3 1
4 1

''

'
I

I

11
12 1

'I

r

I

I

I
I

.0

"'
:
~
I
.,"' c:i .~

I

c,i

i

08

i 15 . 14

'I

.::.

"O
r:

01

i 06 f

C:

0

C:

..J

0

C:

I

'

.~ I
'

~
c, Cl
I
a: 12

I
I

i

I

II

I

l

i

I

!

I

'
I

I

'I

I

I

I

I

I

I

19 I

I

i

'I
'
I

I
I

22 !

I

2s I
26 i

I
I
I

I

'I

I

I

I

27

I
I

I

I

I
I
I
I

I

I
I

I

I

32

I

33 I

I

I
I
I

I

I

I

34 !

I

I

,Â·I

35

I

I

I
I

I

I
I

I

42 1

I

I
i

I
I

I

I

I
!
'I
I

I

I

.

I

I

I

,
i
I

!

I
I

I

I

I

I

I

I
I

I

I

I

:
:

I

I

I
j

I

I

41 I

I

I

'

40j

i

I

i
I
I

I

I

I

I

I

I

I
I

I

'I

39 I

I

I

I

'I

I

'

I

'

I

23 1
24

38 I

I
i

I

I

I

!
31 I

I

I

I

I

36

I

!
I
I
I
I

I

I

'I

I

I

I

I

I

31I

I

I

I

I

OTR A S REA CC IO;\I ES

I ~ ! <{ I
52 i 11 I 32 i

I

I

I

29 1
30 i

â€¢I
I I

I

I

!

I
i

I

21 I

I

I

'
''

I

I

I

''

. .

~

'

i
!

i

I

I

' 20 i

l

I

I

I

I

est a secc ,o n

~

I

I

I
I
I

'

I

I

I

..

.

o a 75(BJD

OM

I

'
'I

I

I

I

I
I

Al rerm inar el esrud io, d evue l va copi a blanca y cop ia am ar ill a de esra form a,
adjuntas a la forma "A" al : (R etenga cop i a colo r de r osa par a sus arch i vos)
M.R. Hi ll eman , PhD, OSc
MERCK SHARP & DOH M E RESEARCH LABORATORIES
WEST POINT, PENNS Y LVA N IA, 19 48 6, U.S.A .
P3957

--ario

me s

â€¢ Es pe c i f iQ u e t ipo en

i .,

I

'I

j

I

I

I 50 , 51
I

I

I

'.':

I~

)(

w

I

I

18

28

-

_

,~
]... iI E II Â·."'s
.o

;;

I

I

i
I

.E

E
;!

I

I

I

m

."

I

!

I
!

I

I

u C:

I

I

I

...

.2 ;

I

j 03

u

I

!

I

I
I

I 11i

C

E
~

C: : --;:

u I ..:

(.!)

;

i

C.

i l > 'I 0 8 I :S
!
~C,

I

I
I

16 I

\.._

i

I
I

15 i

I

j

I

'
'I

14

0

"'

I

I

I

:E

.-~ .

-;:;--::- I

I

10

..)

:

'I

ai

,-'

I
I

I

7 /

9

"O

E

I g i ~.,

16 i 25

I

5 1
6 1

)(

" ! <{

~

I
Â·E
I
.;

.. .. "

-~

;;

I

::l.

E
I-

I

_ __

.

N O M S AE:

D IA

_

Fi rma d e/ med i co :

Nombre de / m edic o (en te tra de mo ldeJ:

Fec h a:

----Table 1
Serological Findings Aaong Children Who Received Combined Live
1;1eaales-~umps-Rubella (RA 27/3) Virus Vaccine, Lot ~o. 621/C-0763 (Study ,442)
Initially
SerQneRative to:
Measles - Rubella
Humps-Rubella
Conversions/Total
r.onversions/Total
Measles Rubella
Mui:ms Rubella

Measles Only
Conversions/
Total

Intâ€¢â€¢ â€¢ 1 1 u Serooositlve
Measles

MumpsOnly
Conversions/
Total

Rubella Only
Conversions/
Total

2/2

3/3

1

Age

10 Months

1

0

11 Months

2

2

1/1

1/1

1/1

1/1

1/1

1 Tear

29

21

7/7

7/7

7/7

4/5

5/5

3/3

3/3

2 Tears

18

15

3/l

3/3

3/3

1/1

1/1

4/4

.,4

2/3

3/3

3/3

1

3 Years

41

33

6/6

6/6

6/S

1/1

1/1

3/3

3/3

6/6

6/6

14/14

3

4 Tears

39

34

2/2

2/2

2/2

5/5

5/5

7/8

8/8

1/1

15/15

3

5 Tears

32

25

3/3

2/3

3/l

2/2

2/2

2/3

3/3

2/2

13/13

2

6 tears

36

28

1/1

1/1

1/t

8/8

8/8

2/2

2/2

1/1

15/15

1

7 Tears

1

1

1/1

1/1
22/25
(88.0%)

25/25
(100%)

3/3

63/63
(100%)

11

Total
!-lean Age:

ll'o.
Heaales-Ht1111t1a-Rubella
Conversions/Total
Serol.
Ta11ted Measles
Rubela
M=s

Heasles -Mumna
Conversions/Total
~ea.sles Hwans

Total
No,
Vacc.

1.99
159
3.7 Years

23/23
( 100%)

22/23
(95.7%)

23/23
(100%)

2/2

.

2/2

28/29
29/29
(96. 6%) (100%}

3/ 3

K...:ps and

Rubella

Ovarall Conversion Rataa

56/57
(98.2%)

49/53
(92. 5%)

140/140
(100%) â€¢

l'J/3/77

:.

to:

-- -------

-- Table

Scrologic.:il
Measles - Rubella

Findings

2

Among Chi ldrcn

(RA 27/3) Virus

Who Receivcci

Vaccine,

Lot

- T11 it _i_:i 11y . SlÂ· l"Oll <'f"L;l ti V(~ to:
---- - --MLâ€¢,,sl C's-11111,cJ] a
Me:1sl <.!'.: On I y
H11hcll.'.l _Only

- - ---Tot:il

No.
V:icc.

I

I

I
I

No.
Scrol.
Tested

----

Comhi necl Live

No. 622/C-D764 (Study

Convcrs ions/To tu]
Convcrsio11s/
Mc:is ]es
Â·R;-;i;clla Â·
Tot:il

-----i-------

---

Conv e rsions/

-----

Tniti:illy

IJ41,2)
Scr~o

Tnt..11

:incl
R11bclJ a

4/4

1

l Year

22

16

11/11

11/11

2 Years

20

16

7/9

9/9

2/2

J/J

2

J Years

li6

36

14/16

15/16

1/1

13/13

6

q Years

40

31

5/5

5/5

2/2

20/20

4

5 Yea r s

28

19

5/5

5/5

1/1

11/11

2

6 Years

37

24

7/8

8/8

t,/4

9/9

J

Totnl

193

49/54

53/54

]0/10

60/60

18

(90.7%)

(98.1%)

(]00 %)

( l 00 7.)

MccJn Age:

3.7 Years

Ovcr.:ill

Conversion

!; i_t_ivc _tn:

MC'.lS 1 cs

Rates

Me:islcs

R11helln

59 / (il,

1)3/JlL,

(92. 27.)

(99.1 7.)

4/'!.B/77

Table
Distribution
of Fold Rises
Who Received Live Attenuated

3

of Hemagglutination - Inhibition
Antibody Titers Among Children
Rubella (RA 27/3) Virus Vaccine, Lot No. 579/C-D418 (Study ll442)
Initially
Seronegatjve
- Conv.
No.
R.,t e
Conv. Failures
Total

Total
No.
Vacc.

No.
Serol.
Tested

Initially
Seropositive
Fold Rise
Total
24X Indet.

1 Year

13

10

1

1

9

9

9/9

2 Years

17

15

1

1

14

14

14/14

3 Years

30

24

2

2

22

22

22/22

4 Years

38

32

1

2

30

30

30/30

5 Years

42

29

3

3

26

26

26/26

6 Years

56

48

8

8

40

40

40/40

7 Years

1

0

Total

197

158

16

17

141

141

100%

Age

Mean Age:

1

1

- - -

0

4.3 Years

4/28/77

Table 4
Distribution
of Post - Vaccination
Antibody Titers
Among Children Who Here
Initially
Seronegative
to Measle s, Mumps and Rubel la and Who Received Combined
Live Measles - Humps- Rubella (RA 27/3) Virus Vaccin e , Lot No. 621/C-D763 (Study #442)

Measles (Ill)
Post - Vaccination
No. of
Titer
Children

Mumps (Neut.)
Post - Vaccination
No. of
Childr en
Titer

Rubel la (III)
Post - Vacc in a ti on
No. of
Titer
Children

<s

<2

1

<8

s

2

4

10

4

4

16

'

8
:,

20

2

8

s

32

1

40

s

16

7

64

4

80

. 5

32

-2

128

9

256

7

512

2

6

160

â€¢

'

320

5

Total

23

23

23

98 . 8

7.1

lq8 . 8

Geometric

Mean Titer

10/3/77

Table

5

Distribution
of Post - Vaccination
A11tibody Titers
Among Children
Who Were Initially
Se r oncgative
to Me:JSles and Rt1bel la and Who Received
Combined Live Measles - Rubella (RA 27 /3) Virus 'Jaccine,
Lot No. 622/C-D764 (Study

Measles (Ill)
Post - Vaccination
Titer

No. of
Childre n

Rubella (III)
-Post - Vaccinalion
Titer

<s

5

<8

No. o f
Children
1

8

5
10

1

16

20

9

32

1

40

4

64

3

80

22

128

30

160

9

256

13

320

3

512

6

->640

1

Total

54

54

)/18 . 7

l 51. 2

Geometric

Me an Titer

-

---

4/28/77

044 2)

Â·Table

6

I

Distribution
of Post-Vaccination
Antibody Titers Among Children Who Were Initially
Seronegative
to Rubella and Who Received Live Attenuated
Rubella (RA 27/3) Virus Vaccine, Lot No. 579/C-l)4]8 (Study

Rubella
Post

Vaccination
Titer

(HI)

No. of
Children

<B
8
,

16
32

2

64

20

128

70

256

41

)512

8

Total

I /,1

-

Geometric

Mean Tit er

)]50.5

4/28/77

0442)

----

Â·Â·-

Table 7
Maxi 111um
Temperatures Reported Among Childre n Who Received Combined T.ive
Me:isles - Humps- Rubella (RA 27/3) Virus Vaccine , Lot No. 621/C-D763 (Study /1442)

Maximum
Temperatur e
(Â°F. Oral)

I nitinlly
Scroncgative
to:
Measles, ?-lumpsand Rube11 ;J (23 Chi_ldrcn)
No. with
l>nvs Post-Vaccinat io n
5-12
19- 28
29-42
13-18
Max. Temp.

0-4

Total Vaccinees (199 Children)
D:ivs Post-Vac cina tion
5-12
13-18
19-28
29-42

<99

147
(73.9%)

138
(69. 3)

160
(81.6)

130
(68.4)

137
(72.5)

83

18
(78.3)

20
(87.0)

99 - 100.9

51
(25.6)

57
(28 .6)

35
(17.9)

59
(31.1)

52
(27.5)

109

5
(21. 7)

3
(13.0)

2
(1.0)

1
(0. 5)

101 - 102.2
1.03 - 104.0

1
(0.5)

2
(1.0)

No. with
Max. Temp.

23
(100.0)

14
(73. 7)

16
(84 . 2_)

16

5
(26.3)

3
(15.8)

7

4

4

3
4

1
(0.5)

Not Taken

0-4

3

10

9

.

Serolo~
Patient I
- {1,116)

Temperature
102.2
103.l
103 . l
104 . 0
104.0

Days
8

20
11
l
5

__________

C_linical

Complaint

Upper Respiratory
Illness,
Malaise
I rritability,
Malaise
Tonsillitis,
Anorexia, Headache, Malaise
Ir ritability,
Malaise
Upp~r Respiratory
Illness,
Irritability,

MC?asles
)20
)20
>20
Anorexia,

Malaise

)20

Mum~s

Rubella

)8
320
32
<8 1024
(8
160
64
128
(2
)640
4
<8
128
Serologies
Not Done
320
<4
16
<8 256

>B

10/3/77

,._.

'

__ ,j
Table
Live

H.1xlmum
T~mrc r.1 tu re
{of
Oro l)

<99
99 - 100.9

8

M.1xiru11m'l'rn11wr .it11r,Â·s llr.purtc,I /\1n11
nr. Ch i l<lrc-n IJho nccc iv ,~d Con,hinc-<I
Mc.1:;lcs.-R11hcll.1 (RA 27/J) Virus Vacci ne , l.ot No. 622/C- 076/e (Slnuy l t,1,2 )

Tnltla lly Scroncg:it iv c to:
Mc:is lrs :ind Ruhr. I I:, (St. C:hi lrlrc-n)
-~â€¢'!J~~
-i,_-V:icd n.:it ion

Tot.il V.iccinccs
(19) Children)
n,,yE..l'ost-V.1cci,'.!:!!_lnn
__
____

No, wi t h

0-4

5-1 2

1J-L8

19-28

29-42

Max . Temp.

0-1,

5-12

13-18

19-28

29-42

No . ut th
p.
~l:ix. Tc 1:1

146
(76. O)

1J5
(70. 3)

138

123
(64.4)

llt.

67

JS
(6 4. 8)

39
(72.2)

JS
(70.4)

23

(59. 7)

42
(77.8)

JS

(72.J)

(64. 8)

46
(24.0)

56
(29.2)

S3
(27.7)

68
(3S.6)

77
(40 . 3)

12
(22.2)

19
(JS. 2)

15
(27.8)

16
(29.6)

19
(35.2 )

102 .0

124

31

1

l

(0 . 5)
Not T.1ken

1

Patient
H
(b) (6)

1

2

2

Te mper.1ture

D.1y

102.0

5

2

1

Clinicnl

Upper Respiratory

Illness,

Compl .1in t

Irritability,

Measles

M:ilaisc

l20,

160

Ruhcll.J

lJ2,

2S6

4/28 /77

- _J
T.thlc

9

tbxlm11n1 Tc,nrcr.,tures
ltepo r te<l Amonr, Cid l,l r en llho Received
Attenu.ttcd
Rubella
(RA 27/3) Virus V.tcdnc , I.at No. 579/C-nt.18

...:__11.:i:dmum
Tcmr ~r ature
(Of, Or al)

(99

99-100.9

Tc,t:il VnccJnNâ€¢s
(197 Children)
l>..:
i_ys r~-V
o1_
c_Â£.!_n:1t_~_~,

No. with
l'cmn .

I.I ve
(Stu dy #111,2)

lnlt J :illy Scron~r,.ttive
co:
Ruhe 11 a ( 1t. I r.ld I ti ren)
n_~s l'ost - V:iccin :iti o n

No . Wit h

0-4

5- 12

13-18

19- 28

29-1,2

Ma~. T-:'1:1r>.

0-4

5-12

13-18

19-28

29-42

162

131
(66 .5)

148

138
(71.5)

116
(82.J)

97
(68.8)

110
(78 .0)

94
(67 . 6)

104
(74.8)

51

(7 S .1)

125
(64.4)

67

(82. 2%)
35
(17 . 8)

66

48

68

55

128

(24.4)

(35 .1)

(28.5)

25
(17.7)

44
(31.2)

30
(21. 3)

44
(31.7)

35
(25.2)

88

(33 .5)

101 - 102 .2

1

1

(O.S)

(0.5)
3

Not Taken

Patient
R
(b) (6)

Tempera t ure

~

102 . 2

20

lfox.

2

1

l

(0 . 7)

(O. 7)

2

4

Clinical
Upper

Resp i ra t ory

Anorexia,

2

Serolog)'._

Complaint

Illness,

2

Halaise

<B, 128

4/29/77

----Table

10

Clinical
Complaints Reported Among Children Who Received Combined Live
Measles - Humps-Rubella (RA 27/3) Virus Vaccine , Lot No. 621/C - D763 (St udy 0442)

Cli nical

Complaint
0-4

Irritability

(16 .1%)

9
(4 . 5)

2
(1.0)

4
(2.1)

30
(15.1)

14
(7.0)

3
(1.5)

7
(3.6)

1
(O. 5)

2
(1.0)

32

Malaise
Headache
Upper Respiratory

Illnes s

Total Vacc inee s (199 Children)
Day s Post - Vaccina ti on
5- 12
13 - 18
19- 28
29-42

9
(4.5)

11

5

8

( 2.5)

(4 .1)

2

3
(1.5 )

(1.0)
Ophthal mopathy

39
1
(0.5)

'

43

0-4
5
(21.7)

(5. O)

5

( 21 . 7)

5

l

1
(4 . 3)

2
(10 , 0)

7

2

(5. 5)Â°

Ot i tis

No. with
Comola int

Initially
Se ronegat iv e t o :
Measles, Mumes and Rubella {23 Child ren)
Days Pos t Vaccination
No. with
5- 12
13-) 8
19-28
29-42
Compl ain t

5
(2 . 6)

23
3

1

0

.

1
(4 .3)

1

(4 .3)

1
(4. 3)

2
(10 . 0)

1
(4 . 3)

1
(5 .0)

1
(5.0)

1

1

0

(0. 5)
Gastrointestinal

Illness

13

7
(3.5)

2
(1 . 0)

(2. 6)

5

3

(2 . 5)

(1.5)

2
(1.0)

(2.6)

(6 . 5)
Anorexia
Mild Der!llatitis

Persons

with Complaint s :

. Pers ons with No Complaints :
Negative Physic ian
Surveill ance

5

1
(0.5)

5

49
(24.6 )

22
(11.1)

150
(75.4)

177
( 88 .9)

22

1

1

(4 .3)
13

1
(0. 5)

1
(5 . 0)

1

1

(5.5)

19
(9 . 8)

(3. 1)

188 .
(94 .5)

175
(90 . 2)

(96.9)

11

5

6
187
6

73
123

3

0

6
(2 6.1)
17
(73.9)

2
(8. 7)
21
(91.3)

1

4

(4. 3)

(20.0 )

22
(95.7)

16
(80.0)

1
.(5. O)
19
(95.0)

J

3

10
12

10/3/77

I
I

tÂ·Â·Â·Â·Â·-Â·Â·

_ __ j

Tahle
Live

11

Cl111ic.1l Co1n1>l:1lnts 111.'poncd Ao1011r,Chlldrr,,
IJho Rl'cci.vrcl Cnmhinr<l
Mc:islcs- Rul>ella (RA 27/J)
Vims V:icc.inc,
Lot No. 622/C-0764
(Study

0442)

Tni ti.:\ I 1y $(. Tl "lfh~ r .: 1t i VC" l O :
1

Clinlc3l

Complalnt

Irritability
M3laise
lleadache

Uppe r Resp'i r.1tory

Illness

0-4

Tnt:il v.,cr:inrcs
(19) ChiJJr,â€¢n)
ll.1y,, l'osc-V :1c c in.1cl,,n __
____
5-12
l l-1 8
19-28
29-'2

29
(15. l)

11
(5. 7)

6
().1)

9
(4. 7)

6
().1)

52

JJ
( 17 . 2)

21

15
(7. 9)

15
(7. 9)

7
(). 7)

65

(10.9)

4
(2.1)

(1.6)

2
(LO)

2
(1.0)

1
(0. 5)

9
(4.7)

8
(4. 2)

8
(4. 2)

l
(0.5)

1
(0.5)

2
(1.0)

2
(1.0)

l
(0. 5)

l
(0.5)

6

6
(3 .1)

4
(2 . 1)

)

23

(1. 6)

4
(2 . 1)

17

____

---

)

Bronchitis

1

Otitis

(0.5)
Castrointestinal

Hepatitis

No. with
Con11>
I ., i n t

---

_ ____
0-4

2l

1)-10

19 - 28

29-42

!Jo. wlth
C(1mr,l.1inc

1)

4

2
(). 7)

l
(1.9)

l
(l.9)

18

(7 .4)

12

8
(14 . 8)

4
(7 . 4)

2
(). 7)

1
(1.9)

18

1
(1.9)

1
( l. 9)

5
(9.))

2
().7)

9

1

5-12

(24.l)

(22. 2)

1

{0.5)

.- __12:ry_?~
,~~_:-_Y:.!.':..r_!_~~-I_!â€¢_~
_
_ ____

(1. 9)

1

1

(1.9)
(). 7)

2

1
(1.9)

1
( l. 9)

2
(). 7)

1
(1.9)

2
(3. 7)

1
(1.9)

1
( l. 9)

1

1
(l.9)

6

. l

1

( 1. 9)
3

5

7

(2.6)

().6)

5
(2.6)

4

6

(2 .1)

(3.1)

1
(0 . 5)

l
(0.5)

l

0

'l

l

0

ll:lness

Anorexia

11,â€¢.,~ l ,.,.. ;1111 ll11h,Â· l l .1 (54 C'h I l<l r,â€¢n )

Asthma

1
(1. 9)

5

4

(0.5)

'
Persons
Persons
N~&ative

wlth
with

Complaints:
No Complaints:

Physician

Surveillance:

8

70

36
(18.8)

24
(12.S)

17
(8.9)

18
(9.4)

156
(81.3)

168
(87. 5)

17/o
(91.1)

183
(95.8)

121

(90.6)

2

2

2

l

1

1

173

(t.. 2)

9
(1 6 .7)

4
(7 .4)

3
(5.6)

l
( I. 9)

19

I, l

,. 5
( 8).))

50
(92.6)

51
(94 .4)

53
(98.1)

)5

(75. 9)

l3
(2l.. l)

4/ 29/77

,

rÂ·Â·

......

THble 12
Clini c,, l Cnmpl.,ints
Rcpoi-tcd
A1n1 nr. Child r en 1./ho Rece i ved Ltve
Attenu:itcd
Ruhe!L.- 1 (llA 27/))
Virus VJcclne,
l.ot Nu. 57')/C-Ol.18
( Slu dy #4 42)

Clint

c;:il Compl;1int

->------

--__
0 - 1,

~falai!:e
lle;:id;:iche
Respirato

r y Illness

J-1:!

----

13-111

--

--

4
(2.0)

3
( 1.5 )

28
(14. 2)

10
(5. 1)

(2.5)

2

1
(0.5)

(1. 0 )
Upper

l>.GÂ·sÂ·Â·Â·l'~;
sc:Â°-v
Â·.,Â·,=r_i~l;:
;,Â·1"({>~;- .. -Â· - -. --

( 11. 2)

22

Jrritability

Tnt :il V:i~c l n~r s (1 97 Cl111drcn)

4
(2.0)

8
( 4 .1)

5

1
(0.5)

)')-:!!!

5

29-f,2

----

~u
ith .
C:0111
11I .1 inl

2
(l. O)

32

9
(4.6)

4
(2 .1)

46

J
(1.5)

l

6

(0 . 5)

1
(0. 7)

6
(J .l )

15

(1.0)

3
(2. 1)

2
(1. 0)

l
(0.5)

Otitis

2
(1.0)

Ophthalmopathy

1
(0 . 5)

l
(0.5)

5
(2 . 5)

6
(J.0)

7
(J.6)

l

5

(0 . 5)

(2.6)

35
(17. 8)

18
(9 . 1)

7
().6)

16
( 8 . 2)

7
(3.li)

60

162
(82.2)

179
(90. 9)

190

180
(9 I. 8)

188
(96 . 4)

137

(96.'4)

Gastrointestinal

Illness

Anorexia

Pe rs o ns uith
Pe rs o ns uith

Compla ln i s:
No Complaints:

l
(0.5)

1
(0 . 5)

1

Inili:11 ly Sen>n1.:r,:itivr
to :
f;u hc l J:i (JI,\ Chi Jtl r ,â€¢11)
lhvs ros t -Va c cln :1tiu 11
- Â·---5-12
I J- J S
19- l K
29 - 42

-- --Â·-- -- -Â·-- -- -- ------- --0-4- -~- - -- ---- --~---

(2. 6)

2

-

4

15
(1 0. 6)

(2.8)

l 'l
(]3.5)

(6 . '4)

9

2
(1.4}

2
(1. 4)

l
(0.7)

23

2
(1. 4)

5

2
(1.4)

32

(J. 5)

6
( 4. 3)

1

5
(J.5)

2
(1.'4)

13

(O. 7)

l
(0.7)

l
(O. 7)

2

1
(0 . 7)

1

l
(0. 7)

(0 . 7)

4
(2.8)

5

l

(J. 5)

(0. 7)

11

lJ

l

1

4

4
(2. 8)

8

14
(9 . 9)

4
(2.8)

10

5

( 16.))

(7 . 1)

(J.5)

J 18
(83.7)

127
(90 .1)

137
(97.2)

131
(92. 9)

(96.5 )

136

.

Ne gative

Physician

Surv ei llance

l

8

1
(0. 7)

(2.8)

2)

2

1
(0. 7)

4

(0.5)

No. v lth
Cn~,r 1a In t

2

4/29/77

4)
98

MEMO
To File

Location
Location

From T . Schofield

Statistical

Subject

Date 2/2/78

Analysis

- Study /1442

Analysis of variance was conducted on post titers
of children
who
were initially
seronegative
to rubella who received
rub~lla vaccine,
lot #579 (Group 1), combined measles-mumps-rubella
vaccine,
lot #621
(Group 2), and combined measles-rubella
vaccine,
lot #622 (Gro up 3) .
No significant
difference
mean titers
were :

exi~s

among the three

Vaccine

GMT

Rubella

150 . 5
143.4
155.5

MMR
MR

There is no significant
three groups .

difference

in conversion

groups .

rate

Geometric

among these

T. S.

:..""'
.":,.:r
_Â·_:Â·..Â·._:
__.._. -. Â·-....._

Â·......

\

. ..
Â·- , â€¢;.__,

'

. ..,

,.._

.. ...:~
..

. _:. ,â€¢.--.;,,:;.

:~-

,.

.. ... .... .

:.:;.t.:.
:r:::
..Â·:Â·\-~.:.~.
: Â·:-:Â·~ ~--:
â€¢'

â€¢â€¢.. â€¢ â€¢â€¢

-;Y":"Â¥'='
~ .Â·.Â· â€¢.~: ~ ... - ....."'f"_.:! Â·Â· - â€¢ â€¢ ..,.'7
..

~ â€¢:: ; .

~ J -.-

..

'"'=:
Â·: . ~. -

Â·!" â€¢

.. .. .. , -::

â€¢

:,,_Â·
._-.. , .,. .

. - -Â·~

. ...

. ,.,:â€¢;;:,.' ._.

-

Reference
Program:

Study #443

Vaccine:

Combined Live Measles -Mumps-Rubella
Lot ~o. 621/C-D763
Live Attenuated
Rubella
Lot No. 579/C - D418

Responsible

Clinical

(RA 27/3)

No. 2

(RA 27/3)
Virus

Virus

Vaccine,

Investigator:

Robert E. Weibel, M.D.
Director,
Division of Preventive
Medicine
Joseph Stokes, Jr. Research Institute
Children ' s Hospital of Philadelphia
34th Street and Civic Center Boulevard
Philadelphia,
Pennsylvania
191 04
Study Location:
Children ' s Hospital of Philadelphia
Darby Child Health Clinic,
Darby, Pennsylvania
G. Starkweather,
M.D., Havertown, Pennsylvania
Dat e Study Initiat

ed :

October

28, 1975

Dat e Study Completed:

January

20, 1977

Study Pro cedu re:
A total of 194 children
10 months to 8 years of age
from the open population
were included in the study.
One hundred ninety-one
children
received a 0.5 ml
subcutaneous
dose of one of two vaccines . Three
children
received a 1.0 ml subcutaneous
dose of the
combined live measles-mumps-rubella
(RA 27/3) virus
vaccine.
Blood samples were obtained prior to and
six weeks after vaccinat i on.

Vaccine,

Pro to col - Study !.1443

Clinical

Combined Live ~leasles-~ Â·!umos -Rubell a (R..-\27/3)
Live Attenuated

Rubella

(RA 27/3)

Virus

Virus

Vaccbe

Vaccine

Purpos e:

To determine antibody and clinical
responses
to combined liv e
measles-mumps - rubella
(RA 27/3) virus
vaccine and to live attenuated
rubella
(RA 27/3) virus
vaccine.

Vaccines:

a)

Combined live
lyophilized
Lot ~o. 621
Vaccine

measles-mumps-rubella

dose is 0.5 ml given

(RA 27/3)

virus

vaccine ,

subcutaneously.

The vaccine is supplied
in two-dose vials.
Each vial of
vaccine should be rehydrated
with 1.2 ml of sterile,
pyr o genfree distilled
water .
b)

Live attenuated
Lot No. 579
Vaccine

rubella

(RA 27/3)

dose is 0.5 ml given

virus

vaccine,

lyophilized

subcutaneously.

Tne vaccine is supplied in single - dose vials.
Each vial of
vaccine should be rehydrated
with 0.7 ml of s ter ile, pyrogenfree distilled
water.

CAUTION: The combined vaccine may contain egg protein and should
not be given to persons with known sensitivity
to egg, chicken or
chicken feathers.
Both vaccines contain neomycin and should not be
given to persons with known sensitivity
to neomycin.
Persons with
leukemia or other immunologic disorders
and persons receiving
immunosuppressive
drugs should not be vaccinated.
Also, th e vaccines
should not be given to persons with any febrile
r ~ spiratory
illness
or other active febrile
infection.
Keep dried

vaccines

stored

Keep dried

vaccines

at 4Â°C in transport.

Keep re constituted
after rehydration.
Procedure

:

Establish
follows:

vaccine

two groups

at -2 0Â°C until

on ice.

Discard

of 50 to 100 children

used.

unused

vaccine

l to 6 years

Group

Vaccine

No. Children

Group 1
Group 2

measles-mumps -ru bella
rubella

50-100
50-100

4 hours

of age as

Clinical
Protocol
Study {/443

-

-2-

Children in Group l will have a negative history
for vaccination
and illness
for measles,
muâ–¡ps, and rubella.
Children in Group 2
will have a ne gative history
for rubella
vaccination
and illness.
Informed
guardian

consent will
prior to his

be obtained
participation

from each child's
in the study.

Each child will be bled (10-15 ml) immediately
and 6 weeks following
vaccination.
Vaccine

dose is 0.5 ml given

Time
Day 0
Days 0-42
Week 6

or

to vaccination

subcutaneously.

Each child will be followed clinically
vaccination.
All local and systemic
on the case report form.
Schedule :

prior

parent

for 42 days following
complaints
will be recorded
Action

Bleed 10-15 ml.
Vaccinate 0.5 ml, subcutaneously.
Clinical
systemic

follow-up
reactions.

for

local

and

Bleed 10-15 ml.

Serology:

Circulating
levels of antibody before and after vaccination
will be
determined.
Measles and rubella
antibody levels will be determined
by hemagglutination-inhibi
tion test.
Mumps antibody
levels will be
determined by serum neutralization
test.

Clinical
Forms:

Attached.

Adverse
Reactions:

Any serious or alarming reaction,
including
death due to any cause
during this investigation,
whether related
or not related
to the
test material,
must be reported
immediately
to Merck & Co., Inc . ,
through Dr. Maurice R. Hilleman,
telephone
( 215 )_ 699-5311, Ext:. 55 32,
or in his absence,
Dr. Allen F. Woodhour, telephone
(215) 699-5311,
Ext. 5588.

Unused
Vaccine:

All unused vaccine should
Cell Biology Laboratories
Laboratories,
West Point,

be returned
immediately
to the Virus
of the :Merck Sharp & Dahme Research
Pennsylvania
19486.

M. R. Hilleman,

Ph.D.

and

~1E
h SL[ S- ~IU:IPS- fiU OELLA VACCIN A1
FAHI LY llo. _______

CASE Ho. _____

_

CH I LO" S h,..,,_( ------.-.-,-,-

--

--

sex _______

-

------

8IA1HOAT[

-

__

----

____

- - -,-,--------------.,-,1 10

_____

_

-,--l.,-l ______________
00

AC[ __

_ _

HI SlORY:

_

~IUMPS -'------------

-

IIUD(LLA

I

I

\

I
PA "(NTS

,....,,[

--------------------------------

TEL CPHON( No â€¢

.,. , D OL(

f I fl ,1

LA.ST

I

rr

AOORCSS -----------

-

-------- .st,cc ,

- -----------

t.11" ---

I -

(

\"
1 1Â·
l I

--

-----

-

----s 1 .t. 1(

-------

consent to have my child,
named above, receive
live atten u ated measles,
mumps, r ubella virus
vaccine .

lOC!TION

)

-

rRE-VACClkATION
__________________

_

CLIMICAL
____________________

_

SI GNJ.lURE

DATE

--.--Â·Â·Â·---.-~~-~?\:,;:/:;?
:Â·:-':~~{~~'.;~~'.-.~
:Â·Â·
,~
.~~ :
.'

I

~

I ~:

{

'\

~\

.. . ' I .

\

I Â·:. i '

,. ,... '

, .-

.Â·Â·Â·,,.

â€¢.

,Â·

,'

\t

â€¢

,-

I

Â·'

,._::.

. ,.

â€¢â€¢

iâ€¢ I

Â· Â· -â€¢Â·Â·

: ;â€¢. IÂ·

'' )â€¢â€¢: â€¢Â·.â€¢llj
. . â€¢â€¢Â·-1
. Â·1Â· j t'\1'''11
' -~Â·..â€¢,_.
..... . ,.;.l ..jÂ° â€¢ 'I-~ ,j ,/,'(i

â€¢ â€¢. â€¢ J

1/ , :.â€¢.Iâ€¢â€¢

â€¢ I

Â·, ': . i

â€¢Â·: Â· ,Â·. ' I ; I;

--;' â€¢1

I

I

,

1.

I , J , '.

.'. 'i:. ', I

'â€¢

I

iI ;

I' \
â€¢ : â€¢ â€¢ ': Â·, .. J â€¢Â·

,.Â·..Â·â€¢Â·. â€¢

. ,.. ., . . '"' . ': ' â€¢ .
,Â·â€¢-Â·-l
)'~ "; ._
Â·,â€¢..J,'/ 1 'J;~;.", , .Â·' ...... Â·:Â· Â·.- .

:

.'' I â€¢ ' ' . :

.

I

' .I:

Â· :Â·_:__
. .:,.:Â·2:},"-Â·.â™¦]:.: _Â·;!:_. ~-~ ---~Â·.~i-~Â·_~ ~~! ::Â·\(:~---~Â·,; ...Â· ..; ...._. . â€¢. â€¢-Â· ;,.:_â€¢
â€¢: :â€¢,I. !

\

:\
;

UCC IOHloÂ«:

.

;

I

T~CCIN[ -------

I. Dll[ _____

-!

__

_

--

--

lDT - ---,

_

SI Tt _______

TDL. _____

171-., 7,--

--

-

_

Pl[-Y&CCIUllON

________

_ _ _

,OST-YACCIUTION_ _ _ _ ______

l.

-.

1 f

..,,

s [R0l06T

llECD l â€¢G
DATC

'Â·,

MUSLÂ£S

>I

I

ICJ~PS

I

J

I

I

,.

I

lU!CLlA

UC.

,

l

ff -JO _

,_"

Jt â€¢ lt-

-

o-q
s-1 2

2.

13-11

3.

,,_2,

,.

eoo..un,

â€¢ tuu,D
D

( U ll(.1 4.. ._ . ,,

-,ulU

Q

IUf

Ull

1

..,

,ou

I

"'

f

,Â·

.,Â· Â·'

l

')

.,,.

.

t.

,.-â€¢
.â€¢r

. ..
'

'... . .:,
â€¢.

.,.,1

c:x

ca<

J1Â·1l

_,-....n_

,ur

....,r.....
_

..

_..
-

,.,, __

u ..u _

...,L,..,_

"

I
PKTSICIU

Â·-...

Â·,â€¢,

I

I

SUNMllT
(0-S'UUU

l

..

\, Â·.Â·

,âœ“

,asr

D1

.Â·

j

I

I

hohl1~

. 'i_,â€¢â€¢â€¢

0 --t l_

k-'5-1-

,_,u

\ .-'.
â€¢i., .

(CID(

I.

....

l.

Cl I I I CAl
1111.U
, 101â€¢ .

â€¢â€¢rs

TECKNIQU[

..,

CJ.SCâ€¢â€¢Â·

_

SYMPTOM RECORD
M-M-R Study No.
CHILD'S NAME----

-

-

--

-

---------

-

tFlrst>

(US!)

DATE

--

~

w

D Rectal

U'I

U'I

z

0 Oral

u

ct
QI~
w w

>

w z

U'I

2 I :,_

!:

U'I

ct

w
c:: fUJ
z
>
0
UJ

~

(!

UJ

0

I

0

--

CASE NO.

I-

J

I-

c:: c:: ct
0

.J
U'I

0

z z
0 :i
z (!

(Check One)

"'

:E I

2

(Mlc<lleJ

0

,.

1--

0

-:-:-:-:------

c::
w
>

0

Temperature

DAY

-

COMMENTS

~

II

1
2
3 I

I

4

5

6

! I
I I I

I

7

l

8

l

9
10

I

11

I I

I

13
14

I

I

I

I

I

I

I

I
I

15
16

I

I I

!

I

I

I

!

I

12

I

I

I I

I

I I

17 I

I

20

I I

I
I

I

18
19

I

I

21 I

I

22
23
24

I

25
26
27
28

29
30
31
32
33

34
35
36
37

38
39
40
41
42 I
,er or unusual reiJcrion develops, cal/:

L H. R. E. WEIBE L
Havertown,

PLEASE RETURN

Pennsyl vania - Phone : Hilltop

FOR FOLLOW-UP VIS>T ON : ___________

~ 111O

OR
Children's Hospital of Philadelphia - EV 7-1309

,.n,,-o7751Do.,.,

:--=----------

BE SURE TO BRING THIS RECORD ALONG

WITH YOU.

_

Table

1

Scrolor,lc;il
fl n~ lngs N<'or:g C~lldr c n l-~ 10 Rc~ clv c d "0.5
t'o<.'
'1s l cs- llur.:p s - k ubc lla (k..\ 27/ 1) Virus V'1ccluc , t o t :;o,

I ,..,.,

!Sc.,s]c-,;-:~ u:,o.-;- Rol, ~l l ;,
Tota l
No.
-C-:;
nv-.;
r~:ro~;<J-/TÂ·;
,;l!:o .
Scro I. ._
.,__
V;.cc4 .._
Test e d !i ,!.l!. )t: ~
!'"Â°U:.' "I~
iittJh
(: llil

___---

I

--~-

!i<":,._) f'<tt-?:ur..p.-:

lnl _t_l_:i_l_l:t..
J~i:5'.~~ ~:!_t~
H-~.1shâ€¢.-:- l<111w1 l .1

1-(l llo;e o{ co ,.l,ln,â€¢d Live
621/C-D761
(StuJy
'44))

to :

1n1tfl1

l''ut jâ€¢S - 1t11h,Â·I l 1

C<inv ~r s Jt'n'S/i ~ti] 1-Conv,â€¢ r!tt onâ€¢;/ T., c.,1 ~. ,,v._.
r:;1ous/To t .,1
--.---c---1------- - - ---i------- - -Y,-..;.1 ~ lt.! S
~h ~r'IS
t-:~.,s lc s Rube 11,,
llur.,y,s ~~1 1~

M~â€¢,1!. l..:-s Onl v

!1u~o s Only

Conv\! r ~ t ,,ns /

Conv,â€¢r.:.
, l ~ ,~

C~n-; r!-~t;->-/

Tot al

To tal

T<>DI

lv ~â€¢â€¢r~<" ~h tw:t ~

l:u~c ll ., On l v

~

n.._lr s

Hu r;- 11t.,1:,J
R,1t.â€¢1 1,

!X or.t i-.s)

8

6

6/6

6/6

6/6

1

68

6'

48 /52

50/52

52/n

0/1

1/1

2

10

10

7/7

6/7

7/7

1/ 1

1/1

J

5

5

J/J

J/J

3/J

's

2

2

J

l

6

4

4

7

l

0

8

l

l

II
(Y~H S)

95
.____i ,, t lL ._LO2
~- â€¢.1n ,; : c : 1.7 Y<:ar ~

7/7

1/ l

1/ 1

7/1

l/1

1/ 1

2/2

2/2

2/2

2/ 2

1/1

1/l

1/ 1

1/l

2/2

2/2

1/1

1/1

2/ 2

1/ 1

l/l

I

64/ 63
04.

1:)

65/6 8
C9S.61)

68/6 8

1/2

2/2

9/9

9/9

9/9

1/1

9/ 9

{1 00 %)

0vcrnll

HS

I

I

.

Conver s ion R.lte

~-~~

l1<-.1r.1.!_!

Hunr5

75 / fl(J

76/79

91/91

(93.8 :t)

(96.2%)

(1 00 %)

5/ 4/77

Table 2
Serological,
Tempen1tureÂ· and Clinic.,l
Fin<ltnr.s for 3 Children Who Received a 1.0 Hl Dose
of Combined L1ve tleasles-Mumps -Rubella (RA 27/3) Virus Vaccine, Lot No. 621/C - D763 (Study 0443)

Vaccinee
~o.

- (b) (6) .I

Ase
(Years)
3

Serology
Measles
numps
Rubella

4

Measles

Results
Pre
Post
Pre
Post
Pre
Post

Days Post-Vaccination
>20
-80

0-1,

>8

13-18
19-2 8
29-42

98.(,

))2

Complaints

Gas tr ointestinRl
Illn ess
Gas tr ointesti nal I1 lness

98.6
98.6

None Reported
None Reported
:lone Repo r ted

0-4
5- 12
13-18
19-28
29- 42

99.4
100.0
99.8
99.7
99.6

None Reported
lfon-Spccific
Rash, Day 5
None
None
None

0-4
5- 12

Not Tnkcn
Not Taken

13-18
19-28

98.6
98.6

None Reported
None Rcport!'d

29-42

98.6

None Reported

256

.

<S
20
4
8
(8
256

Measles

, lÂ·r c
l'us t

<5
10

M\J111ps

Pre
Post

(2

Pre
Post

(8
32

Rnbe'lla

Clinical

100.0
98.6

5- 12

64

Pre.
Post
Pre
Post
Pre
Post

Humps

..
Maximum Temperature
(Of , Ornl)

J

l

Rubella

4

,

Upper Respiratory
Otltis

Illness,

5/5/77

Otltis

Table 3
Serological
Findings Among Children Who Received a 0 . 5 l-11 Dose of
Live Attenuated
Rubella (RA 27 /3) Virus Vaccine, Lot No. 579/C - Ol,18 (Study
In j tin 11 y_ _Sc roros
Fo l rl Rise
- Indct
---- .
)/,x
2x

Total
No.
Vacc.

No.
Serol.
Tested

(Months)
10

1

1

11

8

8

1

(Years)
1

42

41

3

2

13

3

J\ge

j ti ve

Total

0443)

Ini tj <!_!_1)'.Scroneg:1tive
No.
Conv.
Fail ures
Total

Conv.
Rate

1

1

1/1

1

7

7

7/7

3

6

35

35

35/35

12

4

4

8

8

8/8

11

11

4

,,

7

7

7 /7

4

9

9

3

3

6

6

6/6

5

3Â·

3

1

2

2

2/2

6

1

â€¢1

1

1

1/1

7

1'

0

89

86

67

1007.

Totnl
Mean Age:

1

1

4

14

19

67

0

f. 9 Ycnrs

5/l1/77

Table

4

Distribution
of Post - V:iccination
Antibody Titers
Amoni:; Chi.]tlrcn Who Were Jnitial]y
Scroner,ative
to Measles,
Mumps an<l Rubella and h'ho Rec e ived a 0 . 5 Ml Dose of. Combined
Live Measles-Mumps-Rubella
(RA 27/J) Virus Vncdne,
Lot No. 621/C-0763 (Study f/443)

Measles
Post - Vnccination
Titer

<5

(III)

RuhelL,

Mumps (Neut.)

No. of
Children

---

-

4

5

----

--

--

(Ill)

Post - Vaccin:ition
Titer

No. of
Ch ilcl r cn

Post - Vnccinntion

No. oE

Titer

Ch i1 rlrrn

(2

3

(8

2

3

8

-- -

. JO

2

4

16

16

1

20

9

8

26

32

2

40

13

16

8

64

18

80

20

32

11

128

l9

160

12

64

256

25

320

7

128

512

J

640

1

Total

68

68

68

Geometric
Mean Titer:

57.0

8.2

136. 1

1

---

-

5/1,/77

Table 5
â€¢

t

Distri bu t io n of Post -Vaccination
Antibody Titers Among Child r en
Who Were Initially
Seronegative
t o Rubella and Who Received a 0 .5 ml Dose
of Live At tenuat ed Rubella (RA 27/3) Virus Vaccine , Lot No. 579/C - D418 (Study 0443)

Rubella

(III)

Post-Vaccination
Titer

No. of
Children

<8

.

8
16

..

l

32

4

64

10

128

21
,

256

20

-)512

11

Total

67

Geometric

Mean Ti t er:

'

b59.l

5/5/77

Table . 6
Maximum Temperatures Reported Among Children Who Received a 0.5 Nl Dose of Combined
Live Measles - Mumps- Rubella (RA 27 /3) Virus Vaccine, Lot No. 621/C - D763 (St udy 1/4!,3)

MaximumTemperature
(Â°F, Oral)
(99
99 _. 100.9
101 - Â· 102.9

0-4

Total Vaccin ee s (102 Children)
Days Post - Vaccination
No. with
5-12
13-18
19- 28
29-4 2 Max. Temp.

In itially
Seroneg~tive to:
Measles, Mumps, and Rubell a (68 Child ren)
Days Post-Vaccin3tion
No. I.Ji\. â€¢â€¢ 0- 4
5-12
13- 18
J 9- 28
29-42 Hax. Temp.

53
(60.9%)

52
(59 .1)

60
(71.4)

55
(65.5)

32

40
(63.5)

39
(61.9)

52
(83.9)

43
(70. 5)

41
(68. 3)

23

(83.5)

26
(30.0)

22
(25 . 0)

12
(14 .1 )

15
(17.9)

20
(23.8)

31

18
(28 . 6)

14

8
(12.9)

10
(16.4)

14
(23.3)

23

(22. 2)

7

13
(14.8)

1

21

(8.3)

9
(14.3)

1Â·
(1.6)

4
(6.6)

4
(6. 7)

14

(1. 2)

5
(5.9)

7

(8.0)
1
(1.1)

1
(1.1)

3
(3.6)

2
(2.4)

1

1
(1.6)

3
(4 . 9)

1
(1 . 7)

4

71

.

5

(7.9)

~

103 - 104.9

1

(1.2)

1
(1. 2)

105.0
Not Taken

15

14

17

(1.6)

1
(1.6)

1
1a Â·

18

6

11

5

5

6

7

1
8

3

I

5/5/77

,

Table

7

High Temperatures Reported Amons Children Who Received a 0. 5 Ml Dose of Combined
Live Measles - Mumps- Rubella (RA 27/3) Virus Vaccine, Lot No. 621/C - D763 (Study 0443)

Vaccinee
No.

76")(6)

Temperat ure
(Â°F, Orn 1}

Days

102.2
102.0
104 . 0
105.0
104 .0
102.0
103.0
102.0
102.0
102.0
102.0
102 .0
102.0
102 .0
102.0
103.0
102.0
103.0

5

I

'

I

103 . 0
102.0
103.0
102.7
102 . 0
103.0
103.5

2, 5
17
23
24
25
27, 32
33
32
10
9

35-36
2

7
10
7
8

28
4
0
20-21
33
3- 4
24
38- 42

Mensles
Pre
Post

Serolo&v
M11mos
Pre
Post

Pre

Pos t
--Â·-

None Repo rted (llad Measles -Li ke ~sh nays 7-10}
URI
URI, Otitis.
Ophthal mopathy, Anorexia, Allergic Rash
URI
URI
URI
Teething
Teething

<5
(5

160
20

<2
(2

4
4

<8
<8

64
256

Anorexia
None Reported
Gastrointestinal
Illnes s
URI, Irritability.
URI
URI
Rash on nay 12)
None Reported (Developed Heasles-Like
URI, Lymphadenopathy, Anorexia
Illness
URI, Otitis , Ophthalmopa t hy, Gastrointestinal
Illness
URI, Otit is, Ophthalmopathy, Gastrointestinal
URI, Otitis,
Ophthalmopathy. Lymphadenopathy, NonSpecific Rash on Ams , Legs, Face
URt, Gastrointestinal
Illness
URl , ;,11->rexia
Herpes Stomatitis.
Anorexia
URI
URI
Illness
Gastrointestinal
Allergic Rash

(5
(5
(5
(5
(5
<5
(5
<5

'40
40
20
160
<5
80
40
80

<2
(2
(2

B

16
<B

128

-)8(2 )8
(2

4
16
)128
2
8
8
4

(5

80

(2

QNS

QNS

QIIS

<S

80
40
<5
80
80
NS

Clinical

Complaints

(5
(5

<S
(5
NS

-)8

Rubel la

(8

<B
)32
<8

-

64
512
256
)2

128

(8

l 28

<S

256

4

(8

128

QNS

<8

8

->8
->1288
(2

<B
(8
(8
<8
<8
NS

512
256
256
128
256
NS

(2
(2
<2
NS

8
8

32

NS

'

5/6/77

Tab le 8
Maximum Temperatur es Reported hmonr, Child r en 1./
ho Rec eive d a 0. 5 Ml Do!le o f
Live ht t enu a t ed Rubella ( RA 27/3 ) Viru s Vacc i ne , Lo t No. 579/C-n 4J8 ( Study 0443)

Maxim um Ternperature
( Â° F. Oral)

<99
99 - 100,9
101 - 102.9

To tal Vaccine es (89 Child re n)
Davs Pos t- Vaccina t ion

37
(77 .1)

26
21

40

38
(6 6 .7)

37
(66 .1)

40
(7 8 .4)

37
(74 .0)

25

16
(2 8 .1)

14
(25 . 0)

9
(17 . 6)

8

10

(1 6.0 )

(2 0 .8)

3
(5 â€¢.3)

4
(7.1)

1
(2 .O)

3
( 6 . 0)

(2.1)

1

1
(2.0)

(2. 0)

19
(24. 7)

17
(22 . 4)

11

(15.5)

8
(11. 4)

(14. 7)

4
(5.2)

(6.6)

2
(2.8)

{7. 1)

105,0

Max. Temp.

57

57

(8 0 .3)

L

29- f,2

(83 . 8)

5]
(69 . 7)

. (1. 4 )

)9 - 28

55

54
(70.0%)

1

13-18-

(78.6)

13-1 8

(1.3)

5-1 2

No, wi th
Hax . Temp.

5-12

103 - 104 . 9

No. 1J l t h

0- 4

29- 42

0-4

5

In i t ially Se r oner,a ti ve t o :
Rubel la (6 7 Chl l d r cn )
Days Post - Vaccinat i on

19-2 8

5

10
1
(1.5)

10

1
( 1. 4)

J

1

1.

(1. 8)

12

13

18

19

21

10

8

1

J

1
(2. 0)

(1.4) Â·

Not Taken

1

10

16

11

17

1
19

8

':,/6/ 77

,

Table

9

High Temperatures
Reported Among Children Who Received a 0.5 Ml Dose oE
Live Attenuated
Rubella (RA 27/3) Virus Vaccine, Lot No. 579/C - D418 (Study (JL,43)

Vaccince
No.

Tempcrnture
(Â°F, Oral)

Days

102.2

7- 8

None Reported

102.0

23

Upper Respiratory

Illness

102.0

36

Upper Respiratory

Illness,

102.0

6

Upper Respiratory

I]]ness

105.0

24

Pneumonia

102 .1

9

Upper Respiratory

102.0

18

None Reported

102.0

27

None Reported

103.0

18

Gastrointestinal

Illness,

104.0

27

Upper Respiratory

103.0

12

Upper Respiratory

Clinical

Serology
Pre
Post

Complaints

---

(b} (6)

- ----

<8

128

(8

64

(8

128

(8

128

<8

64

->32

-)1021,

<R

-)1024

Illness

<8

512

Illness

(8

256

Otitis,

J.ymphndenopathy,

I]lness

Anorexia

Â·

Hyalgia

5/5/77

TabL

_Q

Cl In! en I Cn ,.p In Intâ€¢ Rrpnrc ,â€¢,I i\<1011i: Ch 11,l rcn 111,o Re eel vc,J n O, 5 )II o, sc- of co,.hl n,â€¢J
LI vc lfoa s lcs-Huc,r~ -R obtâ€¢ l la (RA 27 / J) VI rns VJ cc I nc, Lot !lo, 62 1/C - D76) (SI udy H4 ))

J..------------

I

--.--------~-------------,---------:-l
-

;------Soreness

r--

Co - p l ain t

Clinical

- - - - - -;r- a t Injection

Site

4

, Mc,nlcs-Llke

Rash

7

l

(4.2%)
Ly,,,phadcnopathy

n-1:--t--;l-3
, '""ly---:;S,--e-r
o- n-,â€¢-~-â€¢-t'""l,
-â€¢c-t_n_:_

-=-Toral V,cclncc~
(102 Chtldrcn
.-c---:--:-l---'-'~
D:avs Po.r.t- V;icclri: 1tfo-;; - -~:o.. uit h
0---'------l-'--~
4
5-12
13 - 18
19-is - 19-=-i;yCo;;ip:ai nt
--

5

(LO)
)

2

2

().1)

(2.1)

{2.1)

l
(LO)

9

6

(9.4)

(6.2)

l
(l .O)

l
(LO)

l
(LO)

I

Hy.,l;;ta

2

(3.0)

2
(2.1)

Art~nlgla

6

l

1
( l..S)

(l..S)

ll

Tr rltabl

Headache

Otltls

Ophth al=pathy
Castrolntes

tl nal

Illness

Anorexia

7

.S

I

(10.4)

(7, S)

{l..S)

l
(l..S)

(1.5)

l
(l â€¢ .S)

(l..S)

l

J

3

1

1

l

(1.0)

{}.Q)

(1.0)

(1.0)

(l.O)

2
(2 .1)

(2. 1)

)8
(39.6)

37

24

35

32

(38.S)

(25.0)

(36 . S)

(JJ.J)

l
(l.O)

7

2

(7.J)

{2.1)

5
(5 .2)

(4.2)

2

4

2

4

2

3

2

4

().1)

(2.1)

(4.2)

2
{2.1)

6

{2.1)

18
{18.7)

24
(25.0)

9
(9.4)

17
(17.7)

15
(15.6)

4)

ll
(13 . .S)

19
(19.8)

8
(8.3)

10
(10.4)

13
(JJ â€¢ .S)

28

2
(2.9)

2
{J.0)

2
(J.0)

28
(41.8)

27
(40 . 3)

(29.R)

25
01.J)

l
(1.5)

4
(6.0)

2
{3.0)

20

4
(4.2)

Allugy,

Asthma

fever

Sudoccslâ€¢

4

(4.2)

4
(4.2 )

.S
(S.2)

12

2
(2.1)

3

6

(l.l)

2
(2.1)

l
(1.0)

l

2

3

(2.1)

0.1)

l
(l.O)

l
(1.0)

)

i:c=;,tlvc

-+--~ .s=o
----=-.s

--+--'So Co::n:,1~.!nts:

Phvslctan

SurveJlla

nce

J
().0)

l
(l.O)

c---1--..,.~,.3--t-......,., J,,..,
-~--,""

(.S_2,.C.-"-l'-)-l--'-'(5c.,2
'""
.~l)c.....~() 4 .4)
46
46
6 )-

(47.9)
6

3

2

(4.5)

(3.0)

9

J

2

4

2

(4 .5)

(J.0)

(6.0)

().0)

14

19

9

1~

11

(20.9)

(28.4)

(1).4)

(20.9)

(16.4)

10
(14.9)

12
(11.9)

6
(9.0)

9
(1).4)

11
(J6 .4)

6

JS
20

J
(4. S)

4

1

(6.0)

(LS)

9

l

2

l

(1.5)

().0)

( 1 â€¢ .S)

l

l

(l..S)

(1..S)

2

l
(l..S)

o.o>
r <>rs on â€¢ v I th COlllpla In t-a-:- -

46

2

4

l
(1.0)

r::----,-,-~--,--~,-Pi,rsonâ€¢ Ylth

20
{29 .8 )

1
(l.S)

l
(1.0)

(1.0)

)

() .0)

l
Diape r , Hcat,

1

2
(2.9)

(1.0 )
lle r ~eâ€¢

9

l
(1..S)

r,utgue
P..,~h-C h:, flng,

2
() .0)

l

1
11 ty

2
().0)

(1.5)

(l._O)

!

-----,

"~"c.:â€¢'--::Â·J,=-,â€¢.::.s.L.:l~â€¢"'""
and Ru!>c_lJ..:!..J~S ChJ_!_tlr_,.
_rt_l__ _ _.
D:,vs P\, st - \';ic c in :Hfrâ€¢n
S,, . 1,,
Â·!(h
0 -4
5.:Â·f2 I 13-18 , 19:211-pf.42- â€¢ Ct-i:,phlnt

(H.9)
6

(65 .6)
6

( 1.4.8)

~.s Â·J(5.S.2)
6

6

)

I

,----=

7=s---l

(45.8)
- f2â€¢~-+--c-1-=-8--1
{54.2)
6
6

l

f--~)~8--+-~J-=-s--+--2"'9--+-

- -J1

.U.~-l2_~6.

(43.))

(47.8)

(44.11\

(56.7)
l

(52.~)
J

i C>.S.2)

2?
(43.3)
l

I

o . .s> I (4.o ;

(4 ,4 )

7)

I

2Â·9Â·--'---,
1c'-)~8:-=- +:-,-n=-- -

(tl.

l

l)
I

-Â·Â·Â·Â·-,___
_____-- Â·- Â· -- Â·- - -

3,1

6

I
I

- Jf - .--=9--j
J

5/6/77

,

Table 11
Clt nlc al Co1tpJ,:,h 1t!I Rern rtr d A..of'I& rh 1 l d r en Vho lll"c.- tvcJ a O.S HI Do-sr of
Liv e Att enu 3t ed lul,~ llo (KA 21/}) Virus Vau lne, Lo t 1;0. 579 /c-o qa (S t udy '40)

Cl!nkal

Total

COO!plaint
0-4

Sortne,a

at l njectio

n Site

S- 12

IJ -1 8- -197fa

1
(I. 2)

Illnuâ– 

Uppe r Ruptntory
Low r bs pi ratory

â€¢

l
(1.2)

l
(l. 2)

]

l

().6)

(1. 2)

]

2

2
(2 . 4)

(2. 4)

]0

2)

(3 6 . I)

(?7. 7)

s

1.

Ca,t roi ntaati nal

tllnâ€¢â€¢â€¢

Anorex.1a

13
(ls. 7)

14
(16. 9)

2
(2.4)

s
6

IS
(1 8. 1)

llut

Aâ– tbu

s
(6.0)

l
(I. 2)

l
(1. 2)

3
(l.6)

2
(2 . 4)

l
(1. 2)

4

12
(U. S)

4
(4 . 11)

9
(I 0.8)

10
(12 .0 )

â€¢ JO

(l].

8

1

6

(9.6)

(B.4)

(7. 2)

s

16

ll

3)

l
(1 . 6)

10

(6. 0)

l
(1.6)

3

2
(l.2)

s

I
(1 . 6)

2
().2)

24
( 38. l)

18
(28 . 6)

9
(14 . ])

s

12
( 19 . 0)

12
(19 .0 )

l
( 1. 6)

1

s

4
(6. 3)

1
(1.6)

1
(1.6)

(7 . 9)

1
(1.6)

I
(l.6)

2

I
(l.6)

l
(l .6)

3

(l.2)

ll
(17 . S)

9
(14. ))

4
(6 .])

1

25

(II.

9
(14. ])

1
(11.1)

(9.5)

1

6

1

1)

CU . I)

.'i
(7. 9)

4
( 6 . ))

1
(l.6)

l

2

2

)

0 ,4J

H,2>

0,4)

1
(1.2)

l
( l,6)

s

s

(1. 9 )

(7 . 9)

1

2
(J . 2)

(1 , 6'

6
(9 . 5)

4

1
(1 . 2)

l

l
(I. 2)

(l. 2)

29
()4 .9)

Si.~

(65. l)
6

)I

1
(1.2)

2

2
0.21

2

l
(1.6)

1

U,6)

1
I
(1.6)

l
(1.6 )

l

l
(1. 6)

(l .6)

31

07. ]) (37.))
-f2-- -52
( 62. 7)
6

l
(l.6)

r--,

65

]9
' (61 .9)

18

(62.1)

24
()8.1)

6

4

)0
(47.6)

74

w-- Jll!]9:lL

(S2.4)
4

I c,1.9)
4

27
j_g.9 )
)6(57 . I)
4

'

(6.3)

J

1

2

I]

13

(1. 6)

1

9

l

1

1

(1.2)

37

(I. 6)

2

J7
( 44,6)
46
(SS.4)
6

1
(1. 6)

]

8
02 ._7)

so

l

(4 .8)

IS

(2. 4)

)

I
(L6)

I
(1.6)

4
(4.8)

11tu

I
(l . 6 )

l

l
(1. 2)

1
(1.6)

]

3
(4 . 8)

7
(8 .4)

(60. 2)
Per.sctns \olltth Xo Cosnpl.1.l nta :
)J
() 9 . 8)
N'-â€¢,t,1t 1ve Phy s. IC'tan Surve 11 lonce:
6

No. with
Co:i_e_l.1Snt

I
(1.6)

1
(1.6)

6
(7 .2)

l
(1.2)

1
(1.6)

l

6
(7. 2)

.

Complaintâ€¢:

2

10
(1 2 . O)

TottMnc

vlth

1
(1 .6)

l

l
(1. 2)

Kooquito

45

I
(1.2)

Depr~u ioo

Persons

]

l
(l. 2)

Fever

lwpettio,

1
(1.2)

l
(1.2)
Olapar,

l ~-28 .,__
29- 42

(I .6)

(6.0)

12
(14 .S)

11.uh-Ch afl~&,

l

( 1. 2)

Fatlgue

Allucy,

l
( I. 2)

l
(1.2)

Opb t balmopa thy

13- 18

6

() . 2)

1

Illnua

Ot1ll9

3

(I. 2)

l
(1.2)

(l . 6)

s-12

6

)

1

Headache.

J
(1.2)

l
(1 . 2)

(1. 2)

I rr lubtlltJ

D.l_y'I Po~t-V:s cct n;at 1on

0-4

(9.S)

2
(2 .4)

Hyâ€¢l1la

~o. vl th
Co:;o l â€¢lnt
7

1
(1. 2)

Art hral &la

29-42

7

Ruh

l n t t l .11ly Seron<'~::it tv ~ to:
lt,~hc l \., (6J Cht 1Jrrn)

( 89 Child r en )

ca.4:)

l )'llphdenop ot hy

lube Ila-Like

V,cct nc cs

D.,ys Pos t-V .:icct n.at lon

1

2

( 1. 6)
2

26
(41.))

Sl

-)7

10

(SB. 7)
4

S/6/77

4

â€¢

=:: â€¢ J../:.,

CLINICAL SUM/\,\ARY

S~dy Nome

Combined live Measles-Mumps-Rube
Rubella (RA 27/3) Virus Vacc ine

-

S::.!=YNumber

-

Cli nkol

Protocol

- 443

,'.' .:J terio I

-

M-N,-R Lot #621/C-D763
Rube Ila Lot #579/C-0418

l:':ifi:ited

-

October

Co:npleted

-

lie (RA 27 - 3) Virus Vaccine end Live

28, 1975

Ja nuary 20, 1977

t.'~di cal Opinion
Fer 15 months 194 children (ages 10 months to 8 years) from the open population were enrolled in
this study at Children's Hospital of Philadelphia,
Philadelphia,
Pennsy lvania; Darby Health Clinic,
C:iroy, Pennsylvania; and Dr. G. Starkweather's office, Havertown, Penmylvania.
Informed consent
wos obtained from the parent for each child and a blood sample was obtained from 184 children
initially and approximately 6 weeks later . All vaccine was given subcutaneously in the arm. One
h:..:-icred and hvo child re n (mean 1.7 years} received 0.5 ml. M-M-R; 3 (mean 2.7 years} received
1.0 ml . M - M- R; and 89 children (mean 1. 9 years) received 0.5 ml. rubella vaccine.
All but 12
p::~ents returned report cords with doily temperatures and clinical observations for 42 d:::iysfollowing
c=::iinistiation of the vaccine.
Parent s were instructed to report high fevers and rash by telephone to
R. E. W. and on follow-up were queired -on recorded observations for greater detail.
1

,:-:,orig susceptible and immune vaccinees te mpera t ure elevations were scattered randomly th roughout
tf-.: cSservotion period with no greater association with either vaccine.
Most temperature elevations
p~cSobly reflect unrelated infection occurring among the voccinees at various time periods.
Upper
res?iratory and gastrointestinal
in fections were reported in about 55% and 40% of voccinees respecti ve ly . Temperatur es were not record e d on approximately
10% of the vaccinees.
A faint measleslik: rash occurred in 9 triple susceptible children receiving M-M-R and 3 ausceptibles receiving rubella
vcccine alone.
Mild transient orthrolgio was reported by the parent but not observed by a medical
p-=;5on in one M-M-R susceptible voccinee, age 12 months, on day 17-20 (4 days); and one rubella
sus::eptible voccinee age 5 years on day one and 30 (2 days). N o arthritis or adverse clinical reaction
wc,. reported.

Of 68 children initially susceptible to measles-mumps-rubella
receiving 0.5 ml. M-M-R vaccine 94%,
96~~, and 100% respectively,
res ponded serologically with geometric mean titers as follows: measles
(HI) 57.0; mumps (neut.) 8.2; and rubella (HI} 136 .1. All 67 rubella susceptible vaccinees responded
serologically with a geometric mean hemagglu ti notion titer equal to or greater than 159.1. Of the
three children receiving 1.0 ml. M-M-R, all susce ptibles responded, howe ver, one was initially
i~::-:u,"le to M-M-R and one to mumps.
Ser~.::onv ersion of susceptible children to rube Ila vaccine alone or in combined M-M-R was 100%
wit:i comparable hemog g lutinot ion inhibiting geometric mean titers.
Seroconversion rotes and geometric
rr.ec:i titers to measles and mumps vaccine following M- M-R (RA 27/3) ore similar to th ose following
M-i'-, ',-R (HPV-77) reported in earlier studies . live RA 27 /3 rube I la virus vaccine alone or combined
h live measles and li ve mumps virus vaccine induced measureable antibodies in all rubella susceptible
vccdnees with no significant clinical reacti on .
.-

r,
' -)

,,

RE\'.':ceb

;-

Â·l â€¢-

~

i ff"J /

cLâœ“

I

~

;

,-

(

-i- ---,,-â€¢â€¢

. .

~ -âœ“ -Â· .,

r-Â·

Robert E. \Vei bel,

â€¢
(_.

,.

.. .

.,_

Â·â€¢ --~â€¢ Â· I, . - __
1

/.~.D.

Â·_ Â·- Â·Â· Â·Â·-Â·

- Â· .!::.'..

""Â·Â·- .

..,, â€¢

Â·~ . ,

MEMO
To File
From T . Schofie l d
Subject

Statistical

Date 2/2/78

Location
Location

Analysis

- Study /1443

Analysis of variance was conducted on post titers
of children
who
were initially
seronegative
to rubella
who received rubella vaccine,
lot 11579 (Group 1), and combined measles-mumps - rubella vaccine,
lot
(Group 2) .
No significant
difference
mean titers
were :

exists

between

Vaccine

GMT

Rubella

159 . 1
130 . 9

MMR

There is no significant
two groups.

difference

these

two groups .

in conversion

rate

#621

Geometric

among these

T. S.

- .,,

~ '; _;J,,C;; -

~ ""'Â·Â·-

.

.Â·.- ..

- Â·Â·- -', â€¢" . -- : ~ .
_,

..-:_:Â·Â·
. ...
. ..,

â€¢Â·' Â· , .

- - _...., . , .. ...:.
Â·Â·.:::
;:- .~.;:

..

.: â€¢

.-,-'
..-~Â·Â·::
'.--~'.:,:~~~~
: -~;:_:;
;- ~~;<~,~

.:,..,::Â·' .;:_-:
:â€¢:.Â·Â·â€¢.~:
.-j..

-Â·.â€¢-

.
.
~.
.
. --Â·.
-...~~~~~~~~f'~~~~..?~Â·
-Â·:~-~::7~~;~*
Â·~:.:~~~:
...
:Â·.:~~~Â·:,.Â±~:.~ct
.~::
~â€¢~~~
--{,:- . Â·--Â·..: --Â·Â· ...
..

_

â€¢;,â€¢

.

....

'

~~-

.

..Â·

SYMPTOM nEcono
RUOELLA Study No. ____
_ _ _ _

LO'S NAME -------

----

CUIIJ

0
OAY

DATE

--

CMlddle J

CFlrtlJ

- ---

0

CI

COMMENTS

> ..

w

z

w

:,

O

z z

(CMck One/

_

~

z :z:

0 Oral

CASE NO. _____

..

w
"'
0

Rectal

--------------

0

er

Z

1,,
"\

0
2

I

3

I

I

A

I

5

I I
I I

I

6

I

7

j

8

I
i

10

I

11

I
I

12

I
I I
I

9

I

I

I

I

I

I

I

I

I

I I

I

I I

I

I

I
I

I

I

I

13

I

I

14

I I

!

18

I

19

I

I

I

I

I

I
I

20
22

'

..

I

-

I_J

I

I

I

I

I

. 21 Â·
23

I

Â·--r-, . I I

I

i

I

I

:5 ;

I
I
I

I

I

I
j

I

r

..

I

I

i. I

IÂ·.

I

I f Â·I I
I

I

!

! I

.i

I

I

I

I

..

,.

I

24
I

25

25
27
28 I

I

I

I

I

29
30
31

32
33
34

35
3o

37

3tl
39

40

--

,..

Câ€¢â€¢Ue-i14UI

fâ€¢ltU

â€¢OlHJlt

-

,. .. ., . -Â· .

-..â€¢

with co~bination vaccines.
,..

INFOR:â€¢!ATIO:IAilD co;1srnr FORM: Attached

REACTI
O~lREPORTiilG
FORiÂ·1:Attached

Ste phen J. Lerman, M.D.
Director - Pediatric Infectious Disease Unit
University of Nebraska Medical Center
11/30/76

.. .

~

_,
THE

UN,

_RSITY

OF NEBRASKA

42ND AND DEWEY
OMAHA,
NEBRASKA

MEDICAL

CL

. TER

AVENUE
681 OS

~ri Â·;Â·MENT OF PEDIATRICS
Gl en, . ~ - R vse nquist, M.D.
40 2:s4 1.4e -l 1
Ch;"tirmt1n

William fl. Brown
40 2/54 1-4,!42
Adm in istr ator
CARDIOLOGY
402 / 541-4741, 4 742 o r 4166
Paul K. Moor ing, M.D ., Director
Glenn C. Rosenquist, M.D.
Philip J . Hofschire, M.D.
Edward B. Clark, M,D.
Rog~r N. Ruckman, M.D .
Taney Jahn. P,.N .â€¢ Nu rse A~octate
CYSTIC FI BRO SIS
402 / 54 1 âž”1 1 ti',
Gmd un E.cibbs, M.D .. Ph .D .
DENTISTR Y
402 / 541- 73~4
John F. S imo n, 0.0.S .. D ir<lctor
l.~u ssal M~ ner . D-;O.S.
Curti~ G. Ku,w ,Â·. 0.0.S .
DEVELCF' Ml'fll'AL PEDlATF II CS
40 2/54 1-7706
f>aul H . Pearson , M.D., Dire ctor
E. Jack Trembath, M.B., B.S.
Donald Wuori, M,O.
ENDOCRI NO LOGY
402 / 541 â€¢7335
Carol A . Huseman, M.O.
FAMILY SERVICE SECTION
4 02/541 -4835
Lou ise F . Eaton, M.D.
D irecto r , Psychiatry
Je;il Kittell, ACSW, Social Worker
,n Lothrop
hild Lile Coordinator
GASTROENTEROLOGY
402/ 541 -73~8
Jon A. Vanderhoof, M.D .
GENERAL ANO AMBULATC,RY
PEDIATRICS
402/541 Â·7346
Marl( B. Horton, M.O., Dirt:ctor
402 /541-4208
Peter W. Bickers , M.D.
Samuel Perry, M.O.
Bonnie Shearer. P.A .
HEMATOLOGY & ONCOLOGY
402 / 541 Â· 7349
Rashid Al -Rashid, M.O.
HUMAN GENETICS
402 / 541 Â·4570
James Eisen, Ph.D. , Oirect1,r
Warren G . Sanger, Ph.D.
INFECTIOUS DISEASE
402 /54 1â€¢ 7336
Stephen J . Lerman, M.D.

April 11, 1978

To:

Measles- Mumps-RubellaVaccine Study Participants

From:

Jan Brunken RN
Pediatric Infectiou s Disease Unit

Subject:

March M-M-R Vaccine Study Progress Report
Here is the current brea kdownof the numbers of
children participating in the study to date
(March 31):
Entered
Zah11er
9
Nelson/Rice
2
Wax/McAveney
13
Ellison/Glow/Oberst
2
Maragos
0
Pott. Co. Immun. Clinic 19
Offutt AFB
147
UNMC
Pediatric Clinic
53
Cogley Clinic
11
UNMC-South
OmahaClinic
0
UNMC-5
North
1
Total

METABOLISM
402 /54 1-7350

Com~leted
9
2
13
2
0

18

97
36

...
I
0

1

257

185

Our goal for the month of April is to pass the
halfway mark of 275 children enrolled in the
study!

Hobart E . Wiltse , M.D., Ph.D.

NEONATOLOGY
402 / 541 -7340
Yoshlo Miyazaki, M.D., D irector
David L. Bolam, 1111.D.
Charles L. Pa x 5on, M.D.

NEPHRO LOGY
402/5 41 â€¢7339
Carol R. Angle , NI.D .

NEUROLOGY
40 2/~4 1 -4084
1rd Pellegrino, M.D.
Kade1Â·. M.D.
PSYCHOLOGY SECTION
4102/ 541-7 608
J. Michael Leibowitz. Ph.D.
Director
40 2/5 4 1-488 6
lee M~t the ws, Ph .D.
Susan Ogborn, M.S .
T HE

UNIVERSI

TY

OF NEBRASKA

-L

INCOLN

THE

UNIVERS

I TY

OF NF:Rl'?A!';KA

AT

OMAHA

Reference

3

Program:

Study //459 - To evaluate
and compare clinical
responses
to two combined measles-mumps-rubella
and component vaccines of these .

and immunological
virus vaccines

Vaccine:

Combined live measles - mumps-rubella
(RA 27/3) virus vaccine
Lot #60664/C-EBlO
Combined live measles-mumps-rubella
(HPV-77) virus vaccine
M-M-R
Live attenuated
RA 27/3 r ubella virus vaccine
Lot #60151/C - E665
Live attenuated
HPV-77 + 5 duck embryo cell passages rubella
vi r us vaccine

MEROVAX
Live measles virus vaccine
ATTENUVAX
Live mumps virus vaccine
MITMPSVAX
Rubella placebo
Responsible

Clinical

Investigator:

Stephen J. Lerman, M.D.
Assistant
Professor
of Pediatrics
and Medical Microbiology
Director,
Pediatric
Infectious
Disease
42nd Street and Dewey Avenue
Omaha, Nebraska
68105

Unit

Study Locations:
F. Marshall Zahller,
M.D., Omaha, Nebraska
Larry Rice , M.D. , Paul J. Nelson, M.D. , Omaha, Nebraska
James I . Wax, M.D. , Omaha, Nebraska
Joseph R. Ellison,
M.D., Omaha, Nebraska
George D. Maragos, M.D., Omaha, Nebraska
Mark B. Horton, M.D. , Outpatient
Clinic,
University
of
Nebraska Medical Center, Omaha, Nebraska
Colonel James Hart, M.D., Burt Culpepper, M.D., Offutt Air
Force Base, Omaha, Nebraska
William J. McAveney, M.D. , Omaha, Nebraska
Donald T. Glow , M. D., Byron B. Oberst, M.D., Omaha
Children's
Clinic,
Omaha, Nebraska
Yuksel Inankur, M.D., Izzat Jabro , M. D., Dennis Jones, M.D. ,
C. Edwards, M.D., Jim Mulry, M.D., Anthony Romano, M.D.,
Cogley Clinic,
Council Bluffs,
Iowa
Pottawattamie
County Immunization Clinic,
Lee Martin Therapy
Center, Council Bluffs,
Iowa
Date Study Initiated:

May 31, 1977

Date Study Completed:

In Progress

Page 2
Study Procedure:
To date, 257 children
have entered the study . Each received
a O. 5 ml subcutaneous
dose of "one of the vaccines . Blood
samples were obtained on the day of vaccination
and 6
weeks after vaccination,
at which time each child received
vaccine with those components not in the initial
injection
.
Each child was followed 6 weeks for clinical
complaints .

.

,.

..â€¢ .

COMPARISON
OF MEASLES- MUMPS- RUBELLA(HPV-77:DE-5 and RA27/3)

'

VACCINESIN YOUNGCHILDREN
PURPOSE

This study wi ll compare antibody and clinical

to live,

responses in young children

attenuated measles, mumps, and rubella vaccines, given singly

and together,

utilizing

either HPV
-7 7:DE-5 or RA27/3 as the rubella components.
I

I.
BACKGRO!Ji/0

HPV-77:DE-5rubella vaccine was licensed in 1969 and is the most widelyused rubella vaccine in the United States.

Although HPV
-77: DE-5 vaccinees

appear to be protected against viremia and fetal
vaccine has been criticized

infection,

because up to 80% of vaccinees may experi ence

asymptomatic re-infect ion (antibody titer

on exposure to wild rubella virus.

boost and pharyngeal virus excreti on)

In comparison with natural rubella infection

the seru m antibody re sponse to HPV-77:DE-5 is quantatively
diminis hed, and secre to ry antibody is lacking.
.been proposed as a better

HPV-77:DE-5

and qualit ative ly

RA 27/3 rubella

vaccine has

immunizing agent because the serum and secretory

antibody responses more closely resemble natural rubella infection,
because the rate of asymptomatic re-infection

on exposure to wild rubella

virus is almost as low as that seen in naturally

immunesubjects.

RA 27/3 rubella vaccine, grown in human tissue culture,
problem of allergy to foreign protein.

and

In addition,

should obviate any

Both rubella vaccines have shown.

similar age-dependent rates of arthralgia

and arthritis.

VACCINES

Vaccines will be supplied in single-dose,

coded vials by Merck Sharp & Dahme.

.

Measles (Attenuvax), mumps(Mumpsvax), rub ell a (Meruvax), and the combination

Â·-~---'--

of the three (M-M-R)are lic ensed products.

RA27/3 rubella virus was

originally

lab~ratoryÂ·~rom the third

isolated

in Dr. Stanley Plotkin's

-2-

explant of the 27th fetus aborted because of rubella infection
1964 epidemic.
fibroblast

It has been attenuated by

(bH4)

â€¢,

during the

in WI-38 human ~iploid

tissue culture .

The lot of vaccine to be used has been fully tested for potency and safety
at the Merck Sharp &DohmeResearch Laboratories .

given subcutaneously.
until used.

Vaccine dose is 0.5 ml.

Dried vaccine should be stored at -20 Â° C (freezer)

Reconstituted vaccine should b~ kept at 4Â° C (refrigerat or), and

unused rehydrat ed vaccine should be discarded after four hours.
STUDY
POPULATION
Children one through four years of age who have a negative Â· history of measles,
mumps, and rubell a, both disease and vaccination,

will be recruited by their

pri vate or cl i nic physici an at the time they are due to receive these vaccinations.
CAUTION

Any ch_ild in the fo1l01Â·1ing_ qitegories

should no~ b~ vaccinated,

Â· 1.

Kno'tmsensitivity to chicken or Â·duck, _chicken or duck eggs
or feathers, or to neomycin.

2.

leukemia or other malignancies, immunologic disorders,
immunosuppressive or steroid therapy.

3.

Current febrile i l lness. (Chil dren with non-feSrile upper
respiratory infection may be vaccinated).

..

STUDY
PROCEDURE
After informed consent has been obtained, an 8- 10 cc blood sample will be
drawn and children wil l be randomly assigned toÂ· receive one of the following :
Vaccine

No. of Chi1 dren

Measles-Mumps-HPV-77:DE-5
Rubella

150

Measles-Mumps-RA
27/3 Rubella

150

Measles

Â·Â·50

Mumps

50

-J-

Vaccine

No. of Children

HPV
- 77:DE-5 Rubella

50

RA 27/3 Rubella

50

Placebo

50

Total

550

The parent 1â€¢1ill be given a reaction reporting

for.n and a thern:ometer and \.Jill

be instructed

in ta king temperatures.

They will be asked to take daily

te mperatures

and record all symptomswhich occur during th e folloo,,ling six

weeks.
Six weeks af ter vaccination,
blood sample.

children wil l return for a second 8-10 cc .

At this time, reaction re porting forms will be reviewed with

the parent and coll ected . All children will then receive the st andard
measles, mumps, and rubella vaccine to assure immunization for all t hree
diseases .

SEROL
OGICSTUDIES

.

Particip ating physicians will refrigerate

blood samplesÂ· which ~ill be .

picked up by messenger three ti mes a week.

Serum will be separated,

aliquot sent to Merck Sharp & Dahmefor ru bella preciptin

antibody testing

and the remainder retained f or rubella and measles hemag1lutination
antibody and mumpsneutralization

antibody testing

with an

inhibition

in the University of

Nebraska Medical Center Virus Laboratory of Or. Roberta Hhite.

DATAtlALYSIS
Wewil l compare symptoms (e.g. rash, f~ver, arthra l gia), seroconversion rates
and geometric mean titers

in children who received combination vaccines~

1ndivicua1 component vaccines, or placebo.

Wewill look specifically

evidence of either enhanced reactogenicity

or diminished serologic

for
responsiveness

Table

1

Seroconversions
and Geometric Mean Titers
for Children
Who Were Initially
Seronegative
Prior to Vaccination
(Study
Measles

Age

Vaccine

#459)

Mumps

Rubella

Range

Mean

No. Conv. /Total

ATTENUVAX

14m - 3y

1.5

6/6

MUMPSVAX

14m - 4y

1.7

RUBELLA(HPV-77)

14m - 2y

1.4

6/7

(95)

RUBELLA(RA 27 /3)

14m - 4y

1.6

11/11

(199)

M-M-R (HPV-77)

14m - 4y

1.5

20/20

(77)

20/20

(14)

20/20

(111)

M- M-R (RA 27/3)

14m - 4y

1.6

13/14

(62)

13/14

(17)

14/14

(269)

(GMT)

No. Conv. /Total

(GMT)

No. Conv. /Total

(GMT)

(90)
11/12

(12)

Statistical
nonparametric
comparison shows no suppression
of post - vaccination
when administered
in combined form with rubella
RA 27/3 or HPV-7 7.

antibody

titer

of any component

4/20/78

Table

2

Completed Serology for Children
Receiving ATTENUVAX,Study #459

Measles HI
Case II

Pre

Post

<5
<5

80

(b) (6)

<S
(5
(5
(5

<S
<S
<S

40
80

160
160
80

4/19/78

Table 3
Completed Serology for Children
Receiving MUMPSVAX,
Study #459

Mumps Neut.
Case II

Pre

Post

(2
(2
(2
(2
(2

(2
)64
4
64

4

8
32
2

(b) (6)

(2
<2
(2
2
(2
(2
(2
(2
(2

16
8
8
16
32
8

16

4/19/78

Table 4
Completed Serology for Children
Receiving Rubella (HPV-77), Study #459

Case II

Rubella

HI

Pre

Post

{b) (6)

(8
(8
(8
(8
(8
(8
<8
(8
<8
<8

>512
128
)512
128
)512
32
)512
(8

4/19/78

Table 5
Completed Serology for Children
Receiving Rubella (RA 27/3), Study #459

Case II

Rubella

HI

Pre

Post

<8
<8
<8
<8
<8
<8
<8
<8
<8
256
<8
<8
<8

128
256
128
Â· 64
)512
64
)512

(b) (6)

)512
>512
256
>512
64

4/20/78

Table 6
Completed Serology for Children
Receiving M-M-R (HPV-77), Study #459
Measles HI
Case II
(0)(6)

Rubella

HI

Pre

Post

Pre

Post

Pre

Post

(5

160

(2

16

(8
(8

256

(2

(5

<5
<5
<5
<5
(5
<5
<5
<5
(5
<5
(5

(5
QNS
<5
QNS
(5
(5
(5
<5
<5
<5
<5
(5
<5
<5
(5
(5
<5
(5
<5
* Toxicity

Mumps Neut.

64
>320
160
80
20
160
40
20
40
160
160
40
80
80
QNS
80
120
80
40
80

160
(2

(2
(2
2
(2
(2
<2
(2
<2
(2
<2
(2
(2
QNS
<2
QNS
(2
<4*
<2
<2
(2

8

(8

4
>64
)64

(8
(8
(8

64
16
32
16
16
4
32
8
QNS
QNS
32
32
16
8

160
40
160
160
40
40

(2
(2
2
QNS
(2
(2
(2
(2
(2

(8
<8
<8
(8
(8
<8
8
(8
<8
(8
(8
<8
(8
<8
(8

64
256
64
256
128
16
64
32
128
64
)512
-256
256
64

<B

<2

80

(8

8
256
64
256
256
64

8

<8

>512

)64

<8

128

4
4
32
32
32

<B
<B
<B
(8
<8
<8
<8

32
64
128
>512
16

at 1:2 level

4/20/78

Table 7
Completed Serology for Children
Receiving M-M-R (RA 27/3), Study 11459

Case ff

Rubella

HI

Post

Pre

Post

16
64
8
(2
4
4
16
32
4
8
16
32
(4*
>64
QNS
32
16
16
8
8
)64
-16
)64
16

(8
(8
(8
(8
<8
(8
(8
<8
256
<8
<8
<8
<8
(8
<8
<8
<8
(8
<8

256
256
256
256
128
128
256
>512
)512
256
256
128
8
)512
256
>512
256
128
>512
-256
>512
>512
-256
256

Measles HI

Mumps Neut .

Pre

Post

Pre

(5

<5
160
20
40
80
20
20
40
160
20
160
80
80
80
QNS
160
160
)320
40
80
80
80
40
40

<2

(bf,(6)

<S
(5
(5

<S
80
<5
<S
(5

<5
<5.
<5
<5
<5
<5
(5
<5
<5
(5
(5
80
<5
(5
<5
<5
QNS
<5
* Toxicity

QNS

(2

8
(2
<2
<2
<2
2
4
QNS
<2
<4*
QNS
<2
(2
(2
<2
<2
<2
<2

QNS
>64
-<2
16
<2
QNS
<2

QNS

<8
32
<8
<8
<8
<8
(8
<8

8

at 1:2 level

4/20/78

Table

8

HaxilftWIITemperatures Reported Among Child ren Who Received Combined
Live Heasles - HU111ps
- Rubella (RA 27/3) Virus Vaccine, Lot l60664/C -E810 (Study 1459)
HaxinJm Temperature
(Â°F. Oral)

(99

Total Vaccinees (41 Children)
Davs Post Vaccination
5-12
13-18
19-28
29- 42

0-4

Ho. with
Hax, Temp.

33
(80.5%)

34
(82.9)

32
(78 . 0)

30
(75 .0)

17

(78. 0)

99 - 100.9

7
(17 .1)

3
(7 . 3)

2
(4. 9)

4
(9.8)

3
(7. 5)

4

101 - 102.9

1
(2.4)

5

3
(7.3)

5

14

(12. 2)

(7. 3)

(12. 5)

1
(2.4)

2
(4. 9)

2
(4. 9)

1
(2 . 5)

32

0-4

Initiallv
Serone2at i ves (16 Children)
Davs Post Vaccination
No. with
5-12
13-18
19-28
29-42 Hax. Temo.

(81. 3)

12
(75 .O)

14
(87 . 5)

10
(62.5)

(86 .7)

3
(18.8)

2
(12.5)

1
(6.3)

3
(18 .8)

1
(6.7)

2

2
(12. 5)

1
(6. 7)

5

13

13

1

'

103 - 104.9

3

Fever - Ho
Temperature Taken

1
(2. 5)

Temperature
Hot Taken

l

Case No.
(b) (6)

Max. Teme,
103.0
103.0
102 .0
102.4
102.2

~

103.0
102.1
102 . 0
103.0

13-17

102.0

39-42

102.3
102.2
102 .6

24
38-39
17-18

102.8

0-4

104.5
103.8

15
22

20-21
36
11-12
24-25
40-41
10-11
11-12

5-12

6

2
(12. 5)
1
(6.3)

Meas lea
Clinical
Comelaint
160
Upper Respiratory
Illness,
Gast rointestinal
Illness
<5
Gastrointestinal
lllnese
Gastrointestinal
Illness
Upper Respiratory
Illness,
Upper Respiratory
Illness,
Nonspecific Rash, Anorexia
Ophthalaopathy,
Anorexia,
<5
20
Upper Respiratory
Illness,
Irritability,
Teething
Upper Respiratory
Illness , Anorexia
(5
80
Upper Respiratory
Illness,
Anorexia
None
<5
20
Upper Respiratory
Illness,
Gastrointestinal
Illness,
<5
80
Anorexia, Measles-Like Rash
Upper Respiratory
Illne s s , Otitis,
Gastrointestinal
Illness
Upper Respiratory
Illness,
Anorexia
80
<5
(5
ONS
Anorexia
Upper Respiratory
Illness,
Gastrointestinal
Illness,
NS
80
Anorexia
Upper Respiratory
Illne ss, Ophthalmopathy, Anorexia,
(5
40
Herpes-Type Rash, Soreness at Inje c tion Site
Otitis
<5
40
Upper Respiratory
Illness,
Gast r ointestinal
ti lness,
Anorexia

1
(6. 3)

2

1

Serology
Hunes
<2
64

<8

8

8

<8

256

Rubella
256

<2

4

(8

128

QNS

8

(8

256

QNS

(4

<8

8

<2
(2
NS

) 64

<8

QNS (8
8

NS

>512
8
256

>64

)64

(8

256

(2

16

(8

256

4/21/78

Table 9
Clinical
Complaints
Live Measles-Mumps - Rubella

Clinical

Complaint

Injection
Site:
Soreness

0-4

Reported
(RA 27/J)

Among Children Who Received r.omhined
Virus Vac cine , Lot #60664/C - EBJO (Study #459)

Total Vaccinees (41 Children)
Davs Post Va cc ination
5-1 2
13-18
19-28
29-42

No. with
Complain t

2

2

(4 . 9%)

Systemic:
Measles-Like

Rash

4
(9.8 )

Irritability
Anorexia

1

3

(2.4)

(7.3)

8

(19.5)
Distur bed Sl eep

2

16
(39.0)

2
(4 .9)

J

Otitis
Ophthalmopa t hy
Gastrointestinal
Nonspecific

111.ness

Rash

6

l
(6. 3)

20

3
(18.8)

(7. 5)

5

8

(U.2)

9

(19.5)

(22.0)

17
(41.5)

7
(17.5)

1
10
(24.4)

2

1

(4 .9)

(2 .4)

16
(40.0)

28

(26.8)
3
(7.3)

3
(7. 5)

8

3
(7. 5}

7

11

1

(6.J}

2
(12 .5)

9
(22 . 0)

9
(22.0)

6
(14.6)

10
(24.4}

9
(22. 5)

24

2

4
(9. 8)

2
(4 . 9)

3
(7 . 3)

3

5

(7 .5)

Varicella

1

5
(31. 3)

2
(12 .5)

6
(37. 5}

7
(46 . 7)

10

1

1
(6. 3)

2
(12. 5}

1

4

(6.7}

3
(18.8)
1

(6 .3)

1

(6 . 3)

2
(12.5)

5
(31.3)

(20.0)

2
(12. 5)

2
(12 .5)

2
(12.5)

1
(6.7)

1

1

)_

1

3

1

1

(7 .3)

2

(2.4)

(2 . 4)

(5 .O}

1

1

Persons

with No Complaint:

Negat i ve Surveillance

18
(43 .9)
23
(56 . 1)

16
(39. 0)
25
(61.0)

3

1

4

l

(6.3)

1
(6.J)

1

1

1

(6.3)

(6 .3)

(6.7)

I

26
(63.4}
15
(36 . 6)

10

l

(6.J)

(2.4)

20
( 48 . 8}
21
(51. 2)

3

(6.3)

1

with Complaint:

6

5
(31.3)

1

(2.4)
Persons

3
(20.0)

1
(6.3)

(2.4}

Herpes - Type Rash

2

1

(2 . 4)

Teething

3
(18 . 8)

l
(6. 7)

1

(6 . 3)

l
(2.4)

Allergy

1

(6 . 3)

3
(7. 3)

(4 . 9)

1
(6.3)

1

Illness

0

5

(4 . 9)

(2.4)
Upper Respiratory

Initially
Ser onega tives (16 Children)
Days Post Vaccination
No. with
0-4
5-12
13-18
19-28
29-42 Complaint

22
(55 .0)
18
(45.0)
l

34
7

1
0

7
(43.8)
9
(56.3)

8
(50.0)

6

8

(37.5)

(50.0)
8
(50.0)

8

10

(50 . 0)

(62 . 5)

9
(60.0)
6
(40. 0)

14

2

l

4/21/78

Reference

No.

4

Program:

Study #467 - To compare antibody and clinical
responses
to
combined live measles-mumps-rubella
virus vaccine containing
the RA 27/3 rubella
virus strain
or th e RPV-77 duck rubella
virus strain.

Vaccine:

Combined live measles-mumps-rubella
Lot /1621/C-0763

(RA 27/3)

virus

vaccine

Combined live

(HPV-77) virus

vaccine

measles-mumps-rubella

M-M-R

Responsible

Clinical

Investigator:

Robert E. Weibel, M.D.
Dir ector,
Division of Preventive
Medicine
Jos eph Stokes, Jr. Research Institute
Children's
Hospi t al of Philadelphia
34th and Civic Center Boulevard
Philadelphia,
Pennsylvania
19104
Study Locations:
De La Wair Clinic,
Wilmington,
Delaware
The Northeast
Clinic,
Wilmington,
Delaware
The Riverside
Health Clinic,
Riverside,
New Jersey
The Deborah Clinic,
Browns Hill,
New Jersey
The Mt. Holly Clinic,
Mt. Holly, New Jersey
G. Starkweather,
M.D., Havertown, Pennsylvania
E. M. Craven, M.D., Wilmington Medical Center, Wilmington,
Delaware
James W. Williams State Service Center, Dover, Delaware
Lan kenau Hospital,
Philadelphia,
Pennsylvania
Children's
Clinic of Chester and Vicinity , Chester,
Pennsylvania
Date Study Initiated:

June 7, 1976

Date Study Completed:

May 12, 1977

Study Procedure:
Two hundred seventy-five
children , 10 months to 7 ' years of
age, from the open population,
were in cluded in the study.
Two hundred fifty-five
children
received
a 0 . 5 ml subcutaneous
dose of 1 of 2 vaccines.
Twenty children
received
a 1.0 ml
subcutaneous
dose of combined live measles-mumps-rubella
(RA
27/3) virus vaccine.
Blood samples were ob tained prior to
and 6 weeks after vaccination
from approximate ly one half of
the children.
Each child was followed 6 weeks for clinical
complaints.

Clinical

Protocol

- Studv #467

Combined Live Heasles-Numos-Rubella

(RA 27/3)

Virus

Vaccine

Purpose:

To compare antibody and clinical
responses
to combined live
measles-muraps-rubella
virus vaccine containing
the RA 27/3 rubella
virus strain or the HPV- 77 duck rubella virus strain.

Vaccines:

1.

Combined live
Lot //621
Vaccine

(RA 27/3)

measles - mumps- rubella

dose is 0,5 ml given

virus

vaccine

subcutaneously.

The vaccine is supplied in two-dose vials.
Each vial of
v accine should be rehydrated
with 1.2 ml of sterile,
pyrogenfree distilled
water.
2.

Combined live
Lot (I0131V

measles - mumps- rubella

dose is 0 . 5 ml given

Vaccine

(HPV- 77 duck) virus

vaccine

subcutaneously.

The vaccine is supplied
in single
vaccine should be rehydrated
with
free distilled
water.

dose vials.
Each vial of
0.7 ml of sterile,
pyrogen-

CAUTION: Both vaccines
contain
egg protein and should not be given
to persons with known sensitivity
to chicken or duck, chicken or duck
eggs or fea~hers.
The va ccines also contain neomycin and should not
be given to persons with sensitivity
to neomycin.
Persons with
leukemia or other immunologic disorders
and persons r eceiving
immunos u ppressive
drugs should not be vaccinated , The vac cines should not
be given to . persons with any febrile
respiratory
illness
or other
active febrile
infection.
Â·
Keep dried

vaccine s stored

Keep dried

vaccines

Keep reconstituted
after rehydration.
Procedure:

at -20Â°C.

at 4Â°C in t r anspor t .
vaccine

on ice.

The study population
wil l consist
a negative
history
of vaccination
mumps and rubella.
Children will
of the two vaccines as follows:
Grouo
Group 1
Group 2

Discard

4 hours

of children
1 to 4 years old having
for and illness
caused by measles,
be r andomly assigned to receive
one

Vaccine

M-H-R (RA 27/3)
M-N-R

unused vaccine

(HPV-77. duck)

No. of Children
100-200
100-200

children
children

Clinical
P_otocol
Study /.!467

-2-

-

ln: orrned wri tten consent
or guardian prior to his

will be obtained from each child's
participation
in the study.

parent

Each child will receiv e a sin gle 0.5 ml subcutaneous
injection
of
one of the two combined live measles-mumps -r ubella virus vaccines.
Bleeding samples (10-15 ml) will be obtained from approximatel y
one-third
of t~e stud y participants.
They will be bl ed imnediately
prior to vaccination
and 6-8 weeks following vaccination.
Each child will be followed clinically
vaccination
. All local and systemic
on the case report form.
Schedule:
Tir.ie

for 42 days foll owing
complaints
will be recorded

Vaccination
and Follow-up
(Al l Children)

Day 0

Vaccinate
0.5 ml,
subcutaneously.

Days 0-42

Clinical
follow-up
for lo cal
and systemic reactions.

Week 6-8

(Aporox.

Bleeding
1/ 3 of Children)

Bleed 10-15 ml.

Bleed 10-15 ml.

Serology:

Circulating
levels of antibody before and aft er vaccination
will be
determined.
Measles and rubella
antibody levels will be deter mined
by hernagglutin atio n-inhibition
test.
Mumps antibody lev els will be
deter mined by serum neutralization
test.

Clinical
Forms:

Attached.

Adverse
Reactions:

Any serious or alarming reaction,
including
clea t: due to any cause
durin g this investigation,
whether related
or nee related
to _ the
test material,
must be reported
immediately
to Merck & Co., Inc.,
throu gh Dr. Maurice R. Hilleman,
teleph one (215) 699-5311, Exe. 5532,
or in his abs ence , Dr. Allen F. Woodhour, telephone
(215) 699-5311,
Ext.
5588.

Unused
Vaccine:

All unused vaccine should
Cell Biology Laboratories
Labor ato ries, West Point,

be returned
immediat ely to the Virus
of the Merck Sharp & Dahme Research
Pennsyl~ania
19486.

~~
M. R. Hilleman,

'pii.n.

and

SYMPTOM RECORD
M-M -R Study No .
rH I LoÂ·s NAME - -------

--

-

-,,-,----------

-:-:-:-- ::-.-----

1F 1,s11

(M100 1e 1

CASE NO. __

-

_ ___

_

0 Recta l

DATE

DAY

--

COMMENTS

0 Oral
(Check One /

I I I

j

0

, I

! I

2

!

3 I
4

I

5

I

I l I

I

I I

I

:

I

I
i

I

7 I

I

I

I

i I I
! ! ! I I

I

:

!

!

I

I

I

!

f

I

! I

i

I

i

!

I

I

I

I

I !

9 I

i

,o I

,, I
12 I

I

I

I

I

!

13
14

I

!

I

I

i

!

8

I

I

6 I

! I

i I

I

I

I !

I

I

15 I

I

16

' I
18
19 I

I i

I

20

I

I

I

21 I

I

22

23
24

I

25

26
27
28

.

29

,

3o I
31 I

32
33 I
34

35 I
36 I
37

38 I
39

40
41

I

42 I
er or unu1ual ,e.,crion

develops . call:

D11. R. E. WEIBEL
Havertown,

Pennsyl vania - Phone : HIi itop 6- 111 O

PLEASE RETURN FOR FOLLOW-UP VISIT ON : -

-

--

OR
Childr An's Ho spital of Philadelphia

.

-----------

- EV 7-1309

BE SURE TO BRING THIS RECORD ALONG WITH YOU â€¢

-

----

--

INSTR UCTIO NS TO PARENT:

1. Please fill in the date each day.
2. Please take temperature once daily at the same time and record exact thermometer reading.
3. If no symptoms are present, place a check ( ../) under '"NONE" beside that day's date.

4. If a symptom is present, place a check ( ../) under it beside that day's date.
5. Describe other symptoms and any RASH in the space under "COMMENTS."
6. THIS IS VERY IMPORTANT INFORMATION. Please do not misplace this card.

ME
ASLES-MUM
PS-kUBELLA
VACC
INATIONFAMILY
Ho. __

_ ____

IL:,Â· s .':A.",\ [ ------

_

CASEHo.

.-.- ,-,-----------------,

C!-t

,:-:,
---,
R
:-:
S
:-:
T:----------

- ---~-, '"
.~'"L
_t _____________

~G E ____

B IRTH C'A T;:

_

HI ST O? V :

_

MUMP S

RUBELL"

P J.l! ~N ,S

NAME -

--------------

-

\. A ST

AOC"E~S ----

-

-

---

-

----:--:-----

E"Jq $ T

- ------------

--

LOCATION---------

- --

PRE-VACC
INATION
________

TELE PHONE N O .

'.tl DDLL

- ---

- ----------------

- -------

_ _ _ _ _____

CLINICAL_ _ ________________

_
_ _ _

- -------------

- ---

consent to have my chi l d. named above. rec e i ve
live atten uated measles, mumps, rubella virus
vaccine.
SI GNHllRE
DATE

. .

. .. '

.Â· ..

.. . .......
- ., ..

... -- ...... .. Â·-Â·â€¢*.
-Â·
. - Â·Â·Â·Â·- -Â· Â· Â·Â·...

........ _,_, .._ ____....... ..._ , Â·Â·-Â·Â·Â·--- Â·Â·- Â·-----,

...Â· ..Â·.,,,..

â€¢ ,â€¢.

. ...~-.......
-.-.-~-~..~ :

_____________----- . -- ---- ------ ~- - -Â· .......... __
-Â·Â· . â€¢.. . - - -- â€¢.Â· â€¢ ,. .â€¢ Â·- Â·Â·--Â·- ...
..,

,..__

. ..

.â€¢ .

---=~------

.-...-.. ...._.____ -Â·Â·- -- . .........

t

.â€¢

' â€¢ . â€¢ â€¢' . ; â€¢

-Â·Â· .

--Â·-----

-

-

-Â·-----

Â·---,.,-...-- ---~.:-....
Â·- --------Â·- --------

Â· -Â·

.. - -â€¢. ~â€¢-.Â·.---Â· Â·Â· Â·Â·:-.Â·;..~,_:Â·
;~ --

. -'

~

..

.: .. - Â·.-

~ - HO--

--

â€¢â€¢ â€¢...â€¢ â€¢ -

--â€¢

â€¢â€¢â€¢â€¢--â€¢â€¢Â·-

â€¢ â€¢-----Â·-Â·

â€¢-- â€¢, -â€¢ -

--

â€¢ , ---...-

..---~

, -~â€¢â€¢Â·

.. -

Oâ€¢â€¢ __ _ _: â€¢â€¢â€¢ â€¢--

â€¢â€¢â€¢â€¢ Â· 0

â€¢--â€¢ - â€¢â€¢ ... ... ,.. â€¢ Â· â€¢ -

.... . . .

.. ..Â·;
\'JCCIIC1T
IOJII
~ VlCCIIC(___________

: â€¢ OlTE ___

____

_

_

VOL. _____

_

LOT ---

,-,.-,-, ----

SI TC __

____

'.

...Â·.....

,:_;;;7

BLEEDlâ€¢GS
_ _

PRE-UCCI

NATI ON

PCST- >!CCI MU IOM- ----

!

Dt TE

I

â€¢CtSLES

' ' ''

i

I

:[CHNIQUE

-J.

l

I

I

I

i

--

i

I ,.1I
SUIN Uf

J

!
'I

'Â·

I

I

I

2.

I

i

'

I

,t-sr

I
I

I

J

"'

Il
I

0-â€¢

â€¢U .

JI

:

~ }6â€¢l9_J_ i ,c lI

I
I

1:,9.2
aj

,:

........----

I

j
1\ . 11__.,_

I

Ill

I
Sll,!>7_____,j_ U

.,

I' C01+4EMTS:
,esi

I "" !'

r--+--â€¢'Â·â€¢â€¢

.I
Ii

-,.-,- --

-

l I

1Â£1,tâ€¢.

I

Ii IJ-18 1

I

.,

,os1
,,. J

,, ,m i

I

I

!

,.,

II

'

I

I

I

--

C L I M I Cl L

RU8ELL
l

'OJMPS

I
I
I I

I

I

I.

,-, -. ,-, --

S E ROLOGY

SLH.O I NG

CASE Mo.--

11-::

11,U

S UM M I â€¢ y

CO-, lll â€¢ U

I "" I

.I

I i
; JZâ€¢l lt-

1. ,.,2~0

tODt

)ltâ€¢U-

-â€¢â€¢-

I

'I

I

i
IÂ· s,.,oL
,,.,2-

'

I

i

' !>Oâ€¢Sâ€¢-Â· -Hâ€¢il-

Table

1

Sero l ogi cal Fi ndings Among Children Who Received a 0 . 5 ml Dose of Combined
Li ve Measles-Humps-Rubella (R,\ 27/3) Vir us Vaccin e, Lot 0621/ C- 0763 (Study 0467)
Inttl.,11}' Seroner.,,tive to:
Measlcs-Rubcll:i
Mum[ls
- R11hclla
Conversions/Total
Convcr!':ions/Total
Measles
Mumps
Rubella
Rubelln

Total
No.
Vacc.

No,
Sero 1.
Tested

8

7

6/7

7/7

7/7

l

63

32

29/ 30

30/30

30/30

2

17

10

7/8

7/8

8/ 8

3

11

6

4

9

6

3/3

3/3

3/3

2/2

2/2

5

5

4

1/ 1

1/1

1/1

1/1

1/1

6

3

1

7

1

0

Ar,_e

tleasles-tlumps-Rubella
Conversions/Total
Measles
tlumos Rubella

Inltlallv
Mumns Onlv
Conver sions/
Total

(Months)
11

RubeJla Onlv
Conversions/
Total

Serooosltive
tlcasles
Mumps and
Rubella

to:

-

(Years )

.Â· .:

117
Total
66
Mean Ar,_e; 1. 9 Yeara

0/ 1

1/1

1/1

1/1

1/ 1

1/1

1/1

1/1

1/1

3 /)

2/2

1
1/1

1

1/1

46/49
48/49
(93. 9%) (98.0%]

49/49
{100%)

3/4

4/4

Over all

3/3

3/3

.

5/5

3/J

-

2

Conversion Rates

Henslcs

~lumps

Rubella

49/ 53
(92.5%)

56/5 7
59/59
(98 . 2%) (100%)
8/24/77

---~--~---

Tahle

2

Serological
Findings
Amonr, Children
\~ho Received
Live Measles - Mump~- Ruhella
(RJ\ 27 /3) Vlrus Vaccine,

--"~
(Months)
11

Total
No.
Vacc .

No.
Scrol.
Tested

Jni.tially
Mc.is .1.c:;- Mumps-Hubc l l;i.
Convc rs ions /Tot.il
Measles
Mumps Rubella

1

1

1/1

1/1

1/1

1

11

8

7 /7

7 /7

7/7

2

5

2

3

1

0

5

2

1

1/1

12
20
1. 7 Years

9/9

9/9

9/9

(10 0%)

(100 %)

(100%)

a 1.0 ml Dose of r.omhi n ed
Lot f.!621/C - 0763 ( Stucly //1,67)

to:
Seron~gnti~c
Mc.-islcs - HuhclJ a
Conversions
/T ot Â·a 1
Measles
Rubella

Â·u;,

Mumps
fy
Conversions/
Tot::11

lnitialll

Seropositive
Me.1sles
Mumps and
Rube l l.1

(Years)

Tot.-il
Mean Ar,e:

1/1

1/1
1/1

1/1

1/1

1/1

1/1

2/2

Overall

Conv ersion

Rates

Mensles

Mumps

Ruuclla

1/1

10/10

]1 /11.

10/1'1

( 100%)

(lOO i. )

(100 %)

--

...

0

to :

Table

3

Ser ological
Flntlln gs Among ChlJtlrrn
Who RecelvPd a 0,5 ml Dose of Comb ined
Live Mcilsles - tltJmps -R uhell11 (IIPV- 77) Virus Vaccine,
H- M-R (Study 046 7)

No.
Se r o 1.
Test e d

10

1

0

11

2

2

1/2

1/2

2/2

1

88

46

36/42

36/42

40/ 42

3/3

3/3

2

19

. 10

3/3

2/3

3/3

2/2

2/2

1/1

1/1

3

12

6

4/4

4/4

3/4

1/1

1/1

1/1

1/1

4

12

3

1/1

1/1

0/1

2/2

2/2

5

3

2

1/ 1

1/ 1

1/1

1/1

1/1

7

1

1

Ai:e

Hcas le s - Mumps- Rubella
C'onvers tuns/Total
Me.,s lcs
Mumps
Ruhella

Inltlally
Seronr r,a tlvc to:
tlu111es-ltuhe 11:t
Hc-as l Ps -fluh e l ln
Convl'rslon s/ Total
Convcrslons/Tota
l
tlumps
tlcaslcs
Rubella
Rubel la

Total
llo,
Vacc,

Initl
tlc .,s J cs Onl y
Conv ers ions/
Total

Jlu111psOnly
Conversions/
To tal

o llv

Seroooslt
lve to:
lleasles
Humps and
Ruhe lla

(Honths)

(Years)

138
70
To tal
Hean M1.e: 1.7 Years

1/1

1/1

2/2

1

1

46/5 3
(86.8%)

45/5)
49/5)
(84 , 9%) (92, 5%)

9/9

9/9

2/2

2/2

Ove rall

Conversion

Rates

Measles

!lumps

Rubella

1/1

3/3

2

-50/58
60/64
56/63
(88 . 9%) (86. 2%) (93 . 8%)

8/24/77

Table

4

Distribution
of Post-V:iccination
J\nt.lhotly Titers
/\rnonr, Children
h1ho Were Initi.,l
ly
SC'roncg.itivc
to Mc.isles , M11mps nncl R11hclln, Who Received
:a 0.5 ml nose o f Cornhined
Live Measles - Mumps-:Rubclla
(RJ\ 27 /3) Virus Vaccine,
Lo t fJ621/C -07 63 (Study fll,67)

Mc:1slcs
Post Titer
Distribution

(11/\I)

l~11111hc
r o(
Children

Mumps (Ncu_t . )
Post Titer
Numher o(
Children
Distribution

R11hella (11/\I)
Post Tite r
l~11mbe
r of
0 is trilrnt io n Chi.] cir en

<5

3

<2

1

16

1

5

2

2

8

32

l

10

2

4

ll

61â™¦

11

20

4

8

8

128

22

40

9

)8

1

256

10

80

8

16

10

512

4

160

17

32

7

320

4

64

3

Total

49

119

49

Geometric
Mean Titer

56.2

8.3

131. 7

8/24/77

Table

5

Distribution
of Post - Vaccin.ition
Antibody Titers Among Childre n Who Were Initially
Seronegative
to Measles , Mumps and Rubella, Who Received a 1.0 ml nose of Comhined
Live }leasles - Mumps-Rubella (RA 27 /3) Virus Vaccine, Lot //621/C - O763 (Study 0467)
Measles
Post Titer
Distribution

(Iii\ 1)

Number of
Children

Mumps (Neut.)
Post Tj ter
Numher of
Distrihution
Children

Rubell.:J (111\1)
Post Titer
Number of
Distribution
Children

160

4

2

2

64

1

320

4

4

5

128

2

640

1

8

1

256

3

16

1

512

2

1024

1

Total

9

9

9

Geometric
Mean Titer

254.0

4.3

256 . 0
8/24/77

Tnble

6

l>istrlhutio1\
of Post - Vaccinntion
Ant ihmly Titers
Among Children
Who Were Initially
Se r oner,ative
to Me a s Jcs, M11mps nncl Ruhell.:i,
Hho Heceivcd
n 0.5 ml nose of Combined
Live Mcnslcs - Mumps-Rubell:i
(IIPV- 77) Virus Vnccinc,
M- M- R (Study //467)

Mt';islcs
Post Titer
Distrlbulion

(llA r)

N11111hc
r of
C:hildrcn

M11m_ps(Neut.)
Numhcr of
1'ost Tiler
l)istrjbution
Children

l' ost
Oistd

Rulicl ln
Tit"er
bu lion

(IIAT)

flumhc r of
Child rcn

<S

7

<2

8

<8

4

s

2

2

9

8

9

20

2

4

14

16

7

Lio

6

8

9

32

11

80

14

)8

1

64

7

160

17

16

6

128

9

320

4

32

4

256

,,

640

1

64

2

512

1

1024

1

Total

53

53

53

Gcometrlc
Mean Titer

51.1

5.0

32.4
8/2L,/77

Table

7

Maximum Temperatures Reported Among Oll)Jren \./ho Received a 0.5 ~1 Dose of Combined
Live Measles-Mumps-Rubella
(R/1 27/J) Virus Vaccine, Lot 11621/C-0763 (Study 0467)

Maximum Tempera ture
(Â°F â€¢ Oral)

<99
99 - 100.9
101 - 102 . 9
103 - 104.0
Not Taken

0-4

Totnl Vacc!nccs (117 ChU<lt:cn)
O;iys r os t Vncc1n ;1tl nn
No. with
29- 42 Max. Temp.
5- 12
13-1 8
19-28

61
53
(73 . 5%) (64 .6 )

(75.3)

59
(7J .8)

(72. 2)

39

34
(77. 3)

29
(69. 0)

34
(79.1)

34
(81.0)

32
(78.0)

25

20
(24 .1)

23
(28.0)

17
(21.0)

16
(20.0)

16
(20.3)

26

10
(22 . 7)

8
(19.0)

7
(16. 3)

7
(16.7)

8

12

(19. 5)

1
(1.2)

5

(6.1)

2
(2 .5)

3
(3 . 8)

4
(5.1)

13

4
(9 .5 )

1
(2 . 3)

1
(2.4)

1
(1.2)

1
(1.2)

2
(2.5)

2
(2.5)

7

(1.2)

1

1
(2 .4)

(2.3)

34

35

36

37

J8

32

19

18

61

57

0-4

Tnlt ln l lv S!'ron,.r,:,t I vcs (61 Cltl ldren)
O;iys Post V;icc l na tln n
No. vJth
5-1 2
lJ - 18
19-28
29-42 Max. Temp.

17

l

19

5
1
(2.4)

3

20

16

8/2 4/77

Table
111i;h Tl.'mpcr:ttures
ReportE"d
Live Jlcasles - Mumps-Ruhcll:t

Pat lent
Mo.

7b)(6}

- Max. Te ntp.
102.0
J02.0
l 02 . 0

.

29-31
3
24 - 28

102.0
101.0
103.0
10).2

27
26-29
0 -)
9-11

104.0

22-23

103.6

40-41

102. 0
102 . 0

7-8
12

103.0

30-33

10).0

.18
10 - 12

102.0

â€¢

Ti me Period
(0:iys)

8

flmonr, Cldlclrc-n t-nio Received
a 0. S ml Oose of C:omhinc-cl
(RA 27/3) Virus V:tccine,
Lot 1/621/C - 0763 (Stucly 0467)

S l:r_o 1or.y
<:1.inic:il

r.omp l.,_i n ts

Uppe r Respiratory
Il]ness
Anorexia
Upper Respih1tory
IlJ11css,
lo ~l !-i tt:O i ntc sti11.1l TLln1â€¢ss, l rr it.,bi.l Hy
No Clink nl. C:omp1;1int s
A11orcx i., , Teething
lipper Hcspir;1tory
I l] IIC!SS
lipper Rcspir:itnry
Illness
, Otitis,
T.yn1ph:iclr11npathy, OplithaJmopntlty ,
Gastrointl.'stinal
11Jncss , Anorcxin ,
Sorcm â€¢ss :It Inj rc:tinn Si le
Uppe r Hcspir:tLC'lry Illness,
Gastrointcstinnl
Illness
, llc:1dachc
Upper Hcspirntocy
Illness,
llencl,1clie
i\norc xia
No CJ.in ica] CompJainls
Uppe r Rcspirntory
Illness,
Ophthnlmo pnthy
llppC'r Rcspi r;-itory IlJncss,
C.3stro intcstinnl.
I] 1ncss
Upper Resp i r .,tory
Illn ess , Tecthinr,
No Clinj c-nl CompJnJnts

1cs
--l'n~Mc-:is
- ---l'o
st

NS
NS

- -~~,~
Â·â€¢~!_}~
- - H11hr-l1
-- -- ., l'rl.'.

Post

P1Â·e

Post
--

NS
NS

l!S
NS

MS

MS

NS

NS

t!S
NS

NS

NS

NS

NS

tlS

MS

NS
NS

NS

NS

NS

NS

<5

NS

NS

!IS
NS

160

<2

32

<B

MS
tlS

-)20

40

2

4

->J2

128

-)20

80

<2

Jf,

->32

128

80

l,

512

<S
<s

<2
<2

8

<8
(8

128

<S

<S

10

(2

2

(8

128

<S

5
40

<2
<2

32
32

<R

256
256

<5

<8

128

-----

Â·---

- --

-

---

-------------

--- Â· Â·- .

Table 9
Haxi11tJa,Tem11er3tures Rc,rorted

Live Heasles-Hna,ps-Ruhelln

Kaximu~ Temperature
(OF Oral)
(99

0-4
1)

(76.5%)
99 - 100.9

,

)

(17.6)

101.0
10).0

Not Taken
-

MOOngChUdrc,n Who Received o 1.0 ml Dose of Combined
(Rh. 27/3) Vlrua Vaccine, Lot D621/C -Tl7 63 (Study 1467)

Tot3l V.Jcctnrc,~ (20 Children}
Onys Post Vacclnntlon
5-12
13-18
19-28
29-42
11
(64.7)

13
(81. ))

12
(70.6)

13
(76. 5)

9

4
(2).5)

2
(12.5)

4
(23.5)

)

5

(17. 6)

1

2
(11 .B)
1
(5.9)
3

No. wlth
Hax. Temp.

0-4

Inltlally
Seroner.atlves
(ll Ch!lrlren}
1i:1vs Post V,1c-clnnt I011
No. wit h
. 13-18
5-12
19-28
29-t.2 tlax. TemD.

7
(70.0)

7
(70. 0)

(80. 0)

3
(30.0)

2
(20.0)

(10.0)

1
(5.9)

4

)

3

6
(60.0)

1
{70.0)

6

)

2
(20.0)

3

1
{10.0)

0

1

()O.O)

1
(10.0)

1

(5. 9)
1
(6.)) .

8

1
(10 . 0)

1
(10.0)

1

l

H1r.11
2s

Rubell3

2

1

3

)

Cli nical

Comelnint

l

l
l

1

I

Patient
110.

(b) (6)

Time Period
Hax. Te1112â€¢ ~~

Hcnsles

103 .0

0

No Clinical

Complaint

NS

NS NS NS llS

103.0
103 . 0

13-lS
22

No Cllnlcol
No Clinlc3l

Comrlalnt
Complaint

(5

160

(2

4

NS

<B 256

8/24/77

-- ------

Table

- -- - ' - Â·

10

Haxi111Um
Te~pcrature"
Reported Amonc Child r en \lho Received n 0.5 ml no,.e of Combined
Uve Measles-H umps- Rubella (IIPV- 77) Ytrus Vllcctne, "1-H-R (Study 1467)

tlllxl111U111
Temperature
(Â°F. Oro ll

<99

99 - 100 . 9

Tot :il V"crl11cc" (1J8 Chi l dren)
ru,;t v.,c c l~. l nn
5-1 2
D-lR
19- 28 29- 42

Pays

0- 4

38
(76.0)

35
(70 .0)

4)
(86. 0)

40
(80.0)

39
(81.3)

29

14
(15.1)

27

10
(20.0)

9

5
(10 . 0)

8
(16 .0)

4

10

(ULO)

(8. 3)

5
(5 . l.)

14

(2.1)

2
(l..O)

(6 . 0)

1
(2.0)

1

6

3
(6.0)

l

2

l

(2.0)

(4 .0)

(2.1)

20

20

20

22

66

78

(68. 0)

(81.))

75
(78 .1)

22
{22.4)

24

(24.7)

15
(15,6)

(16 . 7)

3
().1)

(4 . 1)

"

2
(2.1)

103 - 104.9

0-4

70 O ol ltlr cn)
l nlll".!_!y2;~&:!_tlvc,;
D:!J.~ l'o,; t Y;,ccJn.,tJon
lln. v lth
1)-18
5-12
19-21! 29- 42 Hax. Tcmn.

53

73
(74. 5%)

101 - 102 . 9

No. V{th
H.ix. Temn.

16

2

73

(78. 5)

)

1

(). l)

(1.0)

3
(3. 1)

(l.l)

41

42

l.2

45

)8

)

20

tlot Take n

40

Patient
No.
(b) (6)

Hax. Teme ,

(l>.iis)

102.0
104 .0

5-6
19-23

OtJtis
Upper Respi r ato r y t1 Ines" , Nonspeci fic Vira l

10).0
10).0

3t,- ]9
8- 10

10 1,

28

10) . 2
10) .2
102.0
102.0

13-14
25
4-5
27-)6

Teelh ln r,
No Cl l nl<'n l f.Om(I
1ll lnt S
No Cl lnl col Cornpl:tlnts
tlo Cl lnl cn l Complnlnts
No Cl lnl c.,\ r.on,plalnts
llo Cllnlr-:il Cmnpl nlnts
C~,;trolntcstlnnl
lllncsH , Nonspc clflc Rnsh,
Anorc:xl n
Upper Rrnplr:itory lll nesn, llno rcxl:i
llprcr R,,,.pJ rn lory ti I nr ss . Oti tlB
Upper Rcspl r3t ory ll l ncYs
lln Cl! n le:, 1 Cnm111:i
I 11ts
Cast r oln tc etlnnl lll ne oR, Irrit:i bil lt y, Anore.xio,
Tecthlnr.
Opht hal mopat hy

4

8

(8.))
5

18

I

Ti me Per iod

Clinica l Com[!lnint

Hea slcs

Humes

<5 320
(5
320

(2
2

Rubelh

,. (8

16
64

8

8

<S <S (2

32

(2

8

<8
(8

1024

320

<5 61,0

(2

8

(8

256

80 QNS 4 QIIS
40
<2 )A (fl

64

Rac;h, ,\nnrcxlo

.o

102. 0
102.0
102.0
102.4
10).0

5-10
J 0- )4

10) . 0

8-10

15

l
7-12

(5

QrlS

<5

(2

(2
NS
(2

(2

)2

(2

J2

(8
(8
(8

(2

2

(8

<5 160

(2

NS
<S 40
(5
)60
(5
160

llS

<5 160

tlS

<8
11S

<8

32
128
NS
8
128
)2

32
8/24/77

--

-1':t hÂ·lc

. - ------ .---

11

- - -- -

Cltnlc:ol
C'.onrl:o l nt" R,â€¢ronc ,t ,\..,11r.F.hll ,l r c-n 1.1,n R,-cc,lvrd a 0.5 ml llo<c '1f c.,.,l,tnrd
Live llc-as l e<-ll umps- Rul,c II :o (It/\ 21/l) VI rn !I \1;1c cln e , l.o t 1621 /C - D7h) ( S tudy 146 7)

Cltntcnl

Snre nc 9s at

I njection

Vncclnâ€¢ Â·cs

0--1,

5-1 2

~ ~

2

l

1

(2 . 2%)

(I. I)

(I. I )

lJ.1v:1 ~ V.Â·,cÂ·;~

Site

tymrlondenopathy
llea sles - Llke

l
(1. 1)

llr a\dac he
I rrl tab ! 11ty
Fever-TeDpera

4
(4.4)

t ure

Hot Reported

Anorrx.!a

i ,,n

5

J
(J .4 )

l
( I. l)

4
(4. 5)

(I.))

1
( 1 . 1)

10
(U.l)

12
(1).5)

1),"I\''.

0-1,
1
(2 - 1)

)

7

1
{I. 1)

1

1 n It I :o..!._1
~r:,?_nâ€¢â€¢&-it
/lo_ v i th
Cmopl nlnl

l
(L 1)

(U,)

(1.1)

n - 1,2

)

2
(2 . 2)
Rash

(117 tlo l hlr.-11)

Tol:ol

Compl aint

1

I
(2. I)

2

2

2

1
(2.1)

4

)

I
(2_1)

(4. ))

(8.5)

(6 . ) )

I IrÂ£' ~ (f, 1 CloI ldr r u)
r;o_ '-'l lh
19-28
29-1,2 Câ€¢â€¢lllJ'l:oInt

\'.,c-c tn,"lt.lnn

z --u=,n-

1

)

I!

~--i

(2 . 1)
(l. I)

l

r---

Po-;t

)

1
(2.1)

5

I
(2.1)

1

I
(2 . I)

4

I

1

(2. I )
6
(6. 7)

7

6

(8 . 0)

(6. 8)

f lush

23

5
(10.4)

l

7
(I 4. 9)

4
(8 . ))

2

I
(2 . 1)

(4 . ))

11

l

0

2
(2 .2 )

2

0

l
(I. 1)

l

(1. ) )

Dl.rurbed

Sleep

lly algla
llrr er Respiratory

t llneso

Otltl.9

15

29
{JZ. 6)

(19.1)

20
(22. 7)

31
()5_ 2)

5)

(16 . 7)
l
(1.1)

2
( 2.2)

2
(2.2)

1

I
(l . I )

2

( l. I )

9

Orh t hal lMra thy
Ca~t r o lntest
llonsprc
l'ohon

l na l Illnua

9
(1 0.0 )

If 1c Rnsh

5

4

)

(5.6)

(4. 5)

(3.t,)

4
( 4. 5)

15
(16 .9)

10
(I 1.2)

12
(lJ.6)

( 14 . 8)

I

J
(1. I)

(Ll

I
(l. I)

(I. I)

Al ler:;y

Tee t h ing

I

28

\lll h Co~pt.,tnl:

~-

~:;-

(JJ.J)
1,0

((,6 .7 )

I

4

(fo. S)

( f,?.~)

r-i,_5_

(S0.6)

4
(I, . 5)

l

4
(8 .J)

6

1)

9

9

(27.7)

(18.8)

(19.1)

1
(2. 1)

(2. I )

10
(7l. ))

l

)

)

2

(6.t,)

(6 . ))

(4 . ))

12

6

cn.s> (12 . 5)

1
(2 . I )

4

7

4

16

(l l,, 9)

(6.5)

l
( 2. I)

l

2

2

(2_J)

(11,. I)

2?

-

-17-

10
27

71 -

(r,11. 5)

_{511.0)

I

1

(2 . 1)

(~ .I )

I

2

2

(2.1)

((,. 1)

(4. 2)

14

lJ

11

56

-- -i i -

_2_1_

-

(25 . 0)

(M,.7)

)J

("2.1))

- 61 - -~ii-

jl,S.9J

0

2

(2.1)

22

l

l

28
29
_ 2_8_ _) _0_
() I . 5 )

6
(12. 5)

Jl

1

(I.))

27

I)

( 1. l)

(I.I)

~rgat1v e Surv r tll ~ncc

No Co11;,l al 11t:

)

1

4
( 'â€¢. 5)

Pcrs o ns with

l

l

(I. I)

rcr!i'OM

11

(l. I)

Ivy

l
(2 . 1)

j ;,-- --i~-

(75.0!_,

..n.ul.

2

5
I I,

I~

---v.---,-,-,- . -IJ
(2 q.2)

-3,;--

(7 0.ll l

!.~~

J)
_(70.2)

I)

H

(27.))

-- 54
_(!2.JJ

23

8/24/7 7

Table
Cllnlcal
Comrlaints
Rt'ported
Llv c Me aslcs-Hu mps- 1\ubell.i
Clinical

Complaint

at Injection

Among Ch tldr e n \./ho Rec e i ved a 1.0 ml no~e of Combined
(RA 27/J) V1rus Vac cine,
Lot: 11621/C - 07 6] (S t udy /1467)

Totnl VaccJncc,;
( 20 Ch!JJrc n)
l'o s t V.1c c lna t I on
II<>
. vlth
5- 12
lJ-18
19 - 28
29-42
Coin1>l:i 11t

Site

l

(5 . 9%)
Lymphadenop a thy

1
(5.9)

Arthralgia
Measles -Li ke Rash

Irritability

1
(5.9)

Fever - Temperature
Reported

l\norcxin
llrpe r Respiratory

I l ln ess

l Ill ness

(23 . 5)

.

1
(5 .9)

3
(17. 6)

l

l

(5.9 )

( 5.9 )

Impetigo

4

Survelll

anc e

Persons

wit h Complaint:
.,1t h No Complaint:

0
1
(10.0)
1
(10.0)

1
1

1

l
( 5. 9)

8

1

1

1

(5.9)

(5.9)

1
(10.0)

4

l

l
2

(10. 0)

2

4

(20.0)
1

1

1

(10. 0)

(10. 0)

(10.0 )

l
(10.0)

( 20.0)

1

l
2

1

1

(10. O)

3

3

J

3

3

7

G
( H.3)
11
( 64 . 7)

5

5
(29, t,)
12
( 70 .6)

2
(1 l.8)
l5
(88 . 2 )

9

3

(29 .1, )
12
(70. 6)

8

(30. 0)
7
(70.0)

(58.8)

1
(1 0.0)
1
(10. O)

3

( r.1. 2)
JO

1

(10 . O)

1
(5.9 )

Negative

Pe r sons

2

2
(11.8)

5

Otitis

Gastrointestina

l

1

(29.4)

1

1
(5.9)
(5,9)

4

1
(10. O)

1

1

( 23 . 5)

1

1

(5.9)

Ch i l rl r en)
llo . w!th
29-42
Complnfnt

I

1

Not

0 -1;

(ll

1
(10.0)

1

1
(5 .9)

ll,1 â€¢1j

1

J
(5.9)

(5.9)

!-:i_
l !v Scroncfjatlves
l'ost V:tcclnat!nn
5- 12
lJ - 18
19-28

Inlt

Ua\'S

0- 4

Soreness

12

I

1
2

(20.rl)
8
(!lQ. 0)

I Â·

1

1

1

2

3
(JO. n)
7
(70.0)

I
(10. 0 )

5

9

5

{20. O)
B
(80.0)

( 90 . O)

8/24/77

----1Tab

Conpl.ilnt,
Rcporte-,t /lmonr, (1,t ldrC'n 11h11Rccrtvrtl n 0 â€¢ .5 ml Im~â€¢ or Cor.,t,lncd
Livi! HrÂ·11â€¢ks-t~,.,J1s -Rohdl.,
(lll'V-77) Vintâ€¢ Vacc in e , tl-H-R (Study 1467)

Cllnlcnl

Cllnlcat

T .. L,t

Co111f1laln
t

v.,ccli, c,M (138 Oolldr c,n)

o~i,-."'i~o~t
0-4

lnJtectlon

-l-e 13

Slte1

.S-12

Vnr-t:tnathm

o-=--111
19-28

29 - 1,2

1

Sy1t.,.lc

5

2

(5.0)

(2.0)

1

IrrltftbllltJ

4
(4. O)

2
(2.0)

11
(10.9)

17
(16. ti)

(.S.O)

Flush

s

2
1

.5

Sleep

2
)

6
(S. 9)

4

2
18
(17.8)

Otith
Ophthal1110patlty

Illnoae

Cft1trolnte1tln1l
Ra1h - N0Mprclfl

1

,,

15
(14.9)

(1.0)

(4.0)

(2.0)

2

2

3
0.0)

15
(14. 9)

12
(11.9)

(S.O )

1

J
(3.0)

cs.0 )

.5
5

V:1rlc,1la
Otherâ€¢

l
(1.0)

C, nltourtn â–  ry

2
(2.0)

Yerr hln g
_,__J<y.~tlv e Survr.llbncr
rer~on1 vlth
Comrl~lnt:
.,Ith

~n Co,rpl~lnto

lng eRte d lighter

37

r--;6

(3.5.6)
65
(Gr..4)
f l uid

18

1
(1.9)

6
(11.))

9

l

(17.0)

(1.9)

3
(5. 7)

4
)

l

0

4.5

l
(1.0)

I

7

(1.0)

1
(1.0)

(2.0)

5
(.S.O)

(5.9)

6

)

4

(3.0)

(4 .O)

1
(l.O)

(l.O)

1

l

1
(l.0)

2

l

(2. 0)

(1.0)

2
(2. O)
37
41
( 1,0,6)
60
( ~9.4)

and blood1

nooe.

6

I

4

~

,~. 0)
J1

(.S.O)

l

12

24

26
(25. 7)
Vi

(23 . 8)
11
(76.2)

J7

(71, .J)

9

6

(17.0)

(11.))

I

2

(1.9)

(3.8)

2
() .8)

() .8)

7

1

8

(1). 2)

(15.1)

2

4

3

3
(5.7)

1

4

(3.8)

(7 â€¢ .5)

(5 . 7)

l
(l.9f

l

4

l

1

(l. 9)

(7.5)

(1.9)

(1.9)

l
1
(1.9)

4~

6

l
0

2
(J. 8)

II

57

11

0

1

37

20
)

2)

(I).

J
2
(2.0)
31
JO
(29.7)
7l
(70.J)

JO
(1 8.9)

27

2

(1.0)

14

(.S. 7)
0

2'
(23.8)

2

1

1

(17.8)

l
(1. 0)

Infection

Alloriy

l
(1.9)

(1.9)
19
(18.8)

(1.0)

2
().8)

2

(2.0)

c

24

(I, .0)

(2 .0 )

lllneu

1
(1.9)

9

l

Respiratory

2

(J.O)

(1.0)

ttyalgla

1

(2.0)

l
(1.0)

Disturbed

l
(1.9 )

l
(LO)

(3.0)

)

More ala

â€¢ Include-a

2
1

1

(1.0)

Persons

)

1

llud~che

Uppor

{70 Chi lâ€¢lrrn)
No. vllh
29-42
Cocphlnt

)

6

l

He11l,1 - Uke ""â€¢h

'----.

l nltl,1 ! ~..c!!!
~r,,t l vâ€¢~
D~â€¢,g l'oc:t V.1c c l11.1Llon
5-12
lJ-18
19-28

(.S. 7)

6
and Induration

0-1,

7

(6. 9%)
So r f:ntis9
Sore11rss

llo. wlth
Complain t

11
20
Â· ()7.7)

2
(J .8)

2

l

1

(I. 9)

(1.9 )
11

11
Ill
(JI, .O)

-~

17

)1

)5

(l 7.0)
41,

(62. 3)

' (66. 0)

(8).0)

(IS . 9)

2
() .6)
11
12
(22.6)

(111.1)

07.4)

10

- -,,)- ~

l
17
21

26

MEr~O
To
From
Subject

File

Locat io n

T. Schofield

Location

Statistical

Anal vsis

Date
W26-285

- Studv #46 7

Significant
differences
in seroconversion
rates for measles,
mu~ps ,
and rubella
and clinical
reaction
rates among three groups of
vaccinees
were investigated.
The groups were those who received
a 0.5 ml dose of co~bined live measles-mumps - rubella
(RA 27/3)
virus vaccine
(Group 1), those who received
a 1.0 ml dose of the
same (Group 2), and those who received
a 0.5 ml dose of combined
live measles-mumps-rubella
(HPV-77) virus vaccine
(Group 3).
Significant
differenc e exists
in the mumps seroconversion
rate
among these groups.
56 ou t of 57 (98 . 2%) converted
in Group 1,
11 out of 11 (100. 0%) in Group 2, and 50 out of 58 (86. 2%) in
Group 3 , No significant
diff~rences
exist for other rates.
Analysis
of variance
was performed on post-titer
values of triplenegative
vaccinees . The lo g transformation
was used.
Significant
differences
among the groups existed
for all three components.
Multiple
comparisons
showed the following:
a)

For measles,
children
in Group 2 (G: IT = 254 . 0) had significantly
gr ea ter post tit er (in the log scale)
than did those in Group 1
(GHT = 56 . 2) and those in Group 3 (GMT= 51.1);

b) For mumps, children
in Group 1 (GMT= 8 . 3) had significantly
greater
post titer
than did those in Group 2 (GHT = 4.3)
and those in Group 3 ( G"t>'IT
= 5 â€¢ 0) ;
c) for rubella,
children
in Group 1 (G~IT = 131.7) and Group 2
(GMT= 256.0) had significantly
greater
post titer
than did
those in Group 3 (GMT= 32.4).

T.S .
6801

9/ 27/77

CLINICAL SUMMA RY

Study Nome

-

Study Number
Materia I -

Purpose

-

Time Period of
Observation
-

Combined Live Measles-Mumps - Rube I lo (RA 27 / 3) Virus Vaccine
-

Clinical

Prot ocol - 467

Combined live measles-mumps-rubella
Lot #621/C-D763

(RA 27/ 3) virus vaccine

Combined live measles-mumps-rubella
Lot #ol31V

(HPV-77 ) virus vaccine

To compare clinical and antibody responses to co mbined live measles-mumpsrubella virus vaccine containing the RA 27/ 3 rube lla virus strain or the HPV-77
duck rube Ilo virus strain.

Initiated:

June 7, 1976; completed:

May 12, 1977

Medical Opinion
At the following locations : Burlington County Health Care Clinks-Riverside
Clinic, Zurbrugg
Memo rial Hospital, Riverside, New Jersey, Browns Mills Clinic, Deborah Hospital, Browns Mills,
N.J.,
Mount Holly Clinic, Mt . Holly, N , J,; Delaware State Health Clinics, Dover Delaware
and the DelaWor Clinic and Northeast Clinic, Wi lmington, Delaware ; Elizabeth M . Croven 1 M.D . ,
Pediatric Clinics, Wilmington Medical Center, Wi lmington, Delaware; The Lonkenau Hospital Pediatric
Clinic, Philadelphia,
Pa . ; and George A. Starkweather,
M.D. 1s office, Havertown, Po.; 275 child ren ,
10 months to seven years of age were enrol led in this study with parental consent.
Two-hundred fifty five children received a O. 5 ml. subcutaneous dose of either vaccine.
Inadvertently,
twenty ch il dren
received a 1.0 ml . subcutaneous dose of combined measles - mumps-rube Ila (RA 27/ 3) virus vaccine.
Each child received a report card and the parents were encouraged t o record local and systemic reactions
for 42 days . Paired b lood samples were obtained prior to and 6 weeks fol lwing vaccination from 148 of
275 (54%) children to perform measles hemagglutination
inhibitionJmumps neutralization
end rubella
hemaggl utinotion inhibition tests.
Measles-mumps-rubella
(RA 27/3) virus vaccine was given to 137 children, ages 11 months to 7 years
(mean age 1.9 years) with 78 paired sere, seropositive to m-m-r in two and seronegative as follows:
m-m-r 58, measles-rube I la 5, mumps-rube I la 3, mumps 7, rube I la 3 - 13 m-m-r seronegatives hod
only a pre-injection
serology test . Measles-mumps-rube Ila (HPV-77) virus vaccine was given to 138
children, ages 10 months to seven years (mean age 1,7 years) with 70 paired sere serapositive to m-m-r
in 2 and seronegotive as fol lows: m-m-r 53, measles-rube I la 9, mumps- rube I la 2, measles 1, mumps 3 -17
m-m-r seronegotive , had only a pre-injection
serology tested.
Seroconversion rates fo r triple seronegatives were similar to the overall seroconversion rates which ore as follows wi th the geometric mean
titers: m-m-r (RA 27/3) vaccine 0.5 ml. dose; measles 49/53 (92.5%, 56 , 2); mumps 56/ 57 (98% , 8.3);
rubella 59/59 (100%, 131.7); m-m - r RA 27/ 3 vaccine - 1. 0 dose; measles 10/ 10 (254); mumps 11/11 (4 . 37); rubel lo 10/ 10 all 100% (256); m-m-r HPV-77 vaccine 0 , 5 ml. dose; measles 56 / 63 (88. 9%,
51. 1); mumps 50/ 58 (86. 2%, 50) rube Ilo 60/ 64 (98 .8%, 32.4) .

-2Medi col Opini on (cont. )
The seroconversion rote s and geometric mean titers ore greater following 0.5 ml. m-m - r RA 27/ 3
than 0.5 ml. m-m-r HPVos follows: measles - 92 . 5% vs. 88.8 % , 56.2 vs. 51.1; mumps - 98 .2 <:c.
vs 86 . 2%, 8.3 vs.Â· 5.0; rubella - 100% vs. 93.8%, 131.7 vs. 32 . 4. The difference in the mumps
seroconversion rotes, mumps geometric mean titers and rube I lo geometric mean titers ore stotistic:il ly
signifi cant . Int erestingly, all (11) measles vaccine failures were less than 15 months of age (2- 11,
6-12, 2 -13, 1-14 months ) and may be related to the persistence of maternal antib ody. This patte rn
was not observed in previous studies.
Two of 4 rubella failures (13 months) and 4 of 8 mumps failures
were less than 15 months old (l-11, 2-12, 1-13 months.
Clinical report cards were returned on 202 of 275 (73%) of vaccinees with nosig nif icont vaccine related
clinical reaction reported . Temperature elevations were similar among both vaccine groups with no
defini te pattern during the observation period. Most temperature elevations ore related to intercur rent
infection with minima I vaccine related fever occurring between days 5 and 12. Injecti on site soreness
was rarely reported in each group. Measles-I ike rash was reported in m-m-r RA 27 / 3 voccinees as
follows: 0.5 ml. - 7, 1.0 ml. -l, and in 5 m-m-r HPV vaccinees.
No arthralgia or arthritis were
reported.
Lymphadenopothy was reported by 4 m-m-r RA 27/ 3 voccinees o~ly. Non - specific
complaints were simi far in both groups.
Com paring combined m-m-r RA 27/3 vaccine with m-m-r HPV-77 vaccine reveals no difference in
the mild clinical complaints and temperature elevations reported but a greater seroconversion rate
an d geometric mean titer to all three viruses following m-m - r RA 27/ 3 vaccine.
Although both
vaccines ore excellent for immunization, m-m-r RA 27/3 combined vaccine is superior and recommended.

/2/ ~~(

:/

..; " t;_ .,_.,.-\ I' _,./ L Â·'-

,!
~~-

Robert E. Weibel , M.D.
October 5, 1977
REW:ceb

r\

,~

Â·

..:_

Reference

-â€¢-Â·- ---~-~--Â·- ~Â·--------

------------------

----

No. 5

Clinical

Protocol

- Studv ~473

Combined Live :!easles - :!umos- Rubella

(RA 27 /3)

Vi rus Vaccine

Program:

Tes tin g of combined l ive 'Illeasles -mumps- ru beil a vaccines

Purpose:

To evaluate
and compare
t wo measles-mumps-rubella

Vaccines

:

1.

clinical
virus

and immunological
vaccines.

Combin ed liv e measle s-mumps-rubell
Lot /)621/C-D763
Vacci ne dose is 0.5 ml given

a (RA 27/3)

in children.

r esp onses

vi r us vaccine

subcutaneously.

The vaccine is sup pl ied in two-dose vi als . Each vial
vaccine should be rehydrated
with 1.2 ml of sterile,
pyrogen - fr e e distilled
water.
2.

Combined li ve measles - mumps-rubella
Lot #2 127V or 2209V
Vaccine

dose is 0.5 ml given

to

(HPV-77. duck) virus

of

vaccine

subcu tan eously .

The vaccine is supplied
in single dose vials.
Each vial of
vaccine should be rehydrated
with 0.7 ml o f sterile,
pyrogenfr ee distilled
water .
CAUTIO~: Both vaccines may contain egg protein
and should not be
given to per so ns with known sensitivity
t o chicken or duck , ch icken
or duck eggs or f eat h ers.
The vaccines al so contain neomycin and
should not be given to persons with sensitivity
to neomycin .
Persons with leukemia o r oth e r immunologic disorders
and persons
r ece ivin g immunosuppressive
drugs should not be vaccinated.
The
vaccin es sh oul d not b e giv en to persons with an y febrile
r espiratory
illnes s or othe r active
febrile
infection.
Keep dried

vacc in e stored

Keep dried

v ac cin es at 4Â° C in tr an sp or t.

Keep r eco n stit u ted vaccine
after rehydration.
Pr oc edure:

at -20Â°

on ic e .

C.

Discard

unused vaccine

4 hours

The study p opulation
will co nsis t of children
1 to 10 year s of
age who have a negative
history
of vaccination
for and illn ess
c aused by measles, mumps and rub el la.
The childr en will be
as si gned to r ec eive one of the two vaccine as follows :

Page 2
Clinical
Protocol
- Study #473
Combined Live Measles-}1umps - Rubella

Procedure:
(continued)

(RA 27 /3)

Groun

Virus

Vaccine

Vaccine

1
2

M-}!-R

No. of Persons

(HPV-77 + 5 duck)

up to 200 children
up to 200 children

M-M-R (RA 27/3)

Informed written
consent will be obtained
of each child prior to his participation

from a parent
in the study.

or guardian

Each child will be bled (10-15 ml) immediately
prior to vaccination
and 6-8 weeks following
vaccination.
Each child will receive
0.5 ml
of vaccine given subcutaneously.
Each child will be followed clinically
for occurrence
of local and
systemic reactions
within 6 weeks following
vaccination.
Observa tions should include
special
notation
for rash; nodes, arthralgia,
arthritis,
fever, malaise,
and anorexia.
The person(s)
obs e rving
reactions
should not know which preparation
the child received.
Schedule:
Time

Action

Day 0

Bleed 10-15 ml.
Vaccinate
0.5 ml, subcutaneously.

Days 0-42

Clinical
systemic

Weeks 6-8

Bleed

follow-up
reactions

for

local

and

.

10-15 ml.

Laboratory:

Remove serum from clot

Serology:

Levels of circulating
antibody before and ah'2r vaccination
will
be determined.
Measles and rubella
antibody
levels will be
determined
by hemagglutination-inhibition
test.
Mumps antibody
lev els will b e determined
by serum neutralization
test.

Clinical
Forms:
Adverse
Reactions:

aseptically

and store

frozen

at - 20Â° C.

Attached.

Any serious
or alarming
reaction,
including
death due to any cause
during this investigation,
whether related
or not related
to the
test material,
must be reported
immediately
to Merck & Co., Inc.,
through Dr. Maurice R. Hillem an, tele phone (215) 699-53ll,
Ext. 5532,
or in his absence,
Dr. Arlene McLean, telephone
(215) 699-5311,
Ext. 6383 .

Page 3
Clini cal Protocol - Study #473
Combined Measles-Mur.ips-Rubella
(RA 27 /3)
Unused
Vaccine:

All unused vacc ine should
Cell Biology Labora t ories
Laboratori es, West Point,

Virus

Vaccine

be returned
immediately
to the Virus
of the Merck Sharp & Dohme Research
Pennsylvania
19486.

M. R. Hill eman , Ph .D.

and

YaleUr1iversiry

NewHa11en,Connecticuto6510
SCHOOLOF MEDIONE
Depar1men1of Epidemiology
""d Public Health

60 CollegeS1ree1

October

12, 1977

Dr. Arlene McClaine
M:rck Institute
For 'Iherapeutic
Pesearch

West Point , Pennsylvania

tear r:octor M:::Claine:
As a folla.-1-up to our recent telephone conversation,
I sul::Jnit
the follc,..,ring information about our current participation
in stlrlies
cxmcerned with a:moarisons of HPV-77 DEc and RA27/ .1 live attenuated
rubella vin:s vaccines
(b) (4 ), (b) (6 )
our studies in
children have r.0,1 been approved at all levels in each of the various
pediatric
clinic settins-s , but have not yet been started.
After
several prolonged difficulties
in filling
the position of central
cxx:,rdinator, we now have a good person whose interest , capabilities
and prior rerord give both Dr. Horstrrann and rre a feeling of reassurance about essential
features of recruitrrent and follow-up of
eligible
participants.
We anticipate
a vast inprovement in the
studies,
both qualitative
and quantitative.
(b) (4) . (b) (6)

{b) (4), (b) (6)

I will send you a progress report on the
organiza tional effort has begun to bear fruit.

(b) (4), (b) (6)

after

our new

J;k~~-

It:t>ert W. r-teo ll um, M.D.
Chai.man

JW-.Vfn

SYMPTOM
H-M-R

STUDY NO. _________

_
CASENQ __

>.Jo.,:
.. -

RECORD

4 -

I

w

!

I

I

0

'~Describe

"lectal

DATE

I OAY

_ _ _

t-

Tampernure

!

__

(MiCIClle)

(F irs!)

(Last)

COMMENTS

D Oral

I

(Check One)

I

I
I

;

i)
1

I

I

I

I

I

I

I

'.!

!

'.!

I

!

4

'
'

! I

5

!

I

9

i

I

I

I

I I

! i
! I

i

5 I
i

!

I

5 :

I

i

i

io

I

I

13

I

,-

I I
I

I I

ii

12

i= :

I I I I

16

'

17
18

I

19

i

I j
I !
I I
I

i ;

i

I

I

j

I i
I i I I
I

I

I

! l !
I

I

!

I

2J I
21 :
22 I

i

23 !

!
!

2..!
'
25 '
26
27
'
22
29
30

,Â»

31

I

32
3:?
34 I

35

I

I
I

I

'

35 !
37
38 I

I
I

39 ;
40 :
41 I

I
.

I

Â·2

I

. evu or unusual reaccion develops. call :

PLEASE RETURN

FOR FOLLOW-UP VISIT ON : ___________

BE SURE TO BRING THIS RECORD

ALONG WITH YOU.

_

INSTRUCTI ONS:
1. Please fill in the date each day.
2. Please take temperature once daily at the same t ime and re~ord exact thermometer rE;ading.
3. If no symptoms are present, place a cliec k ( âœ“ ) unde r "NONE"
4. If a sy_mptom

beside that day's date.

is present, place a check ( âœ“ ) under it beside that day's date.

5. Describe other symptoms and any RASH i n the space under "COMMENTS ."
6. THIS IS VERY

IMPORTANT

INFORMATION.

Please do not misplace this card.

MEASLES - MUMPS - RUBELLA
Study NoÂ·--~---

Ca,e No.-------tSÂ·91

ClÂ·ll

Saâ€¢ IÂ» )

CT

M

2

F'

mo

OOY

1 â€¢ YES
O.t l c of ons,,et . _______

Co1nn~r11,: ----

Dâ€¢te of â€¢â€¢oosure _________

_

-

-

-

2 â€¢ NO

__________

_

------------

-

_

'----------------,
0
=
I

LOI No. - --

â€¢5ok,fy

'

I

I

I
I

I

-;;

.:
.: !::i
V
I

24

I

1 I
2 I

I

I 16 , 2s I 08 I 15 1 ,.
! I I
I

:

I

I

3 I
.!

j

s

I

oI

03 , 06 l cs 1 12 , so

â€¢ 01

I

I
I

I

I

;

I

I
1

!

7 I

I

I

I
I

I

I

;
I

I

I

!

~ I

li::, :

I

11 '

I 12 I
1'

I

I

I

I

I

I

1

S 1 52 : 11 I 32 I

I

I

I s 1

â€¢ 13

I

l

I

I

j

1

I

15 :

I

I

16 I

I

17 ;

I

!
j

I

I

1s I
19 j
21 I

j

â€¢

I

I

I

I

I
I

I

.

:

I

i
I

I

I

I

I

1

I

I

I

I

I

I
I

I

I
I

20 i

I

I
I
I

23 1

I

I

2â€¢ I
25 I

I

25 I
21 I

I

I

22 I

-1

I

28 !

I

29'

,,

I

I

">O '

I

I

I

32 ,
JJ I

I

I

'

I

I

I

I

J.s I
JS I
36 I
37 I
3a I

39'
â€¢1

I

-'2 I
l'IHâ€¢

(Type,

Lou1,onl

OTHER REACTIONS

! DAV ; DATE

~

-----(7~751

Tempt,â€¢tu,e

3

!
i
i

--------

-4,,-,_-,.
.,..,
---1 5 11

CT

1

8 1..o ,ng o.....

OJte ot ~,accina11on

Con1tol

VaccinH

râ€¢tu111 eomp lll'ftti lorm,

10: (R~t.,Jm PINK copy tor your 1,/f!s}

M. R, HILLEMAN . PhD . OSc
MERCK SHAFIP & DOHME RESEARCH UIBORATORIES
WEST POINT , PENNSYLVANIA, 19486, U.S.A.

P1ty1,c..,,,, Â·â€¢ Signatu1'
Pflt1J1~,,.n â€¢1 /1/â€¢nr~ (Ty~

or Pr;nrJ

lef erence

Program:

No. 6

Study #484 - To evaluate and compare clinical
and immuno. logical responses to two combined live measles-mumps-rubella
â€¢virus vaccines.

Vaccine:

Comblined live measles-mumps-rubella

(RA 27/3)

virus

vaccine

Lot #621/C-D763
Combined live measles-mumps-rubella

{HPV-77) virus

vaccine

M-M-R

Responsible

Clinical

Investigator:

Anne Gershon, M.D.
8th Floor North 16
Bellevue Hospital
1st Avenue and East 27th Street
New York, New York 10016
Study Location:

New York, New York

Date Study Initiated:

December 23, 1976

Date Study Completed :

In Progress

Study Procedure:
Sixty-three
children , 13 months to 15 years of age,
and one adult, have been included in the study thus far.
Thirty received a 0.5 ml subcutaneous dose of one of the
two vaccines . Thirty-four
children received a 1. 0 ml
aubcutaneous dose of combined live measles - mumpsrubella (RA 27/3) virus vaccine . Blood samples were
obtained on day of vaccination and 8-12 weeks after
vaccination.
Each child was followed 6 weeks for
clinical
complaints.
The study continues in progress.

----

.

.

....

[I]
.

NEW YORK UNIVERSITY

MEDICAL

CENTER

School of Medicine
SSOFIRST AVENUE, N[W YORK, N.Y. 10016
AllEA 212 679- .,200

CA8lf ADORÂ£.SS: NYUMEDIC

I

Department of Pediatrics

December 19,

1977

Arlene McLean , Ph.D.
Merck Sharp & Dohme
Research Laboratories
West Point, PA
19486

Dear Arlene,

.

Enclosed is a follow-up
on the progress
report
I
sent you in August.
I have simply updated the tables
because they really
tell
the whole story.
If you want
anything more detailed
than this,
please let me know.

With best

regards.
Sincerely

yours,

..

Anne A. Gershon , M.D.
Associate
Professor
Dept. of Pediatrics
,.
AAG/mac

Enciosure

â€¢

. -~ -

â€¢
# 484
MMR Study:

..

Children

1-15 years

old

12/19/77

RA 27/3
39

HPV 77

13

7

Number susceptible

13/13

7/7

Number with

seroconversion

13/13

7/7

Number with

reaction

0/13

0/7

Number vaccinated
Number vaccinated
follow-up

Reactions

25

with

serum specimens

(none)

I

â€¢ â€¢

â€¢

---

ti
'

NEW YORK

UNIVERSITY

,\\EDICAL

CENTER

School of ,\kdicinc
t5Cl IIRH ,\\"l :'I.II[, l'lllW YOK"-. 'i . Y. 1001h
.\Ill/\ .!I!,.;-,,. ,~uu
C!\UI r AIJl>Rr~~

'<\ 'IJ.\ltUIC

August

17,

1977

Maurice R. Hilleman,
Ph.D.
Director
Â·
Virus & Cell Biology Research
Merck Sharp & Dohme
West Point,
Pennsylvania
19486
Dear Or. Hilleman,

I am enclosing
of rubella
children

.

should

be

a

progress

vaccines

RA 27/3

We are

continuing

report
vs

on our study

HPV 77, in adults

to immunize

and

and more da~a

forthcoming.

With best

regards.
Sincerely

yours,

~
.Anne A. Gershon, ~.D.
Associate
Professor
â€¢ Dept. of Pediatrics
1

AAG/mac
Enclosure
cc:

Dr. Arlene

McLean/

--

-

2.

Infants

and children

were

HPV 77 in combination
vaccine

the

with

(MMR). The ages

to 15 years.
time

Informed

the

rubella.

A second

8-12 weeks

after

given

their

rubella

parental

RA 27/3

regular

measles

of ~he subjects

of MMRimmunization

to determine

5 -

ranged

consent

sample

child ' s immune status

with

blood

sample

At

regard

to

approximately

rubella

HI titer.

who received

HPV 77 rubella

vaccine

the

standard

dose

of vaccine.

received

RA 27/3

rubella

vaccine

the

dose

The subjects
MMR received

usual

subcutaneous

of vaccine.

who

MMRreceived

in

All

Those

vaccines

were

in

double
given

by

injection.

Thirty

four

as MMR. There
so far.

for

from 13 months

was obtained

was obtained

MMR immunization

ond mumps

obtained.

was

a blood

or

received

has been

follow-up

have

27/3

rubella

on 5 of these

vaccine
subjects

HI antibody

with

or 1:256.

No reactions

to the

vaccine

been reported.

Follow-up

on more of these

will

be obtained

with

Seventeen

children

of 1:128

developed

RA

rubella

titer

All

children

as MMR. To date

of these

children;

an initial

.

rubell.i

have

recipients
I

time .

vaccine

be forth=oming

vaccine

a

and 1 adult

received

HPV 77 rubella

follow-up

has been

obtained

on 3

expected

to

additional
Of the

follow-ups

3 ~ho have

III titer

of>

been

32 at

are

followed,
immunization

one had
and an HA

.

.
- 6 -

titer

of 1:128 after

vaccination.

which were <1:8 at v~ccination
1:32 after

Two children
and increased

~ad titers
to 1:16

and

vaccination.

-

- __

...

â€¢â€¢

w

NEW YORK

1

NIVERSITY MEDICAL

,...ENTER

School of Medic ine
SSO ftRST AVENUE, NEW YORI. . N.Y. 10016
AREA ;i12 c,;-9.noo
CABlE ADDl:CSS : NYUMCDIC

ocot b er

Department of Pediatrics

Dr. Arlene Mcclean
Merck Sharp and Dohrne
Research Laboratories
West Point,
Pennsylvania

3 , 1 977

19486

Dear Dr. Mcclean,
Please find enclosed
an information
sheet given to the
mothers of children
receiving
the M-M-R vaccine.
They are
asked to record any reactions
to the vaccine
and return
the
slip to the doctor in the Pediatric
Clinic . This information
is given to Dr. Judy Wallin,
who is supervising
the study
in the Pediatric
Clinic
at Bellevue Hospital.
She keeps
this information
and we are informed via "word of mouth"
with regard to these reactions .

I apologize
Thank

for

the

confusion.

you.
Sincerely
I

f

â€¢

.. . ;: ._.,_.
.. .I,. I

,J': ,
'

yours,

I â€¢

. â€¢Â·
I

I .. . '...' . . )_

I

I

'

Maura Caruth
Secretary
to Dr. Anne Gershon
Dept . of Pediatrics

INFORMATIONFOR MOTHERS
Baby's

Name___

_______

_

Date

of vaccination

-----

Your baby has just received
a measles-mumps-rubella
vaccination.
He/she will probably
have no symptoms afterward.
If you think
the baby is having a reaction,
please
take the baby's
temperature.
Write down any problems
the baby is having :
Fever
Rash
Joint

pain

Swelling
Where?
If the baby seems sick please
telephone
Dr . Gershon . or Dr .
Reese at 561-3612 between 9 AM-5 PM. If the baby is sick on a
weekend or at night take him/her
to the PES â€¢. They will contact
a doctor
for you .
These vaccines
are safe and an important
health
care to prevent
disease .

part

of your

baby's

We will contact
you in 2 months by telephone
or letter
about
drawing a second blood sample from your baby . There will be.
no charge for the second blood drawing.
It will tell
you
whether yourÂ· baby is immune Â·.toÂ· measles, . andÂ· German Â·measles
(rubella)
because of the vaccination.
PLEASE SAVE THIS LETTER 1\ND BRING IT BACK TO CLINIC WITH YOU

- -

-

-~

----~--

-

-~..., ,,,Â·I..
~

..._____,..

NEW YORK UNIVERSITY fv\EDICAL CENTER
School oi Mcc.Jicinc
i'iO fll:ST A\'[SUE. S[\V \ 'ORt.:, ~ . Y. 10011,
..\~U .: I.! 1,~â€¢t-J.!OO
C,\1)1 C ,\l)01:r,,;

, :-.\'l.'~ICOIC.

September

OeparrmenloiPediJlrics

Ar~ene

A. McLean,

21,

1976

Ph.D.

Merck Sharp & Dohrne
Research Laboratories
Division
of Merck & co.,
West Point,
Pennsylvania

Inc.
19486

Dear Dr . McLean:

Enclosed is a copy of the revised
consent
form for measlesmumps-rubella
RA 27/3 vaccine,
and a letter
from the Chairman of the Buman Use committee granting
approval
of the
consent.

I hope we can have

the

new vaccine

soon.

Many thanks.

Sincerely

yours,

Anne A. Gershon, M.D.
Associate
Professor
Department
of Pediatrics
AAG:rr
Enclosure

â€¢

---------

-

~ E\V

YO RK U ~ IVE RSIT Y ,'v\ED I C,\ L C ENT ER

â€¢â€¢ i:1111i , Â·,, .\\1â€¢(jt('fl~1â€¢

.:: 11~-! â€¢. ,1,1,L.,1w,o.:11.

.,.v

l Â·lâ€¢ll 11

Â·. d \ .: : .: -. . ,, .. 1 ~â€¢'â€¢J

:Jtâ€¢n.ir11111
.-n1 oi l'c'lli,llrics

STUDY

OF lÂ·'tEi\SLES

- ?-1UMPS -

RUBELL.~

VACCINE

In the United St~tes,
measles,
mumps and ruoella
(German ~easles)
va==ine should be given to baoies
between the ages of 12 months 15 !~Onths.
These va::::-ines are i.mportant: be=ause they . provide
l)aoies
::lnd ::hildren
wi. Â·:h ~-onq-lastinq
itMmni ty to :nea~ le~. r;ii.1rr.ps
ana ru~ella
(German measl~s).

l

I

Many =lini=s
are now giiing
babies
a oombined measles-mumps-rubella
va:=cine in one inje=tion.
Our clinic
has re=ently
received
a new
vaccine which contains
regular
measles-mumps
vaccine
combi ned wit:h
a new, unli=cnsed
rubella
va:=cine called
RA-27.
This RA-27 va=::ine
has been ~sed experimentally
in many =hildren
(in Europe)
and it
seems to produ:::e better
antibodies
th~n the one which is now licensed
for use in the United States.
Our study is designed
to see how good this experimental
rubella
AA-27
vac:::ine really
is.
It is combined wi-:h the measles-mumps
va::=ine so
that your ~hild will only have to have one injection.
We will also
have to obtain a small sample of blood (5 ml or about a teaspoonful)
before
~nd eight weeks after
the vaccine
is given.
The known side effe:::ts
of this type of vaccine
are very few and occur
only rarely
in children.
The side effects
are fever,
rash,
and joint
pain . Should any of these c::~ur they will disappear
after
a few days
without
any treatment.

If you would like your child to receive
the measles-m~mps-RA-27-rubell
va:==ine you should sign this sheet in the space provided
for your
signature.
Your child does not have ~o participate
in this
study
if you ao not want him (her) to.
In that case your child
should
receive
rcgul~r
measles-mumps-rubella
vaccine
in our clinic.
Should
you d~cidc to have your child participate
in this st~dy,
his (her)
participation
will be kept strictly
confidential
.

SIGNATURE

NEW
.YORKUrJIVERSITY
MEDICAL' 'ffER
:0:.w&"" â€¢ . ,. oa...0 11~' Â·â€¢ â€¢tC I ~

Ann e A. Gorshon,

M. D.

Measle s

Vac~ine Trial
---------

~OINM.â€¢a

I

Â·u-----------------

Rubolla

.,-,_ioo

J~

it9"C 0, NOGâ€¢â€¢w;

Â·x
.
;
â€¢tlt.&II

C H.

..

I

SYNOPSIS OF SPON~o;

rlMKâ€¢â€¢~
SIC:i(bi(6)Â°' IDil"&iiTacaf
_

-- -----

------

- --

--

Podiatries
-Â·

- ---,.-

I_,oo,-

PROGRAM ACTIVITll

---~----.,..

â€¢â€¢ , ~ ,o., ...,, â€¢o.
...........,. â€¢'Câ€¢

. 1tD Tfl&INt",;,
UC &T 10 N
O

---------------

PART IVA HUMAN SUBJE CTS C CONTINUE DI

.

A. List spe cific p,1:1cedv,o to lie vud . hich involv e humon 1ulijects or humo11mo'ter ial s; deto it poten ti al hoza,ds and
indicot e the p, 1:1bob
il1ty thot they moy occur . If p,ocedur â€¢ , 1 heretofore vrmi ecf, ollcf ho101d1 ore not lt11own, 1 0 ,nd ic ote .

8. De1c,ibe the benefit to ti"

111b jecâ™¦ o, odvo11ceme nt of lr.nawledge thot wi ll bolonce the ri 1k involved.

C. Indicate meuur u p,oposed to 111inimi&e,i1lr. ond. if oppl icabl e , method,
,u lljecr1.

A.

1.
2.

for preun,ing

confiden t,o lity ond rights of the

1'Rc. ro cc; t...
Venipuncture
before and 8 weeksafter
vaccine is given . No apprecia~
haza rd . 5 ml or less blood will be obtained .
Measles-rubella
vaccine.
No appreciable
hazard.
Measles component ~
li censed product r outinely
given to infants
of this age . Rubella va ~
cin e i s unlicensed
in the United States,
but has been widely gi ven t :
chil dren i n Europe . Side effects
from this vaccine are very few in
children
and similar
in rate of occurrence
to the rubella
vaccine
which is licensed
in the United States . Possible
side effects
are
ra sh. fever and joint pains all of which are transient
. In a recen~
atu dy conducted by Merck. the following
side effects
were observed.
Those receiving
licensed
rubella
vaccine:
24 . r ash - 0 , arthralgia
adenopathy - o. Those receiving
RA-27 r ubel l a vaccine:
26 .
rash - 3, ar th r algia - 1, adenopathy - O.

B.

Benefit
to patiQ nt - Inf ant wil l he immunized ag ainst rubella
a nd measles
with only one injection
and one clinic
visit.
RA-27 rubella
vaccine may
provide better
i mmunity than the presently
li cen s ed rubel l a vaccine.

c.

St erile
technique will be used at all times ana the i denti ty of th e pati~ .
will not be revealed in any publ ic ations concerning
th is study â€¢

........'"'

Â·.r....---

........
, --â€¢~~~.,.. . -- Â·:- . .,..,,
_.
, .........,..,...â€¢. .â€¢. ,......~ â€¢ .._.......-..-..... -Â·--- -----------

-Â· - -Â· --

-

MEASLES- RUbELLA VACCINATION

c.- No.-------

......, NoÂ·--11""â€¢1'"",---

-Â·......._,

-Â·

.. ,~
,

I:-i.:1,-Â·-Â·Â· lÂ»-011
.... ..

Cf

I

-.

c ..........
o ...............
c ...........,
0..01

.. _

CYlccl-

-

CT

I

DAY

DATl

O.â€¢ol-

1 â€¢ 'l'U

Zâ€¢NO

:

C:.0,,,,,-.

..

:

. OieroMd ttv :

...

LMNo.

Old CIIIICIo..etoo dilllc4il O.-:

0 C-.OI

-111

....,,

T---

~-

.....

es-...o.-:

Dita ol V-inttion

c,o-,,i

-

......

..
~
J
â€¢ .
~
â€¢
t
c
..
...â€¢. 1 ti j I ~" rai =. 6 '&â€¢ ., ..: l " i ,.
I~
}
i .~ , Â·iI,~
Â·! l

I

6

l5
C

<

C

.
:

â€¢â€¢
â€¢â€¢

!

oa 15

2S

24

0
1
2
3

-!
:?

~

'11

~

C

:

i::,

u

!

1'

! 01 : 03 I o,

OS

12 I 50

OTHER REACTION$

1!\

,;

~ :!
Â«:

f 51

!

-=
~

11

:,z

.

"\

I
I
I

:

â€¢

(T,.e, Loutionl

,I

!

Â«:

~

;

..,_,.,

I

I

I

I

I

I

7

:
i
:

10
II
12

I

I

!
I

13

"

II
11

:

17

I

II
19
20

l

21

:

I

I

I

I

â€¢

I

I

:

22

I

23

I

24
JS

i

;

H
2,

I

2t

:

20

:

>o,

!

.JI

I
I

:

:12

I

.

Jl
Joi

!

~

I

37

!
!
I

,.
JI
J9

â€¢o

"42

1..., ,.,.,,.,.
c~â€¢t#d

:
,.,,,,,.

â€¢â€¢ :

ii*,.,,,.
;iN~ copâ€¢ let â€¢ ..,, ,,..,

II, R. ltllUMAN . P~O. D~
MERCI( SHAii, r. DOHM( RESEARCH l.ADORATOIUEI
WUf POINT, ,cNNSYI.VANIA, 1t.ill, U.LA,

........

__

,.,,,, .,,._,.,,.

"""'c-,u,... Ir.,,'1

e,

0..,

,r,~1/

,, â€¢â€¢ o ...

. ..

,

Reference

No. 7

Program:

Study 1511 - To measure antibody and clinical
responses
three consecutive
lots of combined measles-mumps-rubella
virus vaccine .

Vaccine :

Combined live

measles-mumps - rubella

(RA 27/3) v irus

vaccine ,

lyophilized
Lot 160664/C-EB l O
Lot #60665/C-ESll
Lot #60666/C-E812

Responsible

Clinical

Investigator

:

M. Villarej os , M.D.
Director
Louisiana State University
International
Center for Medical
Research and Training
Apartado 10 . 155
San Jose , Costa Rica

Victor

Study Location:

Nicaragua

Date Study Initiated:

July 4 , 1977

Date Study Completed :

September 14, 1977

Study Procedure:

One hundred fifty children , 8 months to 11 years of age,
were included 1n the study . Each received a 0.5 ml
subcutaneous dose of combined live measles-mumps-rubella
-virus vaccine . Blood samples were obtained on day of
vaccination
and 6 weeks after vaccination.
Each child
was followed 6 weeks for clinical
complaints .

--

- - ------

- -----

---- - -

to

(Dr. Villarej

Clinical

Protocol

- Study #511

Combined Live Measles-Mumps-Rubella
Virus

(RA 27/3)

Vaccine

Program:

Combined live

Purpose:

To measure antibody
lots of vaccine.

Vaccine:

Combined live measles-mumps-rubella
Lot. No. 60664/C-E810
Lot. No. 60665/C-E811
Lot. No. 60666/C-E812
Vaccine

os)

measles-mumps-rubella

virus

and c1inical

vaccine

responses
virus

to three

consecutive

vaccine,

lyophilized,

dose is ' 0.5 ml given subcutaneously.

The vaccine is supplied in single dose vials.
Each vial should
be reconstituted
with 0 . 7 ml of sterile,
pyrogen-free
distilled
water which is supplied in prefilled
syringes .
CAUTION: The vaccine contains
egg protein and should not be
given to pers ons wit h known sensitivity
to chicken or duck,
chicken or duck eggs or feathers . The vaccine contains
neomycin
and should not be given to persons sensitive
to neomycin . Persons
with leukemia or other immunologi c disorder
and persons receiving
immunosuppressive
drugs should not be vaccinated . Also, the
vaccine should not be given to persons with a febrile
respiratory
illness
or other active febrile
infection .
Keep dried

vaccine

stored

Keep dried

vaccine

at 4Â° C in transport

Keep reconstituted
after rehydration.
Procedure:

vaccine

at -20Â°

on ice .

Informed written
consent will
of ea ch child who participates

-â€¢

~

-â€¢

I

used.

.

Discard

unused vaccine

4 hours

The study population
will consist
of up to 150 children
with a
negative history
for vaccination
and illness
caused by -measles,
mumps and rubella viruses . The children
should range from 1 to
6 years of age.
Approximatel y 25 to 50 children
vaccine lots.

Revised

C until

4/22/77

â€¢

. -Â·--Â·- -- - Â·- - -- Â· -----

--

will

receive

each of the three

be obtained from a parent
in the stud y .

or guardian

Page 2
Clinical
Protocol - Study #511
Combined Live Measles-Mumps-Rubella
Procedure :
(Continued)

Each child
vaccine.

will

(RA 27/3) Virus Vaccine

receive

a 0.5 ml subcutaneous

injection

of

Bleeding samples (10-15 ml) will be obtained from each child
immediately before and 6 weeks after vaccination.
Each child will be followed clinically
for local and systemic
complaints
occurring
within 6 weeks after vaccination
.
Observations
should include special notation
for rash, nodes,
arthralgia,
arthritis,
fever, malaise and anorexia.
All
complaints
should be recorded on the case report form.
Schedule:
Time

Action

Day 0
Vaccinate

- All Persons

Bleed 10-15 ml
0.5 ml, subcutaneously

Days 0- 42

Clinical
follow-up for local
and systemic complaints

Week 6

Bleed 10-15 ml

Laboratory:

Remove serum from clot aseptically
and store frozen at -20Â° C
until shipped . It is imperative
that sera are sterile
to avoid
interference
with the serologic
assay.

Serology:

Levels of circulating
measles and rubella
antibodies
will be
determined by hemagglutination-inhibition
test.
Levels of
mumps antibody before and after vaccination
will be determined
by serum neutralization
test.

Clinical
Adverse
Reactions:

Forms:

Attached.
Any serious or alarming reaction,
including
death due to any
cause during the investigation,
whether related
or not related
to the test material,
must be reported
immediately
to Merck & Co. ,
Inc., through Dr. Maurice R. Hilleman, telephone
(215) 699-5311,
Ext. 5532, or in his absence, Dr. Arlene A. McLean, telephone
(215) 699-5)11, Ext. 6383 .

Page 3
Clinical
Protocol - Study 0511
Combined Live Measles-Mumps-Rubella
Unused Vaccin e :

Shipping of
Sera & Records:

(RA 27/3)

Virus Vaccine

All unused vaccine should be returned immediately to Merck
Sharp & Dohme Research Laboratories,
West Point, Penns ylvania
19486.
1.

Send sera frozen
are supplied,

within

insulated

containers

which

2.

Send sera and records to Dr. Maurice R. Hilleman,
Virus & Cell Biology Research, Merck Sharp & Dohme
Research Laboratories,
West Point, Pennsylvania
19486.

3.

Alert Dr. Hilleman by cable as soon as possible
flight number, air bill and date of arrival.

regarding

(_ /1 // '~;
/!LQ
JJ!~~
'-----22~ -- Â·M. R. Hilleman, Ph.D.

_

OBSERVACIONES CLINICAS

Oâ€¢I nlno:

I

Emidio No. _____
CT

2

No. Del Caso _ _ _____

I

Nombre

compteto

I

01,eccion

>(3.5) ]

Â·"

F

Fecna de nacimlâ€¢to

I

e11a

mes

NO. de LOTE ________

FECHAS de SANGRIA ______

_ l49-51)

FECHA de VACUNACION

_

(52-6n

_

f46-47J

ano

SEROLOGIA _____

____

(56Â·63)

_ _ _____

Tarnpo reture
i

II
I

Fedie

I

;;;

I

~

'
24

0
1

I
I

2

I

;;;

.;

a:

:E ..
Q)

"O

E

;g

~

0
C
<(

t~

~

~

>

16

2S

08

15

14

o,

.,

.!!?

Ki

:!'

)(

:0
g
.,

.,.,
~

"l

a:

..

,!!?

:?

.,

;;;
0.
0
C

.;;;

RASHâ€¢

., E.,

(J

0
..J
C
0

E

~

~

:,

~

..

0

"O

0

u

...J

03

06

05

-;:;

a:
a:
12 51

62

â€¢ Ea.pecifique tipo .,

Â·;;, "'

.. Â·c 'E.. :.:., 1l :c t
C
:,

(70-75)

~

,,

en. MCCion

OTRAS REACCIONES

~

~
32

I

I

'I

3

I

4

I

I

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29

I
I

I
I

'

!
I
I

'
I

l
I
I

I
I

'
I

I
I
I
I

II
I
I

I
I

I
I
I
I
I

I
I
I

I
I

I
I
I

I
I

30

I
I

31

1

32

I

33

I

I

34

I

35

I
I
I

I

36
37

I
I

t

38

I

39

I

40
41
42

I

I

I

:

Al terminar et tttudio, devu1/v1 copia blanca y copi, Mnttri/11 de esu, form,
(Reteng, copia color de rou p,r, 1111 err:hi110s)
M. R. HILLEMAN, PhD, DSc

MERCK SHARP & DOHME RESEARCH LABORATORIES
WEST POINT. PENNSYLVANIA, 19486, U.S.A.

Firm, def rnBdico:

I

Hombre def medico (tm letra de mo/de):

Ft1eha:

~

TR,Ule-0,77(DOMI

>

I

(36-41)

completa oe Padres o Guardiln:

0 VACUNADO
0 CONTROL {48)

Die

_ _

(!>-9)

0Â·3)

~

--

-- ~

-,.,. -:

Â·-Â£ ~

_

-,

PSFiR "TiiffiiEJ

0st

ET

â€¢

' o"Â½d:~MFrrn FE

a

1-

I. ,.
I

:

I

i

Table

1

Serological
Findi ngs Among Children Who Received Combined Live
Heaelea-Humps-Rubella
(RA 27/3) Virus Vaccine, Lot l60664/C -E810 (Study 1511)
Initially
SeroneRative to:
Measles-Mumps-Rubella
Measles-Munms
Measles-Rubella
Ku1111>s-Rubella Heaalea Only Munma Onlv
Ro, Se'l"ol.
Conversions/Total
Conve.raiona /T otal Conversions/Total
Conversions/Total
Conversion s/ Conversions/
Vacc. Teated Measles Humos Rubella Measles MUIIP& Measles Rubella
Humps Rubella
Total
Total

No.

Aire

(Montha)
8
9
10

1

1

I

1

2

2
1
2
3
2

11

]

12

2
3
2
2

lJ

14
17
21

2
1

(Jean)
2

10

J

6

8
6

4
5

2
4
1

6
7
8

2

2

1/1
0/1
1/1
2/2

1/1
1/1
1/1
2/2

l/1
1/1
1/1
2/2

2/2
1/1

2/2
1/1

2/2
1/1

1/1

1/1

0/1
1/1

1/1
1/1

0/1

1/1

4

1/2

1/2

2/2

1
2
2

1/1

1/1

1/1

1/2
1/1

1/1
0/1
1/1

1/1

1/1

1/1

1/1

1/1

1/1
1/1

2/2

1/1

3/]
3 /3

2

11

ffotal

50

44

Hean Aire:

3.3 Years

1/1
1/1

1

1/1
9/11
10/11
11/11
(81.8%} 1(90.9%1 (100%)

1/1
(100%)

1/1
(100%)

Kea.ales
16/22
(72. 7%)

1

1/1

1/1
1/1

1/1
1/1
2/2

1

14/14
'100%)

2

1/1

6/9
9/9
(66. 7%) (100%)

Overall

Initially
Seronnaitive
to: Â·
Kessles, Mu111pa
and Rubella

1/1

2

2
2

9

1/1
1/1

I

2
l

18

.

1/1

Rubella Onh
Conversions/
Total

4/4
4/4
(100%) (100%}

Conâ€¢eraion

Rates

Rubella
Huns
1718
38/38
(94.4%)

(100%)

0/1

2/2
(100%)

It

,

â€¢

,

â€¢ ,

._

J

â€¢

â€¢

,

â€¢ .., ...

~

-Â·Â· ...

..ir., ~11t. â€¢

â€¢

'

â€¢

iÂ·

Table

,.. '
'

2

Serological
Findings A1110ng
Children Who Received Combined LiTe
Heaeles-Hu111pa-Rubellt1 (RA 27/3) Virue Vaccine, Lot 160665/C- ESll (Study Oll}

I

Inltiallv
Seroneeetive to:
Heaalee -Ku11ma Measles - Rubella
Humos-Rubel la
Heaalee-Humoe-Rubella
Sero!.
Cooverslooe/Total
Conversions/Total
Converelons/Total
Conv relons/Total
Mumoe Rubella
Humos Rubella
Keaslee Huâ– oe
Heaeles Rubella
Teated ~easies
No.

Aire

No.
tacc.

Heeelea Only MUlllpaOnly
Conversions/ Conversions/
Total
Â·Total

Initially
Rubella Onh Seropoeitive
to:
Conversions/
Measles, Humps
Total
and Rubella

(Hontha)

16
17

1
2
1
2
1
1

1
1
1
2
1
1

18

3

3

I

21

1

1

I

(Years)

2

9

9

3
4
5
6
7

7
1

7
6

8
6

8

1

1

11

12

!i

~ . . _J

- -- I

I

'!

13
11,

1/1

1/1

1/2
1/1

1/1

1/1

1/2
1/1

1/1

1/1

1/1

1/1

0/1

1/1

1/1

1/1

1/1

2/2
1/1

1/1

1/1
1/1

s

50
47
Total
Hean Age: 3. 3 Yeara

1/1

J/1

1/1

1/1

0/1
1/1
1/1

1/1

1/1
4/4
2/2
1/1

1/1
4/4
2/2
1/1

1/1

1/1

1/1

1/1

1/1

. 1/1

.,.

4/5
<80.0ll

4/5
(80.0%)

5/5

noo11

1/1
'100%)

1/1
(100%)

5{5
(80.0%) '100%}
lt/5

Overall
Measles
10/12
(83 . 3%)

12/13
C92.3U

13/13
r,nn'I'\

1/1

.

.â€¢. .
. 1/1 Â·
(100%)

5/5
2/2
2/2
6/6
313

1

1/1
1/1

(100%)

20/20
(100%)

1

Conversion Rates

Humps
18/20
(90.0%)

Rubella
43/43
(100%)
1/27/78

l\Â¥Â¥5#

.. ,. ' .

. - . ..,

,..

. r Â·i i -iti, S't,#

i 8I

!WM

â€¢=Â·s

e

Table 3
Serological
Fi ndings Aaong Children Who Received Co111binedLive
Measlea - HU111pa-Ru
bella (RA 27/3) Virus Vaccine, Lot l60666/C -E8 12 (Study 1511)

I

iI
I

Age

Mo,
Vscc .

Ho.
Serol.
Teated

(Montha)
11
13
17
19

1
1
l
1

1
1
1
1

(tea rs)
2

8

3

8

8
8

4

11

11

5

8

8

6

4
5

4
4
1
1

Heaslea-Huups-Rubella
Conversio ns /Total
Meas les
Humps Rubella

Initial
Measles-Rubella
Converalons/Total
Measles Rubella

ly Seronegatlve
t o:
Humps-Rubella
Measles Only
Conversions/Total
Conver sions/
Hu111ps Rubella
Total

Ml111lDII Only

Conversions/
To t al

Initially
Rube lla OnlY Seropo11itive to:
Conversions/
Measles, Humps
Total
and Rubel l a

I

I
!

I
i

..
I

Ii
1

-j

i
j

l

7
9

1

11

I

Total
Hean A"e:

50
4 .~

49
tears

1/1
1/ l
1/1

1/1

1/1

1/1
2/2

1/1

2/2
(100%)

1/1

2/2
(100%

1/1

2/2

1/1

2/2
(100%)

1/1

1/ 1

0/1
2/2

1/1
2/2

J/J

J/J

2/4

4/4

1/1

1/1

3/ 3

J/J

(100%)

(100%)

9/12
OS . OU

12/12
(100%)

Overall

Conversion

Rates

Measles
6/6
(100%)

1/1

1/1

uoou

1/1

1/1

J

4/4
4/4

2

1/1
1/1
1/1

1/1
2/2
1/1
1/1
1/ 1

4/4

17/17
(100%)

(100%)

2
1

1
1

10

KU111p1t Rubella
15/18
34/34
(BJ. 3%)
(100%)

1/27/78

Table 4

Distribution
ot Poet-Vaccination
Antibody Titers AmongChildren Who Were
In1tial1y Seronegative to Measleâ– , Mmaps, and Rubella, Who Received Combined
Live Measles-Mumps-Rubella (RA 2T/3) Virus Vaccine, Lot #60664/C-E810 (Study 1511)

Measle11 (HI)

Mumpâ– 

Poat-Titer

lfumber

Diâ– tribution

ot Children

<5

'

2

5
10

1

20

3
1
3

Ito

80
160

Total
Geaaetric

Poat-Titer
Distribution

Rubella

(Neut)
Jtum.ber

ot Children

{2
2

1

..8

3

16

1
1

32

2
3

1
11

Mean Titer:

Total
Geometric Mean Titer:

Poat-Titer
Distribution

(JII) .

lfumber

or Children

128
256

la

2512

2

Total
Geaaetric

5

Mean Titer:

11
-2225.T

11

1-.8

20.5

l/'ZT/78

Table

5

Distribution ot Poat-Vaccination Antibody Titers AmongChildren WhoWere
Initially
Seronegat!Te to Meaelee, Mumptt, and Rubella, Who ReceiTed Combined
LiTe Meaelea-Mumps-Rubella (RA 27/3) Virus Vaccine, Lot 160665/C-EBll (Study 1511)
Measles (HI)

Rubella (HI)

Mumps (Neut)

Post-Titer
Distribution

Number
of Children

!'()st-Titer
Dhtribution

lumber
ot Children

<5

l

<2

1

10

4

20

6

40
80

3

160

1

1
1

32

5
25.2

64

Total
Geometric Mean Titer:

3
2

256

16
âœ“

l'ium.ber
ot Children

128

2

5

Total
Oeometric Mean~lter:

Poat-Titer
Dhtribution

Total
~etrie

5

Mean Titer:

168.9

2

5
10.6

l/ZT/78

Table 6

Distribution
ot Post-Vaccination Antibod7 Titers AmongChildren WhoWere
lniti&ll7
SeronegatiTe to Measles, Mumps,and Rubella, Who ReceiTed Combined
LiTe Measles-Mumps-Rubella (RA 27/3) Virus Vaccine, Lot 160666/C-E812 (stud7 1511)

Post-Titer
Distribution

Rubella (HI)

Mumps (Neut)

Measles (JII)

!umber

ot Children

Post-Titer
Distribution

Post-Titer
Distribution

lhmtber

ot Children

!umber
ot Children

'

20

i.o

1
1

256

8

2

Total
Ceoaetrle

2

Total

8.0

~etrie

2
I

Total
Geometric Mean Titer:

2

Mean Titer:

2

Mean Titer:

256.0

28.3

l/'n/78

-:-,:,: Â«;;;&td Â·S At4ff M;Â¥>Ct'il#

,: s

cl , : â—„

c, ,;-,;;ms, - ,G ' â–  tsw :atstttÂ·
1

â€¢â€¢

::nr::~-.
â€¢

1

Tab le . 7

L

Ma:dmt111Temperatures Reported AmongChildren Who Received Co111bined
Live Heaales-Humpa - Rubella (RA 27/3) Virus Vaccine, Lot f60664/C-E810 (Study #Sll)

II
I

I
Maximull Temper ature
0
( r . Oral)

'l

(99

99 - 100.9

Total Vaccinees (SO Childr en)
Days Post Vaccination
No, with
5- 12
13- 18
19- 28
29- 42 Max. Temp.

0-4

48
(96.0%)

44
(88.0)

4S
( 90.0)

47
(94.0)

12
13
(92 .3) (100)

10
(76,9)

2
(4.0)

6
(12. 0)

(10 .â€¢0)

s

3
(6. 0)

1
(7. 7)

3
(23.1)

0- 4

50

3S

(100)

IS

lnitiallv
Serone,: a t i ves (13 Children)
Davs Post Vacclnation
No. with
5-12
13-18
19- 28
29- 42 Max. Tem,.
13

(100)

13
(100)

9

4

--~l
\

I
â€¢ 1
' .

i'

1/31/78

t#ftffi'

Pt4

M HF<

t&

..,,

, , ..

â€¢.,

..â€¢

â€¢

â€¢ â€¢ â€¢

.i'- â€¢ â€¢ r

r

â€¢ â€¢

â€¢

>4â€¢-,_ ,.

"" """ Â·Â·"'

Â·,â€¢

.. .

II

I

! ., I

Table 8

'

Maxi111Um
Teaperatureâ–  Reported AIII01lg
Children Who Received Combined
Live Heules-Hu11ps-Rubella
(RA 27/J) Virui, Vaccine, Lot 160665/C-E.811 (Study 1511)

7

Total Vaccineea (50 Children)
Days Post Vaccination
29-42
19-28
13-18
5-12

Hax:l.anl Telll)erature
(OV. Oral)

0-4

09

47
(94.0%)

42
(84. 0)

47
(94.0)

45
(90.0)

(96.0)

99 - 100.9

3
(6.0)

8

(16.0)

.3
(6 . 0)

5
(10.0)

(4.0)

48
2

Mo. vith
Max. r-.
31

19

0-4

Initiall"I' SeroneutiveB
(6 Children)
No. vith
Days Poat Vacci nation
29-42 Max, Tem1:1.
19-28
13- 18
5-12

6
(100)

5
(83. 3)
1
(16. 7)

6
(100)

s

(83. 3)
1
(16.7)

6
(100)

4

2

I

-l

I
I
I
'i
i

1/31/78

WSWJ#

# Witâ‚¬Â§514t46

'3 211#1>

. " ...
-c-----....
. . â€¢ Â·t!M%

._,

Â·.,
.,.
.

-~

Â·'

.

â™¦

Table
Lin

Ha11:t11111111
Temperaturea
Reported Among Children
Keaale11-'Hu111p11-Rubella (RA 27 / 3) Virus Vac~ine,

Kaxiaua Te111perature
(Â°F.

Orall
(99

0-4

50

(100%)
I

Â·Â·--4

99 - 100.9

9

Total Vaccineea
(50 Children)
Daya Post Vaccination
5-12
13 - 1 8
19-28
29-42
40
(80.0)

10
(20.0)

47
(94.0)

3
(6.0)

50
(lOO)

,\7

_ No. vith
Kax. Te11m,

36

(94.0)

.3

14

Who Received Combined
Lot f60666/C-E812
(Study

0-4
2
(100)

1511)

Initially
Serone2ativea
(2 Children)
Dava Post Vaccinat i on
No. rith
5-12
13-18
19 - 28
29-42
Ma11:.T-...

2

(100)

2
(100)

2

2

(100)

(100)

2

0

(6 . 0)

1/31/78

"ittâ€¢e:wmrn:~azwn
\

&:it -:Â· dt!At A}J-3 <;-;a It

iZT?lWZZ-ftWFfft'.i

re a

.. f if WE

SfPFff 'ffiYS

j

g-Â·

ca SM I .â€¢â€¢

.

,Â·

Â· Table

10

'

I

Clinical

l:
I
I

Live

l

1

I

.

,
I

Clinical

Cnanlaint

Headache

0-4

Malaise

1
(2.0)
8
(16.0)
9
(18.0)

2
(4. 0)

1
(2 .0)
6
(12. 0)

1
(2. 0)
1
(2.0)

{2.0)
3
(6.0)

Anorexia
Upper R.eapiratory
Lover Respiratory
Gastrointestinal

Illneaa
lllneaa
Ulneaa

Persona with Complaint:
Persona with No Complaint:

Alllong Children

Total Vaccineea (50 Children)
Days Poet Vaccination
5-12
13-18
19-28
29- 42

(2. Olt)
5
(10. 0)
7
(14.0)

1

lrritabilit1

Coâ– plafnta Reported

Who Received

7

Cl4.0)
43
(86.0)

1
(2.0)

4

18

6

5

(10.0)

4
(8.0)

(8.0)

3
(6,0)

(2.0)
1
(2.0)

4

17

7

8

(18.0)

(14 . 0)

41
{82.0)

43

42

(86.0)

(84.0)

'16.0)

2
(15 . 4)
3

3
(23 . l)
3
(23.1)

3

1

7

(23.1)

(7. 7)
2

1

3

(23. 1)

(15.4)
1

1

(7. 7)
9

2

2

(15.4)
1

4
(8.0)

0

2

1

1
(2.0)

Initiallv
Serone2ativea
(13 Children)
Dave Poat Vaccination
No. vith
0-4
5- 12
13-18
19-28
29- 42 Co,.,,laint

(23. 1)

1

9

No, with
C0111Dlaint

1
(2.0)

(12.0)

Combined

Lot l606f;4 /C-E810 (Study 1511)

Me1111le.a-Hu111pe-Rubella
(RA 27/3) Virua Vaccine,

2

1

1

(7.7)

(7.7)

7

(4 ,0)

2
(4.0)
48
(96.0)

21

29

l
1
(7. 7)

2
(15.4)

3

3

4

(23.1)

(23.11

{30.8)

2
(15.4)

10

10
(76.9)

9
(69. 2)

(84. 6)

06. 9)

11

1
(7 . 7)

3

1

8

(7. 7)
12
(92 â€¢ .))

5

1/31/78

tsÂ«>

D

'.

i.
Table 11
Lin

Clinical

i

Cmmlaint

Headache

-. - !

I
I

Irritability
Malabe

Clinical Complaints Reported Among Children
Heaelee - Ku11pe-Rubella (RA 27/3) Viru11 Vaccine,

0-4

Total Vaccinee11 (50 Children)
Days Post Vaccination
5- 12
13-18
19- 28
29-42

2
(4.0J)
2
(4.0)

I
(2.0)
9
(18.0)

2
(4.0)

7
(14.0)
1
(2.0)

Anorexia

Upper Respiratory

lllne1111

Lover Reapirator:,

Illne1111

Gaatrointestinal

Illneea

Persona vith
Peraon11 vith
Neaative

Complaint:
No Complaint:

Surveillance

2
(4 .0)

(8.0)
4
(8.0)

2
(4.0)
5
(10.0)

2
(4.0)

(6.0)

4

3

3

2

(6. O)

(4.0)

2
(4.0)
48
(96.0)
0

11

(22 . 0)
39
(78.0)
0

7
6
(14. O} (12.0)

43

44

{88.0)
0

18

l

(16. 7)
1

(16. 7)

1
(2.0)

(86 . 0)
0

1
(16. 7)

12

1
(2.0)

1

InitiallT
Seronegative11 (6 Child ren)
Daya Post Vaccination
No. vith
0-4
5- 12
13- 18
19- 28
29-42
Co111t1laint

(6.1)

3

(2 .0)

Ro. vith
Conmlaint
8

4

(8 .0)
1
(2.0)

Who 'Received Combined
Lot l60665/C-E8U (Stud:, 1511)

3
(6 .1)
46

1
(16. 7)

2

1
(16.7)

2

1

0

4

0

1

0

5

0

20
30

(93. 9)
l

1

0

0
6
(100)
0

l

l

1

(16. 7)

(16. 7)

(16. 7)

5

5

5

(83.3)
0

(83.3)
0

(83.J)
0

0

3

5
(100)

3

l

0

1/31/78

:-f\,.,.â€¢.,.'lft:â€¢--..-.
â€¢ â€¢

1

-â€¢

â€¢ â€¢â€¢

â€¢

,,.

~ ..

...

~ â€¢

â€¢

... ...

"'-

a, '11,

â€¢

â€¢â€¢ â€¢ ~

...

..-.-

..., .

â€¢

r

â€¢â€¢

â€¢

~

...,

â€¢

â€¢

Table
â€¢

Clinical Co111plainu Reported Among Children
Live Ke11de11-M11mp11-Rubel111
(RA 27/3) Virua Vaccine.

I

I

i

Total Vaccineea (50 Children)
Davs Poat Vaccination

l

Clinical

I

1

C111mlalnt

0- 4

5-12

13 - 18

2
(4.0%)

(8.0)

9
(18.0)

3

1

(6 .0 )

(2,0)

(4.0)

6
(12.0)

4
(8.0)

1
(2 .0)

3

1

(6 . 0)

(2.0)

l
(2 . 0)

Headache

j
i
I
l

l
I

1. J

~

I

~

12

I

I
t

-I
~

Irritability

1
(2.0)

Malaise

2

Anorexia
Upper R.uphatory

Illnl!.lla

Lover Respiratory

Illneaa

I

'

, I

19 - 28

29 - 42

4

0titia

'

Caatrointutinal

2
(4 .0)

12

Persona vith

Complaint:

Persona with Ko Co111plaint:

1

1

3

13

0

1

(6 . 0)

1

(50.0)
5

0

2
(4.0)

2

0

1

1

0

1

0

2

0

1

Illneaa

Initially
SeroneRativea (2 Children)
Daya Post Vaccination
No. vith
0-4
5- 12
13 - 18
19 - 28
29-42
co-laint
(50.0)

(2.0)

I

No. vith
Co..,laint
6

(2.0)

I

!

Who Receivl!d Co111bined
Lot #60666/C - E812 (Study 1 511)

1

1

1

(2.0)

(2. 0)

(2.0)

2
(4 .0)
48
{96.0)

11
(22.0)
39
(78 . 0)

6
(12.0)
44
(88.0)

1

3

(2.0)
49
(98 . 0)

(6.0)

47
(9 4.0)

17

0

0

33

2
000)

2
(100)

l
(50 .0)
1
(50.0)

0

0

1

2
'100)

2
(100)

1

1/31/78

MEMO
From

Subject

Date 2/6/78

Location

To File

Location

T. Schofield

Statistical
Analysis
Virus Vaccine

- Study #511, Combined Live Measles-Mumps-Rubella

Significant
differences
in seroconversion
rates for measles,
mumps,
and rubella
and clinical
reaction
rates among vaccinees
receiving
three lots of combined live measles-mumps-rubella
vaccine were
investigated
. Lots of vaccine were :
Lot #60664/C-ESlO
Lot l60665/C-E811
Lot #60666/C-E812
No significant
to these rates.

differences

exist

among the three

lots

with

respect

Analyses of variance were performed on post-titer
values of children
who were initially
seronegative
to the individual
components . The
log transformation
was used in each analysis.
No significant
differences exist among the groups (lots)
for any of the three components .
A multivariate

analysis
was performed on post-titer
values of
triple-negative
vaccinees.
Again, the lot transformation
was
applied . There was no significant
difference
among the groups.

T. S.

6801

Reference

No. 8

Program:

Study #513 - To measure antibody and clinical
responses
three consecutive
lots of combined measles-mumps-rubella
virus vaccine.

Vaccine:

Combined live
lyophilized

measles-mumps-rubella

(RA 27/3) virus

to

vaccine,

Lot #60664/C-E810
Lot P60665 / C-E811
Lot #60666/C-Â£812
Responsible

Clinical

Investigator:

Robert E. Weibel, M. D.
Director,
Division of Preventive Medicine
Joseph Stokes, Jr. Research Institute
Children's
Hospital of Phi l adelphia
34th Street and Civic Center Boulevard
Jhiladelphia,
Pennsylvania
19104
Study Locations :
Lnnkenau Pediatric
Clinic, Philadelphia,
Penns ylvania
G. A. Starkweather,
M.D. , Havertown, Pennsylva nia
Elizabeth M. Craven, M. D., Wilmington, Delaware
Pediatric
Medical Associates,
Ravertown, Pennsylvania
Children's
Hospital of Philadelphia,
Philadelphia,
Pennsylvania
Date Study Initiated:

June 15, 1977

Date Study Completed :

In Progress

Study Procedure:
One hundred sixty-three
children,
11 months to 7 years
age, have been included in the study thus far.
Each
received a 0.5 ml subcutaneous dose of combin ed live
measles-mumps-rubella
virus vaccine.
Blood samples
were obtained on day of vaccination
and 6 weeks after
vaccination.
Each child was followed 6 weeks for
clinical
complaints.
The study continues
in progress.

of

(Dr.

Clinical
Com1::iinedlive

Protocol

- Studv

(RA ?.7/3)

Vaccine

Program:

Combined live

Purpose:

To measure antibody
lots of vaccine.

Vaccine:

Combined live
Lot . No.
Lot. No.
Lot. No.

measles-mumps-rubella
60664/C-ESlO
60665/C-ESll
60666/C-E812

Vaccine

is 0.5 ml given

dose

n513

~!easks-Hu::ios-Rubell3
Virus

',!,:-ibel )

measles-mumps-rubella

virus

and clinical

vaccine

responses
virus

subcutaneousl

to three

con~ecutive

vaccine,

lyophilized,

y.

The vaccine
is sup?lied
in single
dose vials.Â·
Each vial s~ould
be reconstituted
with 0.7 ml of sterile,
pyrogen-fr e e distilled
water which is supplied
in prefilled
syringes.
CAUTION: The vaccine
contains
egg protein
and should not be
given to persons with knm-r.1 sensitivity
to chicken or duck,
chicken or duck eggs or feat hers.
The vaccine
contains
neonycin
and should not be given to persons sensitive
to neor.:iycin.
Persons
with leukemia or other i mnunolog ic disorder
and persons receiv in 5
irr.munosuppressive
drugs should not be vaccinated.
Also, the
vaccine sh ould not be given to persons with a febrile
respiratory
illness
or other active
febrile
infection.
Keep dried

vaccine

stored

Keep dried

vaccine

at 4Â° C in transport.

Keep reconstituted
after
rehydration.

vaccine

at - 20Â° C until

on ice.

Discard

unused

vaccine

4 hours

The study population
will consist
of up to 150 children
with a
negative
history
for vaccination
and illness
caused by measles,
mumps and rubella
viruses . The children
should rang e from 1 to
6 years of age.

Procedure;

Approxim~tely
vaccine
lots.

25 to 50 children

Infor med written
consent will
of each child who participates

Revised

used.

4/22/77

will

receive

each

of the three

be obtained
from a parent
in the study.

or guardian

Puge

Clinic a l Protocol
- Study #513
C.:nnbined Liv e Measles-:!umps-Rubella

Proce dur e :
(Continu eci)

Each ch ild
vaccine.

will

2

(R..~ 27 /3)

rec eive

Virus

Vaccine

a 0.5 ml s ubcu tan eous injection

Bleeding
sa~ples
( 10-15 ml) will b e obtained
fron
i ~~ediately
befo re and 6 weeks af te r vaccination.

of

eac h child

Each chil d wi ll be f ollowed clinically
for local and s yste~ic
co~plai n ts occur r ing within 6 weeks after vaccination.
Observations
should in cl~de spec i a l notati on for rash, nodes,
arthralgia,
ar thri tis,
fev er-, r::alaise and anorexia.
All
com?laints
should be rec orded on th e case re po r t for~.
Sch edu l e:
Time

Action

Dav 0

Vacci~ate
Days 0-42
Week 6

Bleed 10-15 ml
0.5 r::l, subcutaneously

Cl inical
fo llow-up fo r l ocal
and systemic
complaints
Bleed

10-15 ml

Levels of circulating
measle s and rubella
antibodies
will be
dete r::!i ned by henagg lutin ation - inhibit i on test.
Leve ls of
mumps antibody
befo r e and a fte r vaccinati on will be deternined
b y seru n neutralization
test.

Serology:

Clinical

- All Persons

For ms :

Adverse
Reactions:

Unused Vaccine:

Att ached.
serious
or alarming
reaction,
includir .g Â· dea th due to an y
cause durin g the i nvestigation,
whether related
or not related
to the test material,
must be reported
immed iatel y to Herek & Co.,
Inc. , thr ough Dr. Maurice R. Hill em3n, telephone
(215) 699 -5 311,
Ext. 5532, or i n his absence,
Dr. Arlene A. McLean , tel ephone
(215) 699-5311, Ext . 6383.

Any

All unused vaccine should be r eturned
i mmediately
to Merck
Sharp & Dohme Research Laboratories,
West Point,
Penn sylvania
194 86 .

M. R. Hilleman,

P~ . D.

RUBELLA

.~.IE________________

SYMPTOM

RECORD

STUDY NO. ___

______

_______________

(Last J

w
,,, <

0 Rectal

INSTRUCT

0

I

I

I

I

'

4

I

I I
!

I

I

I

g

:

10 i
11 I

i

I

'

i5

!

i

15 j

I

!

i

I

I

i

((

i

C.

((

ti)

COMMENTS

LL

c:: 0

<I\ I

I

,,,
"'

..I..

1/)

i

I

I

i

' I

I
I

I

i

I

I

i

I
I

I

I

i

'I
I

I

I I

-

I

I
I

I

I

I

I !

I
I

I

i I

I I

I

i

I

I

i

I
I

'I I
I

I
I

I

I

I

I

i

20 I

,

I

I

!
I
I

i

I

I

19 !

c..

I

I

I

i

I

:.:J

IQ ~ I ~ i
r ,w wl O - w

0

I

I

17 i
18

::,

-

....

I

i

14

er

--'--

I-

~1
~ I "'
T

j I ! !
! I 'I !
i
l I ! I I i I I I I
I I
I I
i
I
I ! I !
i I I I
I
I

13 I

I

I-

I

I
I

i

i2

i

c:: w
,,,

---

â€¢ Describe

l!J

I

I

'I
I

((

CASE NOÂ·--

I

I

I

I

I

' <-.

w

~

I

8

t

((

0

_

c::j (( I >
< < c::
O i ~ u LL
_I
z c:: O
~
r
I ::t "'Io
SI OE i 99 I 01 I ?1 101 ioJ I OSI 06 f '18 i l'B , os I
11 I 12 114 161 l 2-i l 2s I

7 i

I

,,,

z> 11w
~
z
c:
0
0 z C:
z ~ I ~ 8 131~i ~ >
u< j ' l!J
w

Ic;
:i

5 !

6

Io I er
I "'

J.

w

(Check One)
IO NS ON REVERSE

w
"z II "'
>

:!

I

0 Oral

I'. ii

SI

019
z ....

DATE

2 I
3

(Mlaa ,e)

"'
I
~I

I- I

I
I

_ _ ___

(First)

Temp1trature

DAY

_

I

21 I
22 I
23 I
2.i I
25 I

I

I

'

I

I

I

'

25 I
27

I

!

I

I

23 I

!

29 I

I

30 I
31 I

I

I

32 I

I

i

I

~,
33

35 I
36 I
37 I

I

38 I
39 !
40 I

I

41 I
,2 :
If

fev~

or unusual reaction

develops, calf:

PLEAS E RETURN

FOR FOLLOW-UP

VtSIT ON: ___________

BE SURE TO BRING THIS RECORD ALONG WITH YOU .
TRâ€¢I

I l-0477JOOM)

_

REGIS T RAT I ON
Case No. _________

Stud y No.
(!Â·3)

CT
2

(5Â·91

Name

Sex

!

I

Address

M

(35)

F

Birtnca:e
me

(36â€¢41J
day

yr

Telephone

BLEEDING
Dat e of Vaccination __

_ _ _____

Lot No. ________

_ ____

Dose & Route _ _ _ _ _ _ ____

_

(~9)

Pre _______

(49-51)

Pos1________

DATES:

SEROLOGY:

__

_

_

(45)

IND ICATE IF THIS CHILD:
Had d isease

0 measles

D mumps

D rubella

Been vaccinat ed

0 measles

D mumps

D rubella

Been exposed

D measles

D mumps

D rubella

Date of expos ure

INSTRUCTIO NS FOR COMPLETING

SYMPTOM RECORD (Reverse side):

1. Please fill i n the date each day.
2. Please take temperature once da lly at the same time and record exact thermometer
3. If no symptoms are present, place a check ( /) under "NONE"

read ing .

beside that day's date.

4. If a symp tom is present place a check ( âœ“ I under it beside that day 's date.

5. Descr ibe other symptoms and ;iny RASH in the space under "COMMENTS."
6. THIS IS VERY IMPORTANT

INFORMATION.

Please do not misplace chis card .

-Â·-Â·
PleasBrecurn compleced forms to :

Phys ician 's Signacure

'

M. R. HIL L EMAN, PhD . DSe
MERCK SHARP & OOHME RESEARCH LABORA T ORIES
WES T POINT. PENNSY LVAN I A. 19486 , U.S.A.

Physician's Name (Type or Prine/

Dace

_

Table 1
Serological
Ftndings Among Children Who Received Combined Live
Measles-Humps-Rubella
(RA 27/3) Virus Vaccine, Lot #60664/C-E810 (Study 1513)

ARe

(Months)
12
14
15
16
17
18
19
20
21

No.
Vacc.

No.
Sero!.
Tested

2
8
21
4

2
8
20
4

7

7

2

2

l

2
1
1
1
1

l

l
l

1
0

Initiallv
SeroneRative
Measles-Humps-Rubella
Measles-Rubella
Convers ons/Total
Conversions 1 Total
Humps Rubella
Measles
Measles
Rubella
2/2
5/5
11/12
2/2
6/6

2/2
5/5
11/12
2'/2
6/6

2/2
5/5
12/12
2/2
6/6

l

1/1

2
0

1/2

1/1
2/2

1/1
2/2

3/3
6/6
2/2
1/1
2/2

3/3
6/6
2/2
1/1
2/2

1/1

1/1

1/1

1/1

to:
Measles Only
Conversions/
Total

Initially
Rubella Only
Conversions/
Total

Seropositi
Heasles
Humps and
Rubella

ve to:

2/2

(Years)

3
4

5
6
7

Total
Hean A11.e:

53

1

1/1

1

50
I. 7 Years

1/1
28/30
(93 . 3%)

29/30
(96. 7%)

30/30
(100 %)

16/16
(100%)

16/16
(100%)

Overall
Measles
46/48
(95 .8%)

2/2
(100%)

Conversion

Rates

~L

Rubella
48/48
(100%)

29/30
(96.7%)

2/2
(100%)

0

1/27/78

Table

2

Sero l ogical Findings Among Chil<l r en Who Received Co111b
ined Live
Heasles-Mu 111ps-R
ubella (RA 27 /3) Vi rus 'lacci ne , Lot il60665/C -E811 (Study
No.
Serol.
Tested

Heasles-Mumos-Rubella
Conversions/To t al
Measles
Mu1110s Rube lla

A1te

No.
Vacc.

(Months)
12

2

2/2

2/2

l

2
1

2/2

13

14
15
16

5

5

21

21

7

7
4

4/4
15/15
3/3
3/3
0/ 1

4/4
14/15
3/ 3
3/3
1/ 1

4/4
15/15
3/3
3/3
0/1

1/1
3/3

1/1
3/3

1/1
3/3

1/1
1/1

1/1
1/1

1/1
1/1

33/34
(97.1%)

33/3 4
(97 . 1%)

33/34
(97.1%)

17

19
20
21
22

4
2
1
3

3

1
0
3
3

(Years)
2
4

2

2

3

1

Total
Mean Age:

54
so
1.5 Years

Initiallv
SeronP.1tative to:
Measles-Humps
Heasles-Ru bell a
Conversions/T otal
Conversions /To tal
Measles
Mum
1>s
Heas lea Rubell a

11513)
Initially

Measl e s Only
Conversi ons/
Total

Seropositive
Measles
Mumps and
Rubella

to :

I/1
1/1
1/ 1

2/2
1/1

4/4
3/3
1/ 1

1/1
4/4
3/3
1/1

1/1

1/1

1/1

1/1

2/ 2

1

'

4/4
(100%)

4/4
(100%)

10/1 0
(100!)

Overall

Conversion

Rat es

Measles
48/49
(98 . 0%)

Â· Mumps
37/38
(97 . 4%)

Rubella
43/44
(97.7%)

10/10
(100%}

1/1
(100%)

l

1/27/78

Table

3

Serological
Findi ngs Among Children Who Received Comhined Live
Measles-Mumps-Rubella
(RA 27/3) Virus V~ccine, Lot ,6 0666/C -E R12 (Study 1513 )

Age

No,
No, Serol.
Vacc. Tested

Measles-Mumps-Rubella
Conversions/Total
Measles Mumps Rubella

Initiallv
Seronegative
Measles-Humps
Measles-Ruhella
Conversions/Total
Conversions/Total
Measles
Humos
Measles Rubella

to:
Measles Onl_y Humps Only
Conve rsions/ Conversions/
Tota1
Total

Initially
Rubella Only
Conversions/
Total

Seropositive
Meas le s
Humps and
Rubella

to:

{Months)
11

1

1

12
13

1
l

14
15
16

26
9

17

4

19
20

2
1
2

1
0
6
25
7
3
2
1

23

6

1/1
1/1

1/1
1/1

1/1
1/1

5/5
18/19
4/4
1/1
1/1

5/5
18/19
4/4
1/1
1/1

5/5
18/19
4/4
1/1
1/1

1/1
1/1
1/1

1/1
1/l

4/4
2/2

4/4
'1./2

1/1
2/ 2

1/1
2/2

1/1

1/1

10/10
(100%)

10/10
(100%)

1/1
1/1
1/1
1/1

1/1

2

(Years)
2

4

1
2

1
2

Total
56
51
Hean Age: 1.4 Years

1/1

1/ 1
1/1

1/1

32/33
32/33
32/33
(97. 0%) (97 . 0%) (97 .0%)

3/3
(100%)

3/3
(100%)

3/3
{100%)

Overall

Conversion

Rat es

Measles
48/49
{98 . 0%)

HUDlps
36/37
(97. 3%)

Rubella
43/44

1/1
(100%)

1/1

0

(100%}

(97.7%)
1/27/78

Table 4
Distribution
of Post-Vaccination
Antibody Tit ers Amon~ Children Who Were
Initially
Seronegative
to Measles, Mumps, and Rubella, Who Received Combined
Live Measles-Mumps-Rubella
(RA 27/3) Virus Vaccine, Lot D60664/C-E810 (Study 0513)

Measles
Post-Titer
Distribution

(HI)

Mumps (Neut)

Number
of Children

<5

Post-Titer
Distribution

-

)320

1
7
8
8
4

Total
Geometric

30
)70.2

80
160

Mean Titer:

-

Number
of Children

<2
2
4

l .

8
16

6

32
64
)64

6
4

-

4

Total
Geometric

30

2

5
10

20
40

Rubella

2
7

Mean Titer:

Post-Titer
Distribution

(HI)
Number
of Children

16

1
1 .

32
64
12~
256
)512
Total
Geometric

6

9
13

Mean Titer:

30
)256.0

-

-)19.2

f

1/27/78

Table 5
Distribution
of Post-Vaccination
Antihody Titers Amon~ Children Who Vere
Initially
Seronegative
to Measles, Mumps, and Ruoella, Who Received Combined
Live Measles-Mumps-Rubella
(RA 27/3) Virus Vaccine , Lot H60665/C-E811 (Study #513)

Measles
Post-Titer
Distribution

(HI)

Number
of Children

Post-Titer
Distribution

Number
of Children

Post - Titer
Distribution

Number
of Children

1

<2
2
4
8
16
32
64
>64
-

i

<8

1

2
1
3
7
8
-5
7

13

<5
5

10
20
40
80
160
>320

6
2
16
4

-

5

Total

34

Tota l

1_70. 3

Geometric

Geometric

Rubella

Mumps (Neut)

(HI)

Mean Titer:

Mean Titer:

16
1

32
F,4

3

6

128
256
)512
-

34

Total

-)22 .6

Geometric

12
11

34

Mean Titer:

-)200.4

~

1/27 /7P,

Table 6
Distribution
of Post-Vaccination
Antibody Titers Amon~ Children Who Were
Initially
Seronegative
to Meas les, Mumps, and Rubella, Who Received Combined
Live Measles-Mumps-Rubella
(RA 27/3) Virus Vaccine, Lot H6O666/C-E812 (Study 0513)

Measles
Post-Titer
Distribution

Rubella

Number
of Children

Post-Titer
Distribution

Number
of Children

1

<2
2
4
8
16
32
64
-)64

I
1

<8

1
2
7

16
32
64
128
256
)512

<S
5
10
20
40
80
160
-)320

2
5

5
8
6
6

Total
Geometric

Mumps (Neut)

(HI)

Mean Titer:

33

Total

-)65.8

Geometric
,

8

3
10
33
Mean Titer:

-)25.9

Post-Titer
Distribution

(HI)

Numb.er
of Children
1

8

3

1
14
14

-

Total
Geometric

~ean Titer:

33
)250.7

-

1/27 /78

Â·,

Table
Haxiâ€¢um Te,aperatures

Live

Kaxilll\Jâ– 
( 0 -P.

Heasles-Huâ– ps-Rubella

Oral)

0-4

(99
99 - 100.9

Reported Anlong Children Who Received CoMhlned
(RA 27/J) Virus Vaccine, Lot l60664/C-E810 (Study 1513)

Total Vaccinees (53 Children)
Davs Post Vaccination
5-12
13-18
19-28
29-42

T01perature

7

No, vlth
Kax.

y.....,_

30
(60.0%)

22
(44 . 0)

36
(72.0)

27
(54 . 0)

31
(62.0)

17

17
(34, 0)

22
(44.0)

13
(26,0)

19
(38.0)

17

21

(34 ,0)

2
(4.0)

5
(10.0)

3
(6.0)

(4.0)

101 - 102. 9

1
(2. 0)

103 - 104.0
Fever - Tnq,,

Not Taken
Not Taken

3

Case I
(b) (6)

2

1

18
(60.0)

20
(66. 7)

14
(46. 7)

18
(60.0)

9

(36. 7)

10
(33.3)

15
(50.0)

9

13
(43,3)

11

12

(30.0)

(36. 7)

10

1
(3 . 3)

3
(10.0}

3
(10,0)

1
(3.3)

L

1
(3.3)

(2.0)
1
(2 . 0)

l
(2.0)

3

3

Max. Tei,ae, ~

102 .0
102.2

42
33-35

102.6
102.4
102.0
102.0
103 . 0
102.0
104,0

7-10
6-8
.5
8-9

20-25
18-20
0-4

0-4

lnltlallv
Serone2atives
(30 Chlldren)
Days Post Vaccination
Ho. with
5-12
lJ-18
19- 28
29-42 Max. T...,,.,,
11

1

0
3

J

J

(3.3)

1
(3.J)

0

0

l
0

8

Clinical Coâ– elaint
Anorexia, Teething
Irritability,
Gastrointestinal
Illness,
Anorexia, Fatigue
r.lllltrointestinal
Illnes11, Anorexia, Teething
Sores on Face
No Clinical C0111plaints
Gastrointestinal
Illnesn
Upper Respiratory
Illn~uâ€¢
Upper Respiratory Illneo â– 
Upper Respiratory Illne111, Irritability,
Anorexi.a

Measles
(5
80
(5 ~320
<5
(5
<5
(5
(5

<S
(5

0
0

0

SerolORY
Humes
2
32
(2
32

160
160
80
40
40
80
80

(2
(2
2
<2
2

Rubella
)512
256

(8
(8

16 (8
32 <8
64 (8
8 (8
)64 <8

(2

-16

(2

64

0

(8
(8

2S6
256
256
256
256
256
128
1/27/78

Table 8
Maxilll\lmTeaperatures
Reported Among Children Who Received Combined
Live Heaeles-Huinps -Rubel la (RA 27/3) Vlrue Vaccine, l..ot f60665/C-E8ll
(Study 1513)

Maximuâ€¢ Toperature

(Â°F

Orel)

0-4

(99
99 - 100,9
101 - 1.02.9

Tota l Vaccinees (54 Children)
Davs Post Vaccination
29-42
5-12
13-18
19-28

No. vith
Max. Teian,

34
(66 . 7%)

28
(54. 9)

37
(72. 5)

35
(68.6)

37
(72.5)

18

14
(27. 5)

15
(29. 4)

14
(27. 5)

14
(27. 5)

12
(23.5)

21

2
(3.9)

2
(3.9)

1
(2.0)

10

(13. 7)

1
(2 .0)

2

7

103 - 1.04.0

1

(2 .0)
Fever - Te11111.
Not Taken

1
(2.0)

Not Taken

3

0

103.0
102.2

22
(64. 7)

22
(61,.7)

11

(64. 7)

12
(35. 3)

12
(35.3)

10
(29,4)

16

l
(2.9)

5

l

1

2

(2.9)

(2.9)

22
(64 . 7)

18
(52 ,9)

9
(26.5)

02.4)

11

2

4

(5.9)

(11.8)

22

0

l

(2. 9)
3

Caee I Max. Teai2,
102.0
(b) (6)
102 . 0
102.6
104.0

0-4

Initially
SeroneRatives
(34 Children)
Davs Poet Vaccination
No. with
19-28
29-42 Max, Temn.
5--12
13-18

3

3

3

3

0

Clini.cal Com2lafnt
_!!!l:'..!.
8-9
Irritable
Gastrointestinal
IllneRs
7-9
Gastrointestinal
Illness,
Nonspecific Rash
2-8
Upper Respiratory
Illness,
Ophthal1110pathy,
3-8
Gastrointesti
nal Illness,
Anorexia
28-34 Teethi.ng
Illne11a
4-11 Upper Respiratory

0

0

Heaslea

NS
<5
(5
(5

NS
80
80
20

(5
(5

40

0

Serology
Hum2s
NS NS
(2
16
(2
64
(2
32

0

Rubella

NS
<8
(8
(8

BO (2 _t64 (8
<2

0

2 (8

NS
32

256
256
)512
-256
1/27/78

Table

9

Haxilll\llll Teniperature11 Reported Among Children Who Received Combined
Live Hea11les-ffu~ps-Rubella
(RA 27/3) Virus Vaccine, Lot 160666/C-Â£812 (Study 1513)

Haximuâ€¢ Temperature
(Â°F. Oral)
(99

99 - 100.9
101 - 102.9

0-4

Total Vaccineea (56 Children )
No. vith
Days Pos t Vaccination
19- 28
29-42 Kax. Temp,
5-12
13-18

31
(57.4%)

22
(40. 7)

32
(59. 3)

26
(48 . 1)

15

(68.5)

20
(37 .O)

22
(40. 7)

16
(29.6)

22
(40. 7)

21
(38.9)

24

6
(11.1)

14

1
(1.9)

1

J

7

(5.6)

(13. O)

37

1
(1.9)

103 - 104.0
Fever - Te111p.
Not Taken

,

2
(3. 7)

(1.9)

2

2

0-4

.(33.3)

19
(57 .6)

19
(57. 6)

19

6
(18.2)

2
(6.1)

8

1

1
(3.0)

l

9
( 27. ))

(5 7. 6)

16
(48. 5)

16
(48.5 )

(42.4)

2

(6.1)

14

0

1

(3 .0)
0

Clinical Complaint
Max. Te111p. .J!!I.!.
(bJ'(Sj102. 0
12-13 Herpes-Type Rash
11easles-Lilte R;ish, Anorexia
8-9
104.0
Upper Respiratory
Illness,
Non-Specific Raah, Anorexia
103 . 0
42
Illness
30-35 Gastrointestinal
102.0
No Clinical Co111plaints
0-7
102.0
Upper Respiratory
II Jnc1111
. Ophthalmopathy, Anorexia
1-4
102.2
Upper Re.spiratory
Illne1111, Otitis
10
102.2
Upper Respiratory
Illne1111, Headache, Anorexia,
102.0
1-3
Soreneaa at Injection
Site

Measles
(5
40
(5 80

Case I

2

11

(3.0)

0

Not Taken

5

14
(42. 4)

19

15
(4 s. 5)

0

1

tn itlallv
Serone2atives
(33 Children)
No. vit h
Dava Post Vaccination
29-42 Hu. Teao.
19-28
5-12
13-18

2

2

2

0

0
Seroloey
Mumps
(2
32
(2

0

0

>64

Rubella
(8 256
(8
64

(5

80

(2
(2

NS NS NS
<8 128
16 <8 256
fi4 (8 256

trr

NT

l'IT

tlT

NS NS
(5 80
(5 40

NS
(2

. 16

lfT

NT

1/27/78

- -- Â·- ---

Table

10

Clinical
Complaints Reported AmonR Children
Live Measles-Mumps -Rubella (RA 27/3) Vir u~ Vaccine,

Clinical Comnlaint
Injection
Site:
Sorene ss

0-4
2
(3. 9%)

1
(2.0)

Measles-Like

Rash

Hesdache
Irritability

4

Anorexia

(7.8)
4
(7 . 8)

2
I

(2. O)
6
(11.8)
1
(2 .0)
2
(3. 9)
3
(5. 9)

Sleep

Fatigue

Upper Respiratory

Illness

Initially
Seronega ti ves (30 Children)
Days Pos t Vac,i nation
No. with
0--4
5-12
13-18
19- 28
29-42 Coamlaint
1

1

I

I

(2 .0)
9
(17 .6)

(2.0)
12
(2 3.5)

l

l

1
1

1

(2.0)

(2 . 0)

0

6

4

(13. 3)

1
(3 . 3)

1
(2.0)
l
(2. 0)
1
(2 , 0)

2
(3.9)
2
(3.9)

2

(3.9)
5
(9 .8)
1
(2.0)
1

8

4

2

I

(6. 7)
2
(6.7)

(3.3)

10

(13. ))
2
(6. 7)

7

(13 . 7)

12
(23,5)

11

25

l
(3.3)

Nonspecific

Rash

5
(9.8)

4

4

6

8

(7 .8)

(7 . 8)

(11.8)

(15 .7 )

Sores on Face

2
() . 9)

1

1

(2.0)
4
(7 . 8)

( 2.0)

1

5

I

4
(13, 3)

7

6

(23.3)

(20 . 0)

Allergy

1

Teething

(2.0)
2
(3.9)

(7.8)

24
(4 7 .1)
27
(52 . 9)
2

1
(2.0)
27
(52.9)
24
(4 7. 1)
2

llerpes-Type

Rash

Persons with Complaint:
Persons . ~ith
Negative

No Comolaint:

Surveillance

4

7
(23. 3)

8
(26 . 7)

1
(). 3)

18

9

15

()0 . 0)
2
(6. 7)

1

(2.0)

l

0

2

(9 . 8)

7

(3.3)

1

(21.6)

1
(2 .0 )

7

0

1

(21.6)

1
(2.0)
12
(2). 5)

11

1
(3.3)
3
(10 . 0)

I

I

Illne88

2
(6 . 7)
2
(6 . 7)

1

(2 .O)

Gastrointestinal

4
0

(2.0)

0titis

Ophthalmopathy

1
(3.3)

l

1
(2.0)

Hyalgia

No. with
Complaint
2

(3.3)

2

Systemic:
Arthralgia

Disturbed

Total V3ccinees (53 Children)
Days Post Vaccination
5-12
13-18
19-28
29-42

Who Receiv~d Comhlned
Lot ,60664/C -ERlO (Study #513)

14
1

1

l

1

(3.3 )
9
(30.0)
4

l

(3. 3)

(3.3)
4
(13 . ))

15
10

( 13. 3)

1

)

(). 3)

(10.0)

4

5

5

(13. 3)

(16. 7)

(16. 7)

1

1

(3. ))

1
(2 .0)
l
(2.0)

(3.9 )

12
(23 . 5)
39
(76. 5)
2

(2.0)
18
(35. 3)
33
(64 . 7)
2

2

3

2

1

9

(3.3)
l

4

1

(3. J )

(lJ.3)

o.3>

2
(6. 7)

1

l

(3,))

9
(30.0)

(3.3)
12
(40. 0)

(5.9)
2

1

19
(37. 3)
32
(62. 7)
2

39
12

2

14

(46. 7)
16
(53.3)
0

1
(3. 3)

19
(63. 3)

2
1

7

(3 . 3)

2
13

25

(43.3)

11

21

18

17

5

(36 . 7)
0

(70,0)
0

(60 . 0)
0

(56. 7)
0

0
l/27/7R

Table 11
Clinical
Complaint& Reported
Live Heasles-Humps-Rub!!lla
(RA 27/3)

Clinical

ColllDlaint

Inject ion Site:
Soreness
Erythema and Soreneaa
Systerdc:
Lymphadenopathy
Measles-Like

0-4

Rash
4
(7. 7)

Malaise

l
(1. 9)

Anorexia
Disturbed

Upper Respiratory

Illness

Otitis
Ophthalmopathy
Gastrointestinal

Illnesa

Persons
Persons
NeÂ£ative

with Complai nt:
vith

No Complaint:

Surveillance:

4

(7. 7)
1
(1. 9)

5

3

(5.8)

I

l

1

(1.9)
2
(3.8)
10
(19.2)
2
(J.8)
1
(I. 9)
9

(1. 9)

(1.9)

4
(7.

Teething

3

1

(1.9)
5
(9 .6)
6
(ll.5)
l
(1,9)
(9.6)

Nonspecif 1c Rash
Allergy

l
1

5

(17. 3)

7)

No. vith
Complaint
2

(9. 6)

Sleep

Fatigue

Total Vaccinees (54 Children)
Davs Post Vaccination
5-12
13-18
19-28
29-42

2
(3.8%}
1
1
2
(3,8)

Irritability

AmonÂ£ Children \lho Received Comhine~
Virus Vaccin e , Lot 160665/C-Ellll (Study

l

(1. 9)

2
(3.8)

2
(3.8)

4

9

10
(19. 2)
1

l

(3.8)

(1.9)

3

(1.9)
1
(1.9)
4
(7 . 7)
2

(1.9)
6
(11.5)
2

(5.8)

(J.8)

(3,8)

1
(1.9)
1
(1. 9)

l
( 1.9)

24
(46.2)
28
(53.8)
2

26
(50.0)
26
(50. 0)
2

5
(9.6)

1

1
1

1
(2 . 9)

11

25

(21. 2)

1

4

4
(11 . 8)

I

1

(2.9)

l

18

(2. 9)
6
(17. 6)
3

(8. 8)
1

I

(2. 9)
1
(2. 9)

3
(5. 8)

3
(5.8)

4

18
(34. 6)
34
(65.4 )

2l

2

2

18
()4. 6)
)4
(65.4)
2

36

(40 . 4)
31
(59 .6)

16
2

(8.8)
4
(11.8)
1
(2. 9)
4
(11.8)

(2. 9)
2
(5.9)
4
(11. 8)
2
(5 . 9)

5

7

1
(2.9)
3

13

9)

(l.

1

1

I

2

3

2

(2. 9)
3
(8.8)

(7.7)

5
(9.6)
2

(5.8)
10
(19.2)

2
(5.9)

l

2
9
(17.3)
2
(3.8)

Initiallv
SeroneÂ£atives
(34 Children)
Dav& Post Vacc ination
No. vith
0-4
5-12
13-18
19-28
29-42 Coamlaint

7

1
(1.9)

#513)

16
(47 .1)
18
(52.9)
0

2

2
(5,9)

4
I

(2.9)

2
(5.9)

7

1
2
(5.9)

1
(2.9)

3
(8.8)

9

l
2

6
(17. 6)
l

(2, 9)
2
(5. 9)

4

6

7

(11. 8)
1
(2. 9)

{17. 6)

(20.6)

1
(2. 9)

l

7

3

(2. 9)
3

(20.6)

(8.8)

(8.8)

(2.9)
l
(2 . 9)
5
(14 . 7)

2
(5.9)

2
(5.9)

1

3
(8 .8)

15

2
4

11

6

1
1
(2. 9)

1
(2. 9)

1
(2.9)

2
23

18
(52.9)
16
(4 7 .1)

(32 .4)
23
(67.6)

13
(38 . 2)
21
(61. 8)

12
(35. 3)
22

0

0

0

0

11

11

(64. 7)
0

1/27/78

Table
Clinical

Complaints

Reported
(RA 27/J)

Live Measles-Mumps-Rubella

12

AmonR Children
Viru~ Vacc ine,

Total Vaccineea (56 Children)
Dava Poat Vaccination
Clinical
Injection

Complaint

Site:

Soreness

0-4

5-12

13-18

19-28

29-42

Who Rec eived Combined
Lot f60666/C-F.812
(Study

No. vith
Complaint

W51J)

Initiallv
Serone2atives
(JJ Children)
Davs Poat Vacci nat io n
No. vith
0-4
5-12
13-18
19-28
29- 42 Complaint

4
(7 ,4%)

4

3
(9 .1)

3

4

4

3

3

Systeaiic:

Lymphadenopathy
Measles-Like

Rash

6
{11 . 1)

Headache

1
(1.9)

Irritability

4
(7.4)

{7. 4)

6
(11.1)

9
{16. 7)

Anorexia
Disturbed

Sleep

1
(1.9)

Fatigue

2
(J. 7)

4

3
(5. 6)

Ophthalmopathy
Gastrointestinal
Nonspecific

Illness

Rash

8

1

2
(J. 7)

11
(20.4)

20

{1. 9)

2
{3 . 7)

2
1
(1.9)

Herpes-Type

Person s with Complain t :
Persons
Ne2ative

with

No Complaint:

Surveillance

1
(1. 9)

2
(3 . 7)

2

14

JO

2
(3. 7)

15
(27 . 8)
2
(J. 7)

1
(1. 9)

1
(1.9)

4
18

2
(3. 7)
6
(11.1)

l
(1. 9)
4

(7 . 4)

4
(7. 4)

s

7

(9. ))

(13 . 0)

4

8
(14. 8)

6
{11.1)

7
(13.0)

6
(11.l)

13
(24.1)

(25.9)

l
(1. 9)

Rash
27
(50.0)
27
(50 . 0)
2

2
(6.1)

1
(J . 0)

1

1
(J.0)

6

J

2
(J. 7)

33
(61.1)
21
08. 9)
2

22
(40. 7)
32
(59.3)
2

3
(5.6)

2
(6. 1)

3
(9,1)

4
(12.1)

(15 . 2)

1
{3.0)

2
{6 .1)

3
(5.6)

10

12
()6.4)

1
(3 . 0)
l
().0)

3
(9 . 1)

13

12
(36.4)
2
(6.1)

20

1
(J.0)

2

J
(9 .1)

1
(3.0)
t,
(12.1)

J
(9.1)

12

4
(12 .1)

4
(12 .1)

4
(12. I}

13

11

(JJ.J)
2
(6.1)

20
(60, 6)

13

13

2

(39.4)
0

.

l

1
(3 . 0)

5

41

5

9
(27 . J)

1

9
( 27. 3)

(15. 2)

s

1
{3.0)

.

1
(3.0)
4
(12 .1)

2
(6.1)

2

(3.0)

19

3

(9 .1)

5

l

5

l
24
25
C44.4l ~6.3)
30
29
{55 . 6)
(53. 7)
2
2

2
(6.1)

1
(3.0)

(JO. J)

1

( 5. 6)
1
(1.9 )

0

1

19
(35 . 2)
2
( J.7)

Teething

4
{12 .1)

13
{24.1)
1
(1 . 9)

(7 .4)

Sore from Venipuncture

8

2
(J. 7)

Hyalgia

Otitis

1
(1.9)

J
(5.6)

{1.9)

Illnes11

1

1

l

Upper Respiratory

1
(1.9)

3

1
3
(9. l)
1
(3. 0)

2
(6.1)

22
( 66. 7)
11
03.3)
0

16
{l,8.5)

3
(9 .1)

2
(6.1)

4

1

17

(51. 5)
0

19
(57. 6)
14
(42.4)
0

17

(51.5)
16
(48 . 5)
0

27
6

0
1/27/78

MEMO
To
From
Subject

File

Location

T. Schofield

Location

Preliminary
Statistical
Analysis
Mumps-Rubella Virus Vaccine

Date 2/6/78

- Study #513, Combined Live Measles -

Significant
differences
in seroconversion
rates for measles, mumps,
and rubella
and clinical
reaction
rates among vaccinees
receiving
three lots of combined live measles-mumps-rubella
vaccine were
investigated.
Lots of vaccine were:
Lot #60664/C -E810
Lot #60665/C-E811
Lot #60666/C-E812
A significant
difference
exists among the three lots in th e incidence
of non-specific
rash.
15 out of 53 exhibited
diaper,
heat , or contact
rash (28. 3%) who received Lot #60664/C-E810;
7 out of 54 (12. 9i.~ Â·â€¢1ho
received Lot #60665/C-EBll;
and 19 out of 56 (33.9%) who received
Lot #60666/C-E812.
No other rates were significant.
Analyses of variance were performed on post-titer
values of children
who were initially
seronegative
to the individual
components.
The
log transformation
was used in each analysis.
No significant
differences exist among the groups (lots)
for any of the three components.
A multivariate
analysis
was performed on the post-titer
values of
triple-negative
vaccinees.
Again, the log transformation
was
applied.
There was no significant
difference
among the groups.

T. S.

6801

Summary No. 1
of
Clini cal Investigative
Studies
of
Combined Live Measles Virus Vaccine (Moraten Line-ATTENUVAX)
RA 27/3 Rubella Virus Vaccine
for Purpose of Support for
a License to Manufacture and Sell.

M. R. Hilleman,

Ph . D.

Prepared:
August 11, 1978
Merck Institute
for Therapeutic
West Point, Pennsy l vania

Research

Clinical
Investigative
Studies of Combined Live
Measles-Rubella
(RA 27/3) Virus Vaccine
1.

Background
In a separate
submission,
"Summary No. 2 of Clinical
Investigative
Studies
of RA 27/3 Strain Live Rubella Virus Vaccine for Support of a License to
Manufacture and Sell,"
dated January 11, 1978, and in Addendum No. 1 to
that submission dated June 26, 1978, the RA 27/3 strain rubella
virus
vaccine was shown to be safe and highly effective
in eliciting
an antibody response in persons of various
ages.

In extension of clinical
tests with RA 27/3 rubella virus vaccine,
studies were conducted to evaluate
its immunizing capability
when
combined with live attenuated
Moraten measles virus vaccine
(ATTENUVAX)
.
The present
submission relates
to clinical
investigative
studies
of
combined live measles-rubella
(RA 27/3) virus vaccine .
All clinical
studies were conducted under
Measles-Rubella
(RA 27/3) Virus Vaccine.
2.

Lot Numbers of Vaccine

BB-IND-1015, Combined Live

Tested

Experimental
lot prepared by Virus and Cell
Merck Sharp and Dohme Research Laboratories:

Biology

Research,

622/C-D764
Consistency

lots

prepared

by Merck Sharp and Dohme Biologics

Manufacturing:

62343/C-F021
62344/C-F022
62345/C-F023
3.

Serologic

Testing

Serologic
determinations
were made in the laboratories
Biology Research, Merck Institute,
and in the Control
the Merck Sharp and Dahme Division
of Merck and Co.
The hemagglutination-inhibition
antibody response.
The starting

(HI) test
dilution

of Virus and Cell
Laboratories
of

was used to determine
was 1:8 .

rubella

In most cases, measles antibody determinations
were by HI assay with a
starting
dilution
of 1:5 . Where noted, sera were retested
by serum
neutralization
test at a starting
dilution
of 1:2.

Page 2
4.

Clinical

Studies

The clinical
studies were conducted under the overall responsibility
of Dr . Maurice R. Hilleman, Vice President,
Virus and Cell Biology
Research, Merck Institute
for Therapeutic
Research, West Point,
Pennsylvania .
The clinical

tests

were carried

out by three

groups of workers:

a.

Dr . Robert E. Weibel, Director,
Division of Preventive
Medicine, Joseph Stokes, Jr . Research Institute
,
Children's
Hospital of Phiiadelphia,
Philadelphia,
Pennsylvania

b.

Dr . Victor M. Villarejos,
Director,
Louisiana
University
- International
Center for Medical
and Training,
San Jose, Costa Rica

c.

Dr . Louis z. Cooper, Director,
Pediatric
Service,
The Roosevelt Hospital,
New York, New York

Clinical

studies

fall

into

two main categories

State
Research

:
Reference

a.

Comparison of measles-rubella
(RA 27/3)
measles-rubella
(HPV-77) vaccines

b.

Serologic and clinical
responses
rubella
(RA 27/3) vaccine

and

to measles-

2
1, 3, 4

The clinical
studies were carried out by the physicians
at the locations
in the individual
study summaries to follow.
The populations
employed
were defined with respect to age, location
and other pertinent
parameters.
Subjects were bled initially
and again 6 to 8 weeks later . The sera
were tested to define the initial
serostatus
and the subsequent antibody
response.
Clinical
surveillance
was by two procedures . In studies by Ors . Weibel
and Cooper, the observations
were recorded daily by the mother . The
parent was asked to contact the physician
should any significant
or
bothersome reaction
occur . In the studies by Dr. Villarejos,
observations were made on a routine basis by medical or paramedical
personnel;
physicians
were notified
of any significant
illness
which occurred
subsequent to vaccination .
The data presented
in the following sections
are self-explanatory
.
The detailed
background records are on file in Virus and Cell Biology
Research, Merck Institute
for Therapeutic
Research, West Point,
Pennsylvania.
These records are available
for review at any time .

Page 3
5.

Clinical

Study Summaries

Reference 1 - Study 442 - Dr. Victor Villarejos
Details
of the study plan are given in the clinical
test protocol.
The study was designed to measure antibody and clinical
responses
to
the RA 27/3 rubella
component when given alone or combined with
mumps and/or measles vaccine.
Findings presented
in the summary tables
indicate
excellent
antibody response
t o both virus components among
children
receiving
combined live measles - rubella
(RA 27/3) virus vaccine.
No significant
clinical
reactions
were noted following vaccination.
Reference 2 - Study 470 - Dr. Louis Cooper
This study is being conducted among childr en to compare responses
to
HPV-77 and RA 27/3 rubella vaccines when given alone or combined with
live measles virus vaccine.
Details
of the study plan are given in
the clinical
test protoco l , and results,
to date, are presented
in
the summary tables.
The study continues
in progress.
Reference 3 - Study 512 - Dr. Victor Villarejos
Study 512 was conducted to measure antibody and cl in i cal responses
to
three consecutive
l ots of combined measles - rubella vaccine containing
the RA 27/3 rube l la component.
Study details
are given in tbe clinical
protocol.
Findings presented
in the summary tables indicate
excellent
ant i body response to both components of all three lots of vaccine.
No significant
clinical
reactions
were noted.
Reference 4 - St udy 514 - Dr. Robert Weibel
Study 514 is being conducted to measure antibody and clinical
responses
to three consecuti v e lots of combined measles-rubella
vaccine contai n ing
the RA 27/3 rubella
component.
Details
of the study plan are given in
the clinical
test protocol
and results
are presented
in the summary tables.
All three lots showed excellent
antibody response while no significant
clinical
reactions
were npted.
6.

Overall

Summary

The total numbers of vaccinations
given are as follows:

for which supporting

No. Seroconverting/No
Lot II

No.
Vacc.

Measles

622
62343
62344
62345
Unknown

216
107
105
100
30

59/64
46/50
45/45
49/50
26/28

Tota l s

558

225/237

The data show that
the RA 27/3 rubella

data

have been

. Double Negatives(%)
RA 27/3

Rubella

(92)
(92)
(100)
(98)
(93)

63/64
50/50
45/45
50/50
28/28

(93)
(100)
(100)
(100)
(100)

(95)

236/237

(99)

combined live measles-rubella
vaccine
virus component is safe and effective.

containing

Summary of Clinical

Tests

of Combined Live Measles - Rubella

(RA 27 /3) Virus

Vaccine.

Antibody Responses among Double Negatives
Measles
Rubella
No. Conv./
No. Conv ./
No. Seroneg.
No. Seroneg.
(%)
GMT
(%)
GMT

AS1e
Mean
Range
(Yrs . )

No.
Vacc.

622

1 - 6y

3.7

193

49/54

(91)

49

53/54

(98)

151

1

Cooper

622

14m- 6y

2. 0

23

10/10

(100)

57

10/10

(100)

274

2

512

Villarejos

62343
62344
62345

lOm- 9y
llm - 8y
13m- 6y

4.4
4.3
4.1

60
60
55

12/15
18/18
16/17

(80)
(100)
(94)

17
40
70

15/15
18/18
17/17

(100)
(100)
(100)

308
376
289

3

514

Weibel

62343
62344
62345
Unknown

13m- 3y

1.4
1.8
1.4
1. 7

47
45
45
30

34/35
27/27
33/33
26/28

(97)
(100)
(100)
(93)

80*
78
114
51*

35/35
27/27
33/33
28/28

(100)
(100)
(100)
(100)

312
367
415
371

4

558

225/237

(95)

60

236/237

(99)

287

Study
No.

Investigator

Lot No.

442

Villarejos

470

14m- 4y
13m- 4y
13m-1 0y

Totals

* GMTbased on Measles

HI results

only.

Reference
No.

----

Â·- - - ---- ~

Program:

Study 11442

Vaccine:

Combined Live Measles-Mumps-Rubella
Lot No. 621/C-D763
Combined Live Measles-Rubella
Lot No. 622/C-D764
Live Attenuated Rubella
Lot No. 579/C-D418

Responsible

Clinical

Reference

No. 1

(RA 27/3)

Virus Vaccine

(RA 27/3)

(RA 27/3)

Virus Vaccine

Virus Vaccine

Investigator:

Victor M. Villarejos,
M.D.
Director
Louisiana State University
International
Center for Medical
Research and Training
Apartado 10 . 155
San Jose, Costa Rica
Study Location:

Rivas,

Nicaragua

Date Study Initiated:

January

Date Study Completed:

April

19, 1976
28 , 1976

Study Procedure:
A total of 589 children,
10 months to 7 years of age,
from the open population
were included in the study .
Eacn participant
received a 0 . 5 ml subcutaneous
dose
of one of the three vaccines.
Blood samples were obtained
prior to and six weeks after vaccination.

Clinical

Protocol

- Study #442

Combined Live Measles-Mumps-Rubella
(RA 27/3) Virus Vaccine
Combined Live Measles-Rubella
(RA 27/3) Virus Vaccine
Live Attenuated
Rubella (RA 27/3) Virus Vaccine

Purpose :

To determine antibody and clinical
responses
to combined live Â·
measles-mumps-rubella
(RA 27/3) virus vaccine,
to combined live
measles-rubella
(RA 27/3) virus vaccine,
and to live attenuated
rubella
(RA 27/3) virus vaccine.

Vaccines:

a)

Combined live
Lot No. 621
Vaccine

measles-mumps-rubella

dose is 0.5 ml given

(RA 27/3)

subcutaneously

virus

vaccine

.

The vaccine is supplied in two-dose vials.
Each vial
vaccine should be rehydrated
with 1 .2 ml of sterile,
pyrogen-free
distilled
water.
b)

Combined live
Lot No. 622
Vaccine

measles-rubella

dose is 0.5 ml given

(RA 27/3)

virus

vaccine

subcutaneously.

The vaccine is supplied
in two-dose vials.
Each vial
vaccine should be rehydrated
with 1.2 ml of sterile,
pyrogen-free
distilled
water .
c)

Live attenuated
Lot No . 579
Vaccine

rubella

(RA 27/3)

dose is 0 . 5 ml given

of

virus

of

vaccine

subcutaneously.

The vaccine is supplied in single
of vaccine should be reconstituted
pyrogen-free
distilled
water.

dose vials.
Each vial
with 0.7 ml of sterile,

CAUTION
: The combined vaccines
contain egg protein
and should not
be given to persons with known sensitivity
to egg, chicken, or
chicken feathers . All three vaccines
contain neomycin and should
not be given to persons with sensitivity
to neomycin.
Persons
with leukemia or other immunologic disorders
and persons receiving
immunosuppressive
drugs should not be vaccinated.
Also, the
vaccines
should not be given to persons with any febrile
respiratory
illness
or other active febrile
infection .
Keep dried

vaccines

stored

Keep dried

vaccines

at 4Â°C in transport

Keep reconstituted
after rehydration.

vaccines

at -20Â°C until

on ice.

used .

.
Discard

unused vaccine

4 hours

Clinic~l
Protocol
Study 1/442

Procedure:

-2 -

-

The study population

will

consist

1 to 6 years

of children

of age .

Children r eceiving a given vaccine will have a negative history
for
vaccination
with and illness
caused by viruses
represented
in that
vaccine . Children will be assigned to receive one of the three
vaccines
as follows:
Vaccine

Vaccine

measles-mumps-rubella
measles-rubella
rubella
Informed
guardian

No. Children

Lot

150-200
150- 200
150-200

621
622
579

consent will be obtained
prior to bis participation

from each child's
in the study .

Each child will be bled (10-15 ml) immediately
and 6 weeks following vaccination
.
Vaccine

dose is 0.5 ml given

Days 0-42
Week 6

to vaccination

for 42 days fo l lowing
complaints
will be recorded
Action

Time
Day 0

or

subcutaneously.

Each child will be followed clinically
vaccination.
All local and systemic
on the case report form.
Schedule:

prior

parent

Bleed 10-15 ml.
Vaccinate 0.5 ml, subcutaneously.
Clinical
systemic

fol l ow-up for
reactions.

local

and

Bleed 10-.15 ml.

Laboratory:

Remove se r a from clot aseptically
and store frozen at -20Â°C until
shipped.
It is imperative
t hat sera are sterile
to avoid interference with the se r ologic assay.

Serology :

Circulating
levels of antibody
to each vaccine component will be
determined
for samples drawn before and after vacci nation.
Measles
and rubella
antibody levels will be determined by hemagglutinationinhibition
test.
Mumps antibody levels wi l l be determined by serum
neutralization
test.

Clinical
Forms:

Attached .

Clinical
Protocol
Study #442

-

-3-

Adverse
Reactions:

Any serious or alarming reaction,
including
death due to any cause
during the investigation,
whether related
or not related
to the
test material,
must be reported
immediately
to Merck & Co. , Inc.,
through Dr . Maurice R. Hilleman,
telephone
(215) 699-5311, Ext .
5532, or in his absence, Dr. Allen F. Woodhour, telephone
(215)
699-5311, Ext. 5588.

Unused
Vaccine:

All unused vaccine should be returned
immediately
to Merck Sharp &
Dohme Research Laboratories,
West Point, Pa. 19486.

Shipping
of Sera &
Records:

a)

Send sera

b)

Send sera and records to Dr. Maurice R. Hilleman, Virus and Cell
Biology Research, Merck Sharp & Dohme Research Laboratories,
West Point, Pa. 19486.

c)

Alert Dr. Hilleman by cable as soon as possible
number, air bill,
and date of arrival.

frozen

within

insulated

containers

which are supplied.

as to flight

.

,
,
,
VACUNACION CONTRA SARAMPIO"' PAPERAS RUBEOLA

'\_,

Estudio No.

"'':.- -- --

C:INombre Completo del Nsno

!

CT 6
Dope CT 2
(141)Â·

Olrecdon

NO. DEL CASO~

(1-31

I

I

Fecha de naclmlento

sexo (35)
M

F

dla

(36-411

mes

114f>-4n

do

compteta de Padres o Guardian:

(5469)

~ IN OIOUE SI INDIVIOUO

HA:

1. Teoldo Enfermedad
2. Sido Vacunado
3. Estado Exvuesto

s - S.rampion

s (70)
I
2
3

P â€¢ Paperas
P(711
R (721
I
1

R â€¢ Rubeola

2
3

2
3

Fecha de expuesto

I

I

Fecha de e,cpuesto

I

I

Fecha de e ><
puesto

I

I

(Durante Ultimas Cuatro Semanasl

,
PERIODO DE VACUNACION

D

(48)

I

D Control

Vacunado

No. de lote

O CONTROL
I

Fecha de vacunacion
Fecha de primer sangrado

I

(49-61)

I

Fecha de segundo .sangrado (despues de vacunado)

I

I

(52-!;n

I

I

15"3)

SEROt.OGIA
PAPERAS

SARAMPION

Neut

Neut

HI
Pre

Post

Pre

RUBEOLA

Post

Pre

Neut

HI

Post

Pre

Post

Pre

Post

I

(52-67)

(antes de vacunadol

tndique si el nin<>contrajo Sarampion cli~ico:

1 = Si

2 =No

lndique si el nin'o con trajo Paperas clinica :

1 = sf
,
1 = Si

2= No

lndiQue si el niho contrajo

Rubeola c11nica:

m

Fecha de comienzo:

I

2 ~ No

I

Ouien hizo diagno stico?

Firma de/ Medico :

Despues de completadas, devue/va formas al: (Retenga copia rosa para svs archivosl

M. R. Hit.LEMAN,

PhD. DSc

MERCK SHARP & OOHME RESEARCH LABS., WEST POINT, PENNSYLVANIA
P39l57Â·087S(SPANISH

lit ENGLISH!

19486

Nombre def Med ico (en letra de moldel :

Fecha :

,

,

VACUNACION

CONTRA SARAMPION

,
PAPERAS RUBEOLA

HOJA CLINICA

NO. OE CASQ ______

B

(

I

FECHA OE VACUNACION

di~

DIA

FECHA

..
"i
.z
~ E
..
Â·;;
..
c
en
.,
"j
Â·;.
..
.. ., :0., ;;;â€¢.. ri.
.2
t:.,
..
...
Â·c
0
i
:i
.. .. ! >..: 0 Â·= a: -~-E
"i "0

~

..
..

0

I-

2

e t:.,.,

...
-~
s;

E ;
:,

a. E
0

S

0 "

i-:(~
.,

"'.
., E ,_
:,
O Â·-

li

'O â€¢

Ill

C: ~ .c
C: ., 0

f! :e !

!lo:i ~
â€¢ z .l)

-~
... li

~

z ;. ..
2.
(JC:
z0

::> .,
ct C: â€¢â€¢
CJ -.. ct
1-

"'co
f8z

:,

';

C

~

ct

16

25

C)

08

0

(.)

(.)

15

14

01

03

06

_ __
aifo

1
2
3
4
5
6
7
8
9
11
12
13
14
15
16
17
18
19
20
21

..J

C

C

"0

u

..J

0
â€¢

"ii

~
.. 0

RASHâ€¢

... ~ ..~ â€¢â€¢ .

I
I

CD

I

E
:: ~~

I
I

X

.0
:,

0

w

a:

~

~

~

50

51

52

11

32

C

I

I

12

i:0 ],!:! :~

..

I

OTRAS REACCIO NES

'I
I
I
I
I

I

I
I

I

I

I
I

'I

I

I

I
I
I
I

I

I

I
I

'I
I

I

I

I
I

23
24
25
26
27
28
29

I

30

I
I

31

I
I

32

I

I
I

I
I

I

I

:

I
I

I
I

I

33

I
I

-

I
I

I
I
I

I
I
I

I
I

I
I
I

35
36

I
I

:
I
I

37

I

38
39

(_

_

â€¢Especi f iQue tipo en
est a seccio n

I
I
I

22

34

0

I
I

I

0

10

( -'=-

Cl.

:2

,_

:!
E

0

... .â€¢e

â€¢!!?

Cl,

~

_,__...,_
mes

NOMBRE:

.,

J_
....
..

_-,-

_

40
41
42

I

i
I

Al termin ar el esrudio, de11uel11a
copi11blanca y cop i11amarilla de esta form a,
adjuntas a la forms "A" al: (Reten~ copia color de rosa para sus archi11os}
M.R. Hlllem 1n, PhD, OSc
MERCK SHARP & DOHME RESEARCH LABORATORIES
W EST POINT, PENNSYLVANIA,
19486, U.S.A.

I
I
I

I

I
'
I

Firma de/ med ico:
Nombre de/ medico (en tetra de mo/de}:

Fecha:

Table 1
Serological
Measles-Rubella

Findings Among Children
27/3) Virus Vaccine,

(RA

Initiallu
Measles-Rubella
Conversions/Total
Rubella
Measles

Age

Total
No.
Vacc.

No.
Serol.
Tested

1 Year

22

16

11/11

ll/11

2 Years

20

16

7/9

9/9

3 Years

46

36

14/16

4 Years

40

31

5 Years

28

6 Years

Total
Mean Age:

Who Received Combined Live
Lot No. 622/C-D764 (Study fl442)

Seronegative
to:
Measles Only Rubella Only
Conversions]
Conversions/
Total
Total

Initially

Seropositive
Measles
and
Rubella

4/4

1

2/2

3/3

2

15/16

1/1

13/13

~

S/S

5/5

2/2

20/20

4

19

S/S

5/5

1/1

11/11

2

37

24

7/8

8/8

4/4

9/9

3

193

142

49/54

53/54

10/10

60/60

18

3.7 Years

(90.7%)

(98.1%)

(100%)

(100%)

Overall

Rubella

59/64
(92.2%)

113/114
(99 .1%)

l

I
t

f

Conver sion Rates

Measles

to:

I, l?R /77

Table

2

SerologJcal Fin dings Among Children 'Wh
o Received Combined Liye
ljeaalea-Muaps-Rubella
(RA 27/3) Virus Vac~ine, Lot lfo, 621/C-D763 ( St11dy 1442)

Total

Heasles-H.,..ns-Rubella
Conversions/ Total
Ke.asles
"'â€¢-s
Rubella

Int<â€¢

0

n-

~e--- - sfrivo

Vacc.
10 Manthe

1

0

11 Months

2

2

1/1

1/1

1/1

1/1

1/1

1 Year

29

n

7/7

7/7

7/7

4/ 5

5/ 5

3/3

3/ 3

2 Years

18

15

3/3

3/3

3/3

1/1

1/1

4/4

4/4

2/3

3/3

3/3

l leara

41

3-3

6/6

6/6

6/6

1/1

1/1

3/3

3/1

6/ 6

6/ 6

14/ 14

,

4 leara

39

34

2/2

2/2

2/2

5/5

5/5

7/8

8/8

1/ 1

15/15

)

5 Yea.rs

32

25

-3/3

2/3

3/l

2/ 2

2/2

2/3

3/3

2/ 2

13/13

2

6 Years

36

28

1/1.

1/1

1/t

8/8

8/8

2/2

2/2

1/1

15/15

1

7 Yea.ra

1

l

1/1

1/1

28/ 29

29/ 29
(lOOX)

22/ 25

25/2 5
(100%)

3/3

63/63
(100%)

11

~

Total
Hean Age:

!lo.

199
159
3.7 Years

23/ 23
(lOOX)

22/23
(95 . JI)

23/ 23
(100%)

Me&ltlea-Humps
Conversions/Total
Measles Hu-s

Initially
SeroneRative to:
Measles-Rubella
lfllffl1'>s
- Rubella
Conversio ns /Total C<lnversions / Total
Measles Rubella
lhmma
Rubella

lfo.
Serol.
Teated

2/ 2

2/2

(96. 6%)

Overall

56/ 57
(98 . 2%)

( 88 .0%)

Conversion

49/ 53
(92.5%)

Measles Only
Conversions /
Total

3/3

Muans Onlv
Conversions/
Total

Rubella Onlv
Cooversione/
Total

Hwapa and

2/2

3/3

1
1

lkulea

"""â€¢' â€¢a

Rates

140/ 140
(100%)

l 'J/3/77

-- , .

â€¢o:

Table 3
Distribution
of Fold Rises of Hemagglutinati on-In hibition
Antibody Titers Among Children
Who Received Live Attenuated Rubella (RA 27/3) Virus Vaccine , Lot No. 579/C- D418 (Study #442)
Initially
Serone gat ive
Conv.
No.
Rate
Conv. Failure s Total

Age

Total
No.
Vacc.

No.
Sero l.
Test ed

Initially
Seropositi ve
Fold Rise
24X Ind e t. Tota l

1 Year

13

10

1

1

9

9

9/9

2 Years

17

15

1

1

14

14

14/14

3 Years

30

24

2

2

22

22

22/22

4 Years

38

32

1

2

30

30

30/30

5 Years

42

29

3

3

26

26

26/26

6 Years

56

48

8

8

40

40

40/40

7 Years

1

0

197

158

16

17

141

141

100%

Total
. Mean Age:

1

1

0

4 .3 Years

4/28/77

Table 4
Distribution
of Post-Va ccination Antibody Titers Among Children
Who Were Initially
Seronegative
to Measles and Rubel l a and Who Received
Combined Liv e Measles-Rubella
(RA 27/3) Virus Vaccine, Lot No. 622/C-D764 (Study 0442)

Measles (HI)
Post - Vaccination
No. of
Titer
Children
<5

5

5

Rubella
Post-Vaccination
Titer
<8

(HI)
No. of
Â·Chi ldren
1

8

10

1

16

20

9

32

1

40

4

64

3

80

22

128

30

160

9

256

13

320

3

512

6

->640

1

Total

54

54

-)48 .â€¢ 7

151.2

Geometr ic Mean Titer

l,, / ? R /77

Table 5
Distribution
of Post-Vaccination
Initially
Seronegative
to Measles,
Live Measles-Mumps - Rubella (RA 27/3)

Measles (HI)
Post-Vaccination
No. of
Titer
Children

Antibody Titers Among Children Who Were
Mumps and Rubella and Who Received Combined
Virus Vaccine, Lot No. 621/C - D763 (Study #442)

Mumps (Neut.)
Post-Vaccination
No. of
Children
Titer

Rubella (HI
Post-Vaccination
No. of
Titer
Children

<5

<2

1

<8

5

2

4

8

10

4

4

16

20

2

8

5

32

1

40

5

16

7

64

4

80

5

32

2

128

9

160

6

256

7

320

5

512

2

Total

23

23

23

98.8

7.1

148.8

Geometric

Mean Titer

10/3/77

Table

6

Distribution
of Post-Vaccination
Antibody Titers Among Children Who Were Initially
Seronegative
to Rubella and Who Received Live Attenuated
Rubella (RA 27/3} Virus Vaccine, Lot No. 579/C-D418 (Study 8442)

Rubella
Post Vaccination
Titer

(HI)
No. of
Children

<8
8

16
32

2

64

20

128

70

256

41

-)512

8

Total

141

Geometric

Mean Titer

->150.5

4/28/77

Table 7
MaxilllWII Tewiperaturea Reported Among Children Who Received Combined
Live Heaslea-Rubella
(RA 27/3) Virus Vaccine, Lot No. 622/C-D764 (Study 1442)

Max. Team.

0- 4

Initially
Seronegstive to:
Measles and Rubella (54 Children
Daya Post-Vaccination
5-12
13-18
19-28
29- 42

114
(59 . 7)

67

42
(77 . 8)

35
(64 . 8)

39
(72. 2)

38
(70.4)

35
(64.8)

23

77
(40 . 3)

l24

12
(22 .2}

19
( 35. 2)

15
(27 . 8)

16
(29.6)

19
(35 . 2)

31

0-4

Total Vaccinees (193 Children)
Daya Post-Vaccination
5-12
13-18
19-28
29-42

(99

146
(76.0)

135
(70. 3)

138
(72.3)

123
(64 . 4)

99 - 100.9

46
(24.0)

56
( 29. 2)

53
(27 . 7)

68
(35.6)

Hax:1-

Temperature
(OF Oral)

102.0
Not Taken

No. vith

1
(0.5)
1

1

No. vith
Max. Temp.

1
2

2

2

1

Serology
Patient #
(b) (6)

Tellll)erature

!!!I

102.0

5

Clinical
Upper Respiratory

Illness,

CoSJ>laint
Irritability,

Malaise

Measles

Rubella

>20 160

1_32 256

4/28/77

Table 8
Haxi111UlaTemperatures Reported Among Children Who Received Combi ned Live
Keasles-K11111ps-Rubella (RA 27/3) Virus Vacc ine, Lot No. 621/C-D763 (Study 1442)

Initially
Se ronegative to:
Measl es Kumns and Rubella (23 Children)
No. with
Dave Pos t-Va ccinati on
5-1.2
13-18
19-28
29-42
Hax. l'emo.
0- 4

tÂ°F . Oral)

0-4

Total Vaccinees ( 199 Children)
Davs Post -Vaccination
19-28
29-42
5- 12
13-18

(99

147
(73.9%)

160
(81.6)

130
(68 . 4)

137
(72.5)

83

(69 . 3)

18
(78 . 3)

20
(87 . 0)

51
(25.6)

57
(28.6)

35
(17 .9)

59
(31.l)

52
(27.5)

109

5
(21.7)

3
(13 .0)

2
(1.0)

1
(0 . 5)

Kaximua

Tea,perature

99 - 100.9

138

101 - 102.2
103 - 104.0

l
(0.5)

No. with
Max. Temo.

3

Not Tak.en

14
(73.7 )

16
(84 . 2)

16

5
(26. 3)

3
(15.8)

7

4

4

3
4

1
(0 . 5)

2
(1.0)

23
(100 . 0)

9

10

SeroloB,I
Patient

{b)W)

I

Te!!Eerature
102.2
103.l
103. 1
104. 0
104. 0

Days
8

20
11
l

5

Clinical

Measles

Complaint

Upper Respiratory Illness,
Mal.alee
Irritability,
Malaise
Tonsillitis,
Anorexia, Headache, Malaise
Irritability,
Malaise
Upper Resplratory
Illness,
Irritability,
Anorexia,

) 20
) 20
)20
Malaise

)20

Hum2s

Rubella

320
>8 32 ( 8 1024
64
160 )8 128 <8
)640 (2
<8 128
4
Serologies Not Done
256
320 <4 16 (8
10/3/77

Table 9
Haxi111waTempuaturea Reporte.d Among Children Who Received Live
Attenuated Rubella (RA 27/3) Virua Vaccine, Lot No. 579/C-D418 (Study #442)

Maxi.mum

Teapera .ture
(Op Oral)
<99

99-100.9

Kax. Te.mo.

0-4

Initially
Ser onegative to :
Rubella (141 Children)
Davs Post-VaccL ation
5-12
13-18
19-28
29-42

138
(71.5)

67

116
(82 . 3)

97
(68.8)

110
(78 .0)

94
(67 .6)

(74 .8)

55

128

25
(17.7)

44
(31.2)

30
(21 . 3)

44
(31. 7)

35
(25.2)

1
(0 . 7)

1
(O. 7)

0-4

Total Vaccinees (197 Children)
Davs Post-Vaccination
5-12
13-18
19-28
29-42

162
(82.2%)

131
(66 .5 )

148
(75.1)

125
(64 . 4)

35
(17.8)

66
(33.5)

48
(24 . 4)

68
(35.1)

(28 ,5)

1

1
(0.5)

101 - 102.2

(0. 5)
Not Taken

3

Patient

f

Teaiperature

~

102 . 2

20

No. with

2

4

2

Clinical

Complaint

No. With
Max. Team.

104

51

2
2

Serology

(b) (6)

Upper Respiratory

Illneaa,

Anorexia, Kalaiae

(8

88

128

4/29/77

Table

10

Clinical Complaints Reported Alllong Children Who Received Combined
Live Measles-Rubella (RA 27/3) Virus Vaccine, Lot No. 622/C-D764 (Stu dy #442 )

Clinical

Complaint
0- 4

Irritability
Malaise

Headache
Upper Respiratory

illness

Total Vaccinees (193 Children)
Davs Post-V acc i nation
29- 42
5-12
13-18
19-2 8

29

11

6

(5. 7)

6
(3.1)

9

(15 .1)

(4. 7)

(3.1)

33
(17.2)

21
(10. 9)

15
(7.9)

15
(7.9)

7
(3.7)

4
(2.1)

3
(1.6)

2
(1. 0)

2
(1.0)

1
(0 . 5)

9
(4. 7)

8
(4.2)

8
(4.2)

1
(0 .5)

(0. 5)

Bronchitis
0titis

Gastrointestinal

Illness

Anorexia

13
(24 . 1)

4
{7.4)

2
(3. 7)

1
(1.9)

1
(1.9)

18

65

12
(22.2)

8
(14.8)

4

2
(3.7)

1
(1.9)

18

(7 .4)

1
( 1.9 )

1
(1.9)

5
(9. 3)

2
(3 . 7)

1
( 1.9 )

6

1
(1. 9)

1
(1.9)

1

9
1
(0.5)

21

2
(1.0)

l
(0. 5)

1
(0.5)

6

5
(2.6)

7
(3.6)

6
(3.1)

4
(2.1)

3
(1.6)

23

5

4
(2.1)

6
(3.1)

4
(2.1)

17

l

Asthma

1
(1.9)

l

l

2
(1.0 )

(0 . 5)

2
(3. 7)

1
(1.9)

1
(1.9)

2
(3. 7)

1
(1.9 )

2
(3.7)

l
(1.9)

1
(1.9)

No. with
Comolaint

1

3

1
(1.9)

5
4

1
(0 .5)

l

0

1
(0.5)

l

0

36
(18.8)

24
( 12 . 5)

17
(8.9)

18
(9.4)

8
(4 . 2)

70

13
( 24 .1 )

9
(16.7)

4
(7 . 4)

3
(5.6)

1
(1.9)

19

156
(81. 3)
Phys i cian Surveil lan ce: 1

168
(87 .5 )
1

174
(91.1)
2

173
(90.6)
2

183
(95.8)
2

121

41
(75. 9)

45
(83.3)

50
(92.6)

51
(94.4)

53
(98.1)

35

Persons with Complaints:
Persons with No Complaints:
Negative

52

No. with
Comvlaint

1
(0.5)

(2.6)
Hepatitis

0-4

Initially
Seronegative to:
Measles and Rubella (54 Children)
Davs Post -Vacc ination
5-12
13-18
19-28
29-42

1

4/29/77

Table

11

Clinical Complaints Reported Among Children Who Received Combined Live
Measles-Mumps - Rubella (RA 27/3) Virus Vaccine, Lot No. 621/C-D763 (Study 1442)

Clinical

0- 4

Total Vacci nees (199 Children)
Days Pos t-Va cc ination
29-42
5-12
13-18
19-28

32
(16.1%)

9
(4.5)

2
(1.0)

4
(2.1)

30

14
(7 .0)

3
( 1.5)

7
(3.6)

1

2
(LO)

Complaint

Irritability
Malais e

(15 .1)

Headache

(0. 5)
Upper Respiratory

Illness

9
{4.5)

11

(5.5)

Otitie

Gastrointestinal

39

Illness

Anorexia

l
(5.0)

5

1
(0.5)

43

5

(21. 7)

5

2
{10.0)

1
{4 .3)

7

2

5
(2.5)

8

5

(4.1)

(2.6)

2
(1.0)

I 3
(1.5)

23

0
1

(4.3)

1
(4.3)

3

1
(4 .3)

2
(10.0)

1

1

(4 .3)

(5,0)

1
(5.0)

7
(3.5)

2
(1.0)

5
(2.6)

5
(2.5)

3
(1.5)

2
(1.0)

(2.6)

1
(0. 5)

0

22

1
(4.3)

1

l

1
(5.0 )

13

5

0

1

1

3
1

1

13
(6.5)

Mild Dermatiti.e

0-4
(21. 7)

l
(0.5)

Ophtha11110pethy

No. with
Complaint

Initially
Se ronegative to :
Measles. Mumps and Rubella (23 Childr en)
Days Post Vacc in a ti on
No. with
5- 12
13-18
19- 28
29- 42
Complaint

(0.5)
Persons with Complaints:
Persons with No Complaints :
Negative Physician
Surveillance

49
(24.6)
150
(75.4)

22
(11.1)
177
(88 . 9)

11

19

(5.5)

{9 . 8)

6
(3.1)

73

188
(94.5)

187
(96.9)

123

(90. 2)
5

6

175

6
(26 . 1)
17
(73. 9)

2
(8. 7)
21
(91.3 )

l
(4 . 3)
22
(95.7)

4
(20.0)

l
(5 .0)

10

16
(80 . 0)

19
(95.0)

12

3

3

10/3/77

Table

12

Clinical Complaints Reported Among Children Who Received Live
Attenuated Rubella (RA 27/3) Virus Vaccine, Lot No. 579/C-D418 (Study 1442)

Clinical

Malaise

Headache
Upper Respiratory

Illne_es

Otitis

Gastrointestinal
Anorexia

Persons with Complaints:
Persons with No Complaints:
Negative Physician

Surveillance

2
(1.4)

(1.4)

19
(13.5)

9
(6.4)

2
(1.4)

(3..5)

4
(2.0)

3
(1.5)

5
(2.6)

2
(LO)

32

28
(14.2)

10
(5 . 1)

5
(2.5)

9
(4.6)

4
(2.1)

46

2
(1.0)

1
(0.5)

3
(1.5)

1
(0.5)

6

1
(0. 7)

4
(2.0)

6
(3.1)

2
(1.0)

15

(4 .1)

3
(2.1)

2
(LO)

1
(0.5)

4

1
(0.5)
Illness

4
(2.8)

22
(1L2)

8

1
(0 . 5)

2
(1.0)

Ophthalmopathy

15
(10.6)

0-4

Complaint

Irritability

0-4

Initially
Seronegative to:
Rubella (141 Children)
Days Pos t-Vaccination
5-12
13-18
19-28
29-42

Total Vaccinees (197 Children)
Days Post-Vaccineation
29-42
5-12
13-18
19-28

1
(0.5)

No. with
Complaint

1

5

6

1

1

1

(3.0)

(0.5)

(0.5)

(0.5)

7
(3.6)

(0.5)

35
(17.8)

18
(9.1)

7
(3.6)

16
(8. 2)

162
(82. 2)

179
(90. 9)

190
(96.4)

23

2
(L4)

32

1
(0. 7)

2
2
(1.4)

13

I

I

(O. 7)

1
(0. 7)

2

(0.7)
1

4
(2.8)

6
(4. 3)

1
(0. 7)

1
(0. 7)
5
(3.5)

1
1
(0 .7 )

1
(0. 7)
4
(2.8)

8

13

4
(2.8)

7
(3.6)

60

23
(16.3)

14
(9 .9)

4
(2.8)

5
(3.5)

43

(7 .1)

180
(91.8)

188
(96.4)

137

118
(83.7)

127
(90.1)

137
(97. 2)

131
(92. 9)

136
(96.5)

98

1

2

5
(2.6)

l

11

5

1
(0.7)

5
(3.5)

(0. 7)

(2.5)

2

No. with
Comolsint

10

8

4/29/77

MEMO
To File

Location
Location

From T. Schofield
Subject Statistical

Date 2/2/78

---------

- -Study #442

Analysis

..___

Analysis of variance was conducted on post titers
of children
who
were initially
seronegative
to rubella who received rubella
vaccine,
lot 0579 (Group 1) , combined measles-mumps-rubella
vaccine,
lot 1621
(Group 2) , and combined measles-rubella
vaccine , lot #622 (Group 3) .
No significant
difference
mean titers
were :

exists

among the three

Vaccine

GMT

Rubella

150 . 5

MMR
MR

155 . 5

There is no significant
three groups.

difference

groups .

Geometric

143..4

in conversion

T.S.

rate

among these

Reference

Program:

Study #470 - To evaluate
responses
to two rubella
combination with measles

Vaccine:

Combined live measles-rubella
Lot f/662/C-D764

(RA 27/3)

virus

vaccine

Combined live
M-R-VAX

(HPV-77) virus

vaccine

and compare clinical
and immunoloRical
vaccines,
administered
alone and in
virus vaccine .

measles - rubella

Live attenuated
RA 27/3 rubella
Lot /1579/C- D418
Lot #60664/C-E668

Responsible

Clinical

virus

vaccine

Investigator:

Louis Z. Cooper, M.D.
Director,
Pediatric
Service
The Roosevelt Hospital
428 West 59th Street
New York, New York 10019
Study Location:

New York,

No. 2

New York

Date Study Initiated:

June 25, 1976

Date St udy Completed:

In Progress

Study Procedure:
Fifty-four
children,
11 months to 18 years of age,
have been included in the study thus far.
Thirty-six
received
a 0.5 ml subcutaneous
dose of combined live
measles-rubella
virus vaccine;
eighteen received a
0.5 ml subcutaneous
dose of live attenuated
RA 27/3
rubella
virus vaccine.
Blood samples were obtained
immediately
prio r to vaccination
and six weeks after
vaccination
from a sample of the population.
Each
child ~as followed 6 weeks for clinical
complaints.
The study continues
in progress.

Addendum f.!1
Clinical

Protocol

- Study ~~70

Cor.ibi:-ied Liv a ~!easles-Rubella
Purpose of
Adden dum:
Vaccines:

To perr.ih: vaccination
virus vaccines.
1.

with

(RA 27 /3)

Vacci:1e

monova l en t R.-\ 27/3 or HPV-77

Combin ed live measles-rubel
Lot fi6 7..2/ C-'J764
Vaccine

Virus

l a (RA 27/3)

dose is 0.5 ml given

duck Tuoe lla

v i rus vac cine

subcutaneously

.

The vaccine
is supplied
in t wo- dose vials.
Each vial should be
rehydrat ed with 1 . 2 ml of st erile,
pyrogen - free distilled
water
without
pres e rv at iv e.

2.

Combined live
Lot {,f06 19 W

meas l e s-rub e lla

(HP\'-77 duc k embrvo) virus

Vaccine

is 0 . 5 ml given

su bcutaneo usly.

dose

The vaccin e is su ppl i ed in sin gle dose vials . Each vial
rehydra.:: ed with 0.7 ml of st e ri le, pyro ge n-fre e distilled
without
pr e s e rvative.

3.

Live HPV~77 duck emby ro rub e lla
Lot //0406W
Vaccine

dose

is 0.5 ml given

virus

4.

Live RA 27/3 rubella
LoL #60640/C - E668
Vaccine

virus

dose is 0.5 ml given

should be
wate r

vaccine

su bcu taneousl

The vaccine
is supplied
in single
reh yd rated with 0.7 ml of sterile,
without
preservative.

vsc::ine

y.

dos e vials.
pyrogen-free

Each vial sh ould be
distil l ed water

vaccin e
subcutaneously

.

The vaccine
is supplied
in single
doseâ€¢vials.
Each vial should
be reh ydrated with 0.7 ml of sterile,
pyrogen-free
distilled
water without preservative.

Page 2
Addendu::i ill
Clinical
Protocol
- Study 0470
Combined Live ~-!easles - Rubella
(R.-\ 27 /3)
Vaccines:
(continued)

Vaccine

CAUTIO~;: Both combined vaccines
and the HPV-77 duck rubell;:
virus
vaccine
contain
egg protein
and should not be given to perso~s with
known sensitivity
to ch i cken or duck, chicken or duck eggs or feather::;.
All of the vaccines
contain
neomycin and should not be given to
persons sensitive
to neomycin.
Persons with leukemia or other
immunologic disorder
and persons
receiving
immunosuppressive
drugs
should not be vaccinated.
The vaccines
should not be given to persons
with any febrile
respiratory
illness
or other active
febrile
i nfection.
Keep dried

vaccines

stored

Keep dried

vaccines

at

Keep reconstituted
after
rehydration.
Procedure:

Virus

at

-2o0 c.

4Â°c in transport.

vaccine

on ice.

Discard

unused

vaccine

4 hours

The study population
will consist
of children
1 to 6 years old having
negative
histories
for vaccination
and illness
caused by measles and/er
rubella.
Children will receive
one of the four vaccines
as follows:
Grau?

Vaccine

1
2

Measles-rubel
l a (RA 27/J)
Measles-rubella
(HPV-77 duck)
HPV-77 duck rubella
RA 27 /3 rubella

J
4

Informed written
consent
of each child participating
Each child will
one of th e four

will

No, of Children

be obtained
in the study.

receive
a single
vaccines.

Up to
Up to
Up to
Up to

from a parent

0.5 ml subcutaneous

500
500
200

200
or guardian

injection

of

Bleeding
samples (10-15 ml) wil l be obtained
from approximately
one-third
of the study participants.
Samples will be drawn
immediately
before and 6-8 weeks following
vaccination.
Each child will be followed
clinically
All local and systemic
complaints
will
form.

for 42 days
be recorded

after vaccination.
on the case report

Page

Adden dum i,11
Clinical
Protocol
- Stud y 0470
Combined Liv.e ~!eas l es - itubella
(RA 27 /J)

3

Virus

Vaccine,

Schedule:
Time

a nd fol l ow- Un
Children)

Bl eecl,:!.ng
(Approx . 1/3
of Chil dre n)

0. 5 ml , sub cu taneously.

10-15 ml

Vaccination
(All

Day 0

Days 0- 42

Vaccinate

I Clinical

for local
follow-up
s ys te mic r e actions.

-

and

--

Week 6-8

10-15 :nl

Remove se r un from clo t as pecti cally

Serolog y :

Circ ul a ting levels
of measles
and rubel la antibodies
before and
after: vacc i nation will be determined
by hema ggl utination
- inhibition
test.

Clinic a l
Forra:
Adve r se
Reactions:

frozen

at

Attached.
Any serious
or alarning
r eaction,
in cluding
death due to any cause
during
the i nvestigation,
whether relat e d or not rel ated to t he
t est mate ri al, must be r epo rt ed immediat ely to ~lerck & Co. , Inc. ,
throu gh Dr. Mauri ce R. Hill enan , teleohone
(215) 699- 5311, Ext. 5532,
or in his absence,
Dr. Allen F. Woodhou r, telephone
(215) 699-5311,
Ext.

Unused
Vaccine:

and store

- 20Â°c .

Labor atory :

55 S8 .

All unused vaccine
should be returned
imr:ie diat elv t o Merck Sharp
Dahme Rese arc h Labora caries,
West Point,
Penns y::..\Â·3.nia 19486 .
'

'

"----

-~

/ )/

--7

.-

--;;.~~a~~~,1/
~~
M. R. Hilleman,

Ph.D.

&

Clinical
Conbined

Protocol

- Study

Live Heasles - Rt.:bella

1470
Virus

(R .\ '27 I J)

Vacc ine

Puri)o s e:

To conpare antibody
and c linical
responses
to conbined liv E
measles - ru be ll a virus vaccine
containin g the RA 27 / 3 rub ella
virus strain
or t he i-i.P'.
'-77 du ci<: rub ella virus
strain.

Vaccine:

1.

Combined live measles-rubâ‚¬ll
Lot d622 or Lot #623

a (RA 27/3)

Vaccine

subcutaneously.

dose is

0.5 ml given

virus

vaccine

The vaccine
is supplied
in two-dos e vials.
Each vial
of vaccine
should be r ehydrated
with 1 , 2 ml of st erile,
pyr ogen - free distilled
water.

2.

Combined live
vaccine
Lot #2412T
Vaccine

measles-rubella

dos e is

0.5 ml given

(HPV-77 duck) virus

subcutaneously.

The vac c ine is suppl ied in single
dose vials.
Each
vial of vacci~e should be r ehydrated
wi th 0.7 ml of
sterile,
pyrogen - free disti ll ed water .
CAL'.'I'IO:!: Bot h vaccines
contain
egg prot e in and sh ould not be
giv en to pers ons with known sens i civity
to chicken or duck,
chick en or duck eg g s oi fe at hers.
The vaccines
also contain
neomycin and should not be given to persons wi t h sens i tivity
to neomyc in . Per so ns with leukemia or other i.Imnunologic
disorders
or persons
receiving
i r:unun osupp res si ve drugs should
not be vaccinated
. The vaccines
should not be given to persons
with any febrile
respiratory
ill ness or other active
feb ril e
in f ection.
vaccines

stored

Keep dried

vaccines

at 4Â°C in transport.

Keep reconstituted
vaccine
4 hours a fte r rehydration.
Procedure:

at - 2OÂ°C.

Keep dried

on ice.

Discard

unused

vaccine

The study population
will consist
of children
1 t o 6 years old
having ne gat ive histories
for vaccination
and illness
caused by
measl es and rubella.
Children
will be rand omly assigned
to
receive
one of the two vaccines
as fol lo ws:
Group

Vaccine

No. of Children

l
2

measles -r ubella
(RA 27/3)
measles -r ubella
(HPV-77 duck)

up to 500 children
up to 500 children

Cli~ical

Protocol

-~-

-

S t :l.:iy {!470

Infor~eci written
consent
parent
or guardian
p r ior

will be obt a ined
to participating

Each child will receive
a single
of one of the two combined live

from each child
in the study.

0.5 ml subcutaneous
measles - rubella
virus

's

in jectioL
vaccir.es.

Bleeding
samples (10 - 15 ml) will be ob tai.led from approximotely
one - third
of the study participants.
They will be bled
imn edia tely prior
to vac cination
and 6- 8 weeks following
vaccination.
Each child will be followed
clinically
vaccination.
All local
and systemic
on the case r eport forr.i.

for 42 days aiter
complaints
will be rec o rd ed

Schedule:
Ble ed i,ig
Ti~e

Day 0

Vaccinate

Days 0-42

Clinical

Serology

:
:

Remove serum

0.5 ml,

10- 15 ml

subcutaneously.

follow-up
for local
systemi c reactions.

from clot

Circulating
levels
after
vaccination
test.

aseptically

1/ 3

(Ap?rDX.

or Children)

--

and

--

Week 6-8

Laboratory

I

Vaccination
and Follow - up
(!,11 Children)

10-15

and store

frozen

at

ml

-2occ.

of measles
and rubella
antibodies
before
and
will be deterr:1ined
by hemngglut ination-inhibiti

Clinical
Form:

Attached.

Adverse
Reactions:

Any serious
or alarming
reaction,
including
death du e to any
cause during
the investigation,
whether related
or .not r elated
to
the test material,
must be reported
ir:un.ediately
to Herek & Co.,
Inc,,
through Dr . ~~u ric e R. Hilleman,
telephone
(215) 699-5311,
Ext. 5532., or in his absence , Dr. Allen F . Woodho ur, telephone
( 215) 699-5311, Ext. 5588 .

Unused
Vaccine :

All unused vaccine
should be r etur n ed immediately
to Herek
& Dohme Research Laboratories,
West Poiht,
Pa. 19486.

/H . R. Hilleman,

Sharp

Ph.D.

on

MEASLES -

RUBELLA

VACCll\:r\TION

:-c
,---

St udy N o . __

C;1~ No. _ _ _____

,.,..,_
11 3

..

, CT I Namâ€¢

I

, 2

0,V

If tnl\ cnn a :

1 lftC 1(.lt â€¢

I

â–¡ had diseJH

I'

0.lle

l

_

'lf O.,Ut . -

0 b\.'en eâ€¢ccseo

Commt;?l'llts

C,Hi: :)f ex:osure _________

01a9,.,,o~t0 0â€¢1

',---

------

-

I â€¢ YES

2 â€¢ NO

-

-

-

--

-

-

- - - ---------------

(41 1

-

-

- ,

Blee,all"lgOates: ----

0 Conv::,1

-

--

-

-

--

-

-

-

Oaie of 'âœ“xc1l"'-dtio,,

i â€¢
L:: 'wo. ----,

.I ,
'

-,.,,,-_, .,.,. --1 9 11

I

I

I' CT
J

I

i

CAY

I

Tomp erat u, a

,- - ,

I
CATE

.f

'I

r

.. '

I

'

.,

24

I 1s J 25 I cJ . 1s 1 14 , 01

0

OTHER A E,>CTI ONS

I
OJ I os , cs 1 12 1!;0

51

11

32

C

;

â€¢:

I

:

s'
I e I

I

!

~o ,
f

!
I

12
iJ

I

..

I~

I

I

i

lo I

11 I

lo I

I

I

I

I

I

I

I

I

I

I

I

I

!

I

I

I

I

:

I

I

I

i

'

'

I

I

' i

I

I

I

I

I

I

I

I

I
I

I

I

I
I

!

i

I

I

I

!

I

I

I

I

I

I

I

I

I
I

I

i

i

I

I

I

I

I
I

I
I
I

I

I

I

I

I

I

I

I

I

I

I

I

I
I

I
I

I

I

I
I

I
I

I

I

I

I

I
I

I

I

I
I

I

I

:

I
I

23 I

1

I

I

I
I
I

I

I

I

I

I

I

I
I

I

I

I

I

I

I

I

I

'

I

I

'

I

I

f

I

I

I

I
I

I
I
I

I

I

I

I

I

I

I

I

I

I

I

I

I

I

i

I

I

I
I

I

I

!

i

2~ I
27 ,
2S I
21) I

;

:

:)()

:

.

:

I
I

!

I

J! I

;

I

I

I

!

32 â€¢
33 â€¢

I

I

~

I

I

3!t I

!

'

I

I

I

I

I
I

I

I

I

I

I
I

!: '.

!

I

.I '

' .
I

I

'

I

I
I

I:

I:
l'.

I

I

I

I

I

Il

I

I
I

\: I

I
I

!
!
:
:

37 I
38 I
:?'J I

'

L

I .

I
I

I
I
I
I

41 I
(2 I
:
Ptu l# rtrurn como 1â€¢u<1 form, to; (R er~,n PIN1' cooy tor y our l,l1tsl

PhyJ1c1â€¢rt Â·, S,grwrurâ€¢

D4râ€¢

M , R . HI LLCl ,IM I, PhD, OS c

ME RCK ~H ARP & OOI IM E RESE A RCH LAiJOR A TOA ICS
W EST POIIH, PENNSYLVAtllA , 19486. U.S.A .
T " â€¢ I >O-O , , e t DOM

I

!

I

I
I
I

I

t

1.

I
I

I

~
I

I

I

I

I
I

I

I

I

I

I

i

30,

I
I

â€¢ I

I

I

I

I

I

I

I

I

I

I

I
I

I

I

2â€¢ I
25 I

I

I

I

I

'

I

I
I

I

I

I

I

I

I

I

I
I

I
I

I

20 I
21 I
22 I

(:)

I

I

I

!

19 I

I

I

I
i

I

I

I

.

1~

I

I
I

I

I

I
I

i

11 â€¢

I

I

sâ€¢
9 .

I

I

1

I

I
I

Phy1,c1â€¢11Â· 1 N.1mâ€¢ (Typ,

or Pn rul

ll
j

Tabl e 1
Serological
Measles-Rubella

Findings Among Children Who Received Combined Live
(RA 27/3) _Virus Vaccine, Lot #622 / C-D764 (Stud y #470)
Initially
Seronegative
Measles - Rubella
Conversions/Total
Measles
Rubella

Age

No.
Vacc.

No.
Serol.
Tested

Not
Given

1

1

14

4

15
16
17
18

3
3

1/1
1/1

1/1
1/1

1

1
1
0
1
1

1/1
1/1

1/1
1/1

6

3

2

2

1
1

1
1

3/31/1
1/1
1/1

3/3
1/1
1/1
1/1

10/10
(100%)

10/10
(100%)

{Months)

(Years)
2
4

s
6

Total
Mean Age:

1

23
12
2.0 Years

to:

Initially
Measles

Seropositive

to:

and Rubella
1

.

Overall

Conversion

Measles
10/10
(100 %)

1

2

Rates

Rubella
10/10
(100%)
5/18/7?.

Table 2
Serological
Findings Among Children Who Received
Combined Live Measles-Rubella
(HPV-77) Virus Vaccine, M-R-VAX (Study
Initi al ly Seronegative
to:
Measles Only Rubella Only
Measles-Rubella
Conversions/
Conversions/Total
Conversions/
Measles
Rubella
Total
Total

Age

Total
No.
Vacc.

No.
Serol.
Tested

(Months)
11

1

0

14

2

0

15

2

2

2/2

2/2

16

2

2

1/1

1/1

21

1

l

(Years)
4

1

1

s

1

1

1/1

1/1

7

1

1

1/1

1/1

9

1

1

18

1

1

1/1

1/1

Total
Mean Age:

13

10

6/6

6/6

0470)

Initially
Measles

Seropositive

to:

and Rubella

1/1
1/1
1/1

1

1/1

2/2

1

4.1 Years

Overall

Conversion

Measles
8/8
(100%)

Rates

Rubella
7 /7
(100%)
10/6/77

Table
Dis tr ibution
Who Received

of Fold Rises of Hemagglutination
Live Attenuated
RA 27/3 Rubella
Initially
No.
Serol.
Tested

3
Inhibitio n Antibody Titers
Among Children
Virus Vacci n e, Lot #579/C-D418 {Study #470)

Seropositive

Initiallv
Paired Sera
No.
Fail.
Total

Serone2ative

Age
(Years)

No.
Vacc.

1

6

0

2

2

2

2

2

2/2

2

4

1

1

1

l

1/1

1

5

1

1

Total
10
4
Mean Age = 2.1 Years

Total

0

No.
Conv.

3

0

3

Conv.
Rate

100%

Pre - Vacc.
Sera Onlv

Total

1

1

1

4

4/3/78

Table
Distribution
Who Received

of Fold Rises
Live Attenuated

of Hemagglutination
Inhibition
RA 27/3 Rubella Virus Vaccine,
Initially
No.
Serol.
Tested

Age
(Years)

No.
Vacc.

1

7

0

5

1

Total
Mean Age :

4

Seropositive
Paired Sera

->4x

Ris e

Total

1

1

1

8
1
1.8 Years

1

1

Antibody Titers Among Children
Lot #60664/C - E668 (Study #470)
Initially

Seronega tiv e
Total

0

4/3/78

Table 5
Distribution
and Rubella,

of Post-Vaccination
Antibody Titers Among Children Who Were Initially
Seronegative
to ~easles
Who Received Combined Live Measles-Rubella
(RA 27/3) Virus Vaccine, Lot #622/C-D764 (Study 0470)

Measles
Post-Titer
Distribution

.

Number
of Children

10
20
40
80
160
)320

Post-Titer
Distribution

1
2
5

1

Mean Titer:

(HI)

Number
of Children

128
256
)512
-

1

-

Total
Geometric

Rubella

(HI)

Total
Geometric

3
3
4

Mean Titer:

10
)274 . 4

-

10
-)56.6

5/18/78

Table

6

Distribution
of Post - Vaccination
Antibody Titers Among Children Who Were Initially
Seroneg a tive to
Measles and Rubella , Who Received Combined Live Measles - Rubella (HPV-77) Virus Vaccin e , M-R-VAX (Study il470)

Measles

Rubella

(HI)

Post Titer
Distribution

Number of
Children

Post Titer
Dis tribution

(HI)
Number of
Children

20

1

128

2

40

2

256

1

80

1

-)512

3

160

1

Total

6

-)320

1

Total

6

Geometric

Mean Titer:

Geometric

Mean Titer :

-)287.3

-)71.3
10/6/77

Table
Distribution
Who Received

7

of Post-Vaccination
Antibody Titers Among Initially
Seronega tive Children
Live Attenuated
RA 27/3 Rubella Virus Vaccine, Lot #579/C-D418 (Study #470)

Rubella

(HI)

Post-T iter
Distribution

Number
of Children

256

1

-)512

2

Total

3

Geometric. Mean Titer:

-)406.4
1/5/78

STUDY11470

Thus far,

two children
CASENO. -

in the study have exhibited

clinical

compla ints:

(b) (6)

AGE -

4 Years

VACCINE-

Measles-Rubella

(RA 27/3)

CLINICALCO~LAU:T - Rubella-Like

Rash, Days 2-3

SEROLOGY
-

32
)320

Rubella HI
Measles HI

)512
160

(b)(6)

CASENO. AGE-

15 Months

VACCINE-

Measles-Rubella

(RA 27/3)

CLINICALCOMPLAINT
- Upper Respiratory

Illness,

NS
NS

128

SEROLOGY
-

Rubella HI
Measles HI

Day 3

20

1/5/78

Referen ce No. 3

Program:

Study #512 - To measure antibody and clinical
responses
to
three consecutive
lots of combined measles-rubella
virus
vaccine .

Vaccine:

Combined live
lyophilized,

measles - rubella

(RA 27/3)

virus

vaccine,

Lot #62343/C-F021
Lot #62344/C - F022
Lot #62345/C-F023
Re sponsible

Clinical

Investigator

:

Victor M. Villarejos,
M.D.
Director
Louisiana
State University
International
Center for Medical
Research and Training
Apartado 10.155
San Jose , Costa Rica
Study Location:

Nicaragua

Date Study Initiated:

October

11, 1977

Date Study Completed:

November 26, 1977

Study Procedure:
One hundred seventy - five children,
10 months to 9 years
of age were included in the study.
Each received
a 0 . 5 ml
dose of combined live measles-rubella
virus vaccine ,
Blood samples were obtained on day of vaccination
and
6 weeks after vaccination.
Each child was followed
6 weeks for clinical
complaints.

Dr. Vill ar ejo s )

Clinical

Protocol

- Studv

#512

Combined Live ~!easles-Rubella

(RA 27/3)

Program:

Combined live

virus

Purpose:

To measure antibody
lot s of vaccine.

Vaccine:

Combined live

measles-rubella
and clinical

measles-rubella

Virus

Vaccine

vaccine

resoonses
virus

to three

vaccine,

consecuti

ve

lyophilized,

Lot no. 62343/C-F021
Lot no. 62344/C-~022
Lot no . 62345/C-F023
Vaccine

dose is 0.5 ml given

subcutaneously.

The vaccine is supplied
in single dose vials.
Each vi a l should be
reconstituted
with 0.7 ml of sterile,
pyrogen-free
distilled
water
which is supplied
in prefilled
syringes.

CAuTI0N: The vaccine should not be given to persons with known
sensitivity
to neomycin, chic ke n, eggs or feathers.
Persons with
leukemia or other immunolo gic disorder
and persons receiving
immunosuppressive
drugs should not be v a ccinated.
Also, the vaccine
should not be given to persons with a febrile
resoiratory
illness
or oth er active febrile
infection.
vaccine

stored

Keep dried

vaccine

at 4Â°C in transport.

Keep reconstituted
after rehydration
Proc ed ure:

at - 20Â°c until

Keep dried

vaccine

on ice.

used.

Discard

unused vaccine

4 hours

.

The study population
will consist
of up to 150 children
with a
ne gative history
for vaccination
and illness
caused by measles and
rubella viruses.
The children
should rang e from l to 6 years of
age.
Informed written
consent will
of each child who participates

be obtained
from a parent
in the study.

or guardian

Each child will receive
a 0.5 ml subcutaneous
the three vaccine
lots .

injection

Bleeding samples (10-15 ml) will
diately
before and 6 weeks after

from each child

be obtained
vaccination.

of one of
imme-

Page 2
Clinical
Protocol
- Stud y #512
Cor,1bined Live ~!easles - Rubella (RA 27 /3)
Procedure:
(continued)

Virus

Vaccine

Each child will be followed clinicall
y for loca l and syste mi c
compl a ints occurrin g within 6 weeks after vaccinat i on. Observations
should include special
notation
for rash, nodes, art h ra lg ia,
arthritis,
fever, malaise and anorexia.
All complaints
should be
rec orced on the case report
form.

Schedule:
Time

Action

Day 0
Vaccinate
Days 0- 42

- All Persons

Bleed 10-15 ml
0.5 ml, subcutaneously

Clinical
follow-up
for local
and systemic complaints

Week 6

Bleed

10-15 ml

Laboratory:

Remove serum from clot aseptically
and store frozen at -20Â°c
until
shipped.
It is imperative
that sera are sterile
to avoid
interference
with the serologic
assay.

Serology:

Levels of circulating
measles and r ubella
deterr.iined
by hemagglutination-inhibition

Clini cal Forms:

Attached.

Adverse
Reactions:

Unused Vaccine:
Shipping of
Sera & Records:

antibodies
test.

will

be

Any serious
or alarming reaction,
including
death due to any cause
during the investigation,
whether related
or not related
to the
test material,
must be reported
immediately
to ?-1erck & Co., Inc.,
through Dr. :Maurice R. Hilleman,
telenhone
(215) 699-5311, Ext.
5532, or in his absence,
Dr. Arlene A. McLean, telephone
(215) 699-5311,
Ext.
6383.
All unused vaccine should be returned
immediately
to Merck Sharp &
Dohme Research Laboratories,
West Point,
Pennsvlvania
19486.

1.

Send sera
supplied.

2.

Send sera and records
to Dr. Maurice R. Hilleman,
Virus
Cell Biology Research,
Merck Sharp & Dahme Research
Laboratories,
West Point,
Pennsylvania
19486.

3.

Alert
flight

frozen

Dr. Hilleman
number, air

within

insulated

containers

which are

by cable as soon as possible
bill and date of arrival.

reg arding

Q;SJ-B-,__-M. R. Hilleman,

Ph.D.

&

Estudio No. _ __

I

CT

Nomo,e

2
O"eccoon

__

_

No . Del Caso __

OBSERVACIONES CLINICAS

_ ______

(1Â·3)

I sexo(JS)

comp teto de1 nuio:

co mole la c;e Pao re Â·-,-G-Ua-,o- ,...,
, -n -, --

---

--

NO. do:>LOTE ________

0 VAC UN ADO
0 CONTROL (48)

_

(5-9 )

-----__

----

(49Â·51)

FECHA de VAC U NACION

M

- ~ --

I Fecna ae nac1m 1eto (36 4 1)

F

--L.-

FECHAS de SANGRIA

di'a

mes

- --

-------

_ _ ___

(52-57)

--

---

_ ScROLOGI
-

,

aiio

---'1
A _ __

(56-63)

------~~7~
-Â·;:~

T empo ratur a

I

Dia

'-'

''
Fecha

I
I
I
I

;;

I
I

,=;

08

5

I

6

I

7

''
l

I

I

I

I

I

I

'

!

i

I

'

I
I

!

17

I

'I

18 !

I
I
I
I

I

I

i

j

I

21

'

I

!

f

f

'

I

I

I

I

I

I

i

i

I
I

l

I

I

25 l
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42

'

I
I

I

'

'

I

l

I

I

I

I

I

I

I

I

!

I

I

I

'
I

I

:

I

I

'l
I

I

f
I

I

I

I

I

I

i
I

i

i

I

I
I

i

I

I

I

:

I

I

i

i

I

!

I

i

''I
I

I

I
I

i
I

!

I

.,
I

I
!

j

I

I

I

I

!

I

:

l

!

'!

i
I

:

I

I
I

I

i
I

!

I

I

i

I

I
I
I

I

I

I

I

I

I
I
I
I
I
I

I
I

I
I

I
I

:

I

'

Al terminar el esrud i o, devuelva cop ia blanca y copia amarilla
(Retenga copi;, color de rosa para sus archivos)

M. R. HILLEMAN, Ph D. OSc
ME RCK SHARP & DOHME RESEAR .CH LABORATORI
WEST POINT. PENNSYLVANIA . 19486. U.S.A.
819-0477

!

I
I

I

i

I

l

I

I

I

!

II

I

i

i

I

I

I

!

I

j

I

I

'

I

I

I

I i

I I

I

24 j

TR-'

j

i

I

I
I

I

I

16

I

i

I

!

I

20

!

l

I

I

15 !

I

l
!
I

I
I

19

I
I

;

l.

I

i

I

'

i

I

I
I

13 i

I <(

I

I

I

I

!

OTRAS REACCICNES

i 52 I 11 I 3 2 :
'

I

I

I

I

10

"'

<I~

I

I

I

I

I

i

I

I

9

22
23

i

-= .~
:,:

I

I

8

"

12 I 51

lI

â€¢ Especifiqu a tipQ en esta seccion
~

"' 0
.g
,.,.
~

"'

a:

l

C

~

=

u
'-'

"'
C

...J

I

I
I

'O

C
0

05

I

I

2

o

c.;

I

I

C

'J

6

l

!

C

:!!

E

03 '. 0 6

i

I

C

"'

G)

15 I 14 ! 01

I

3 I
4

14

<(

"
a.
"' 3
0
'-'

'-

'
'

2

U1

"'

ii

I

0
..._ 1

12

0
C

~

"?

~ I ~ 2'- a:
C"
C >

Q)

I 16 l 25

24

11

X

;;;
id

,:;:

:2

~

C
c;

2

..,

'O

RASHâ€¢

-Â·

.2

"'

fOOM'

de esra form a

ES

I
F i rma de/ medico:

Nombre
'â€¢4A,o

de/ med i co (en /etra de mo/de):

-n,.. .,-, ,

(4647)

I

Fecha :

__

_

Table 1
Serological
Combined Live Measles - Rubella

Age
(Months)
10
12
13

16
21
23
(Years)
2
3
4

5

6
7

No.
Vacc,
1
1
2
1
1
1

7
9
6
12
9
7

8

2

9

I

Total
Mean Age:

No.
Serol.
Tested

Findings Among Children Who Received
(RA 27 /3) Virus Vaccine,
Lot ll62343/r. - F021 (Study

Initially
Measles - Rubella
Conversions/Total
Measles
Rubella

1
1
2
1
l
1

0/1
1/1
1/2*

1/1
1/1
2/2

1/1

1/1

6
7
6

1/2**
3/3
1/1
1/1
1/1
2/2

2/2
3/3
1/1
1/1
1/1
2/2

12/15
(80. 0%)

15 /15
(100%)

11

9
7
2
1

60
56
4.4 Years

Seronegative
to:
Measles Only Rubella Onlv
Conversions/
Conversions/
Total
Total

Seropositive
Measles
Mumps and
Ruhella

t o:

1/1
1/1
4/4
4/4
5/5
6/6

1/1

7/7

1/1

2/2
2/2
1/1

3/3

32/32
(100%)

(100%)

Overall

Conversion

Measles
15/18
(83.3%)
* Antibody titer
** Antibody titer

Initially

fl 512)

QNS,2 by serum neutralization.
QNS,4 by serum neutralization

3

1
2

6

Rates

Rubella
47/47
(100%)

.

3/23/78

Table
Serological
Combined Live Measles - Rubella

No.
Vacc.

No,
Sero 1.
Tested

11
13

1

1

3

3

l7
22

1
1

1
1

Age

2

Findings Among Children Who Received
(RA 27/3) Vi rus Vaccine, Lot #62344/C-F022

Initially
Measles - Rubella
Conversions/Total
Measles
Rubella

Seronegative
to:
Measl es Only Rubella Only
Conversio ns/ Conversions/
Total
Tota l

Initially

(Study

#512)

Seropositive
Measles
Mumps and
Rubella

to:

(Months)

(Years)
2
3
4
5
6

7
8
Tot al
Mean Age:

4
9
9
1.4
16
1

1

2

9
8
14
14
1
1

60
55
4.3 Years

1/1
2/2

1/1
2/2

1
1/1
1/1

1/1
3/3
3/3
1/1
6/6
1/1

1/1
3/3
3/3
1/1
6/6
1/1

4/4
3/3
8/8
3/3

0/1
1/1

1
2
1
5

4

1/1
18/18
(100%)

18/18
(100%)
Overall

1/2
(50.0%)
Conversion

Measles
19/20
(95.0 %)

21/21
(100 %)

14

Ra t es

Rubella
39/39
(100 %)
3/23/78

Table
Serological
Combined Live Measles - Rubella

Age

No.
Vacc.

(Months)
13
14
17
20
22

1
1
2
1
1

No.
Serol .
Tested

3

Findings Among Children Who Received
(RA 27/3) Virus Vaccine, Lot #62345/C-F023

Initially
Measles - Rubella
Conversions/Total
Measles
Rubella

Seronegative
to:
Measles Only Rubella Only
Conversions/
Conversions/
Total
Total

1

Initially

(Study

#512)

Serooositive
Measles
Mumps and
Rubella

to:

1/1

1

1/1

1/1

2
1
0

1/1

1/ 1

2/2
3/3
4/4
3/3
2/3

2/2
3/3
3/3
3/3

16/17
(94 . 1%)

17/17
(100%)

2/2

(Years)
3
9
14
12
11

Age:

47
55
4.1 Years

Total
Mean

3

3
4
5
6

2

8

12
11

8

1/1
4/4
7/7
6/6
5/5

1/1
0/1

4/4

Overall

26/26
(100%)

1/2
(50.0 %)
Conversion

Measles
17/19
(85.5 %)

2
2

Rat e s

Rube lla
43/43
(100 %)
8/11/78

Table

4

Distribution
of Post-Vaccination
Antibody Titers Amon~ Child ren
Who Were Initially
Seronegative
to Measles and Rubella, Who Received
Combined Live Measles - Rubella (RA 27/3) Virus Vaccine, Lot ll62343/C - F021 (Study

Measles

Rubella

(HI)

Post -T iter
Distribution

Number
of Children

<5

4
6

2

1

64
128

1

256
)512

8

Total

15

Geometric

Mean Titer :

5

-

Geometric

15

Total

Number
of Children

32

5

10
20
40
80

(HI)

Post - Titer
Distribution

3*

#512)

Mean Titer:

->308.0

17 .4

3/23/78

* Two cases post - positive

by serum neutralization.

Table

5

Distribution
of Post-Vaccination
Antibody-Titers
Among Children
Who Were Initially
Seronegative
to Measles and Rubella,
Who Received
Combined Live Measles-Rubella
(RA 27/3) Virus Vaccine,
Lot ll62344/C - F022 (Study

Measles

(HI)

#512)

Rubell a (HI)

Post - Titer
Distribution

Number
of Children

Post-Titer
Distribution

Number
of Children

5
10
20
40
80
160
->320

1
1
3
8

128
256
>512
-

1
6
1-1

Total

18

Total

18

Geometric

3

1
1

Geometric.

Mean Titer:

Mean Titer:

->376.3

>40.0

-

3/23/78

Table

6

Distribution
of Post-Vaccination
Antibody Titers
Among Children
Who Were Initially
Seronegative
to Measles and Rubella, Who Received
Combined Live Measles - Rubella
(RA 27/3) Virus Vaccine, Lot l/62345/C - F023 (Study

Measles

(HI)

Post-Titer
Distribution

Rubella
Number
of Children

<S

1

5

10
20
40
80
160
)320

2
2
5
5
2

Total

17

-

Geome tric

Mean Titer:

(HI)

Post-Titer
Distribution

of

Number
Children

128
256
)512

4

Total

17

6

7

-

Geometric

/1512)

Mean Titer:

)289.3

-

->69 .9

8/11/78

Table

7

Maximum Temperatures
Reported Among Childre n Who Received
Combined Live Measles-Rubella
(RA 27/3) Virus Vaccine, Lot 462343/C-F021

Maximum Temperature
(OF Oral)

<99
99 - 100.9
101 - 101.9

0- 4

Total. Vaccinees
(60 Children)
Davs Post Vaccination
5 - 12
13-18
19-28
29-42

No. with
Max . Temp.

4)
50
(83. 3%) (71. 7)

45
42
(75 .0) , (70.0)

41
(68.3)

20

10
(16. 7)

14
(23.J)

19

39

(31.7)

17
(28.3}

l
(1.7)

18
(30. 0)

l

(Study

~512)

Lnitiallv
Serone2atives
Days Post Vaccination

(15 Children}
29-42

No. with
Max. Temp.

11

11

8

(73. 3)

(73. J}

0-4

5-12

H-18

1.9-28

14
{9).J)

14
(9).3)

11
(73. ))

l

1

(6. 7)

4
(26.7 )

4

(6 .7)

(26.7)

4
(26.7 )

7
0

3/23/78

Table

8

Maxlmum Temperatures Reported Among Children Who Received
Combined Live Measles - Rubella (RA 27/3) Virus Vacclne, Lot #62344/C - F022 (Study #512)

Maximum Tempera t ur e
(Â° F, Ora l )
<99
99 - 100 . 9

0-4

Total Vacclnees (60 Chlldren)
Davs Post Vacc i natio n
5- 12
29- 42
13- 18
19- 28

47
(78.3%)

29
(48. 3)

41
(68.3)

35
(58.3)

(55.0)

13
(21.. 7)

Jl
(51. 7)

19
(Jl. 7)

25
(41. 7)

27
(45 .0)

33

No. with
Max . Temp.
14
46

0- 4

lnitlally
Seronegatives
(19 Children)
No. with
Davs Post Vacci nation
29- 42 Hax. Temp.
5- 12
13- 18
19- 28

15

5

13

11

(26.3)

(68.4)

(57 .9)

12
(63. 2)

4

(78.9)
4
(21.1)

14
(73 . 7)

6
(31.6)

8
(42 .1)

7

15

(36. 8)

3/2 3/78

Table

9

Maximum Temperatures Reported Among Children Who Received
Combined Live Measles-Rubella
(RA 27/3) Virus Vaccine, Lot H62345/C-P023 (Study 1512 )

MaximumTemperature
0
(
P, Oral)

(99
99 - 100 . 9
101 - 101.9

0-4

Total Vaccinees (55 Children)
Days Post Vaccination
5-12
13-18
19-28
29- 42

No. wit h
Max. Temp.

44
(80 . 0%)

27
(49.1)

33
(60,0)

33
(60.0)

38
(69. l)

8

10
(18. 2)

27
(49.1)

22
(40. 0)

21
(38 . 2)

17

44

(JO. 9)

I

I

I

(1.8)

(1.8 )

(1.8)

0-4
12
(70,6)

8
(47 .1)

8
(47.1)

11

10

(64 . 7)

(58 . 8)

5

9
(52 . 9)

9
(52. 9)

5
(29.4)

(41.2)

(29 .4 )
3

Initially
Ser one~atives
(17 Children)
Days Post Vacc inatton
No. W'ith
5-1 2
19-28
lJ-18
29-42 Max. Temp.

I

7

3

13
1

(5.9 )

8/11/78

Table.

10

Clinical
Complaints Reported Among Children Who Received
Combined Live Measles-Rub ella (RA 27/3) Virus Vacc ine, Lot C62343/C- P021 (Study ~512)

Clinica l Complaint

0-4

Total Vaccinees (60 Child r en )
Oavs Post Vaccination
No. with
5-12
13-18
19- 28
29-42 Complaint

Headache

1-

lnitiallv
Seron e2atives
(15 Children)
Days Post Vaccinati.on
No. with
0-4
5-12
13-18
19-28
29- 42 Comolaint

I

0

1

0

l

0

(1. 7:!:)
I rritability

1
(1. 7)

Malaise

1
(1.7)

l
(1. 7)

Upper Resp iratory
Gast r oin t estinal
Persons

Illness

2

1

2

(3 . 3)

(l.7)

(J. 3)

Illness

with Complaint:

2
(3.3)

Persons with No Complaint:

58
(96.7)

J
(5.0)

2
(3 . 3)

7

5

2

2

2

2

(3 .3 )

(3.3)

(3.3)

(3. 3)

3
(5. 0)
57
(95.0)

4
(6. 7)
56

(93.3)

5

4

(8.3)
55
(91. 7)

(6. 7)
56

(93.3)

l

1

(6.7)

12
48

1

l

(6.7)

(6. 7)

0

1

15
(100)

(6. 7)
14
(93 . 3)

0
15
(100)

2
(13.3)
13

(86 . 7)

1
(6.7)

2

1
(6. 7)
14
(93 .3 )

3

12

3/23/78

Table

11

Clinical
Complaints Reported Among Children Who Rece ived
Combined Live Measles-Rubella
(RA 27/3) Vi r us Vaccine,
Lot #62344/C-F022

Clinical

Complai nt

0- 4

Total Vaccinees
(60 Children)
Days Post Vaccination
5-12
13- 18
19-28
29-42

Headache

1

No. with
Comvlain t.

(S tu dy #512)

Initial]v
Seroneira tiv es (19 Children)
Davs Post Vaccination
No. with
0-4
5- 12
13-18
19- 28
29- 42 Complain t

1

0
0

(1. 7%)

Malaise
Upper Respiratory

Illness

l
(1.7)

Gas tr oint e stinal

Illness

Pe r so n s with Complaint:
with

No Complaint :

3

2
(3 . 3)

4

(5 .0)
3
(5.0)

3
(5.0)

6

1

4

3
(5 . 0)

1

3

(1.7)

(5 .0 )

2

6
(10.0)
54
(90. 0)

(3 .3)

Persons

1
(1. 7)

58
(96. 7)

2

(3.3)
( l.

1
7)
3

(S. O)
57
(95.0)

(1. 7)

3
(5.0)
57
(9 5.0)

4
(6.7)
56
(93.3)

10

50

1
(5 .3)

l

(5 .3)
1
(5.3)

1

1

(5 .3)

2
(10 . 5)
17
(89.5)

2
(10.5)
17
(89. 5)

l

0

0

0

2

19
(100)

19
(100)

19
(100)

17

3/23/78

Table

12

Clinical
Complaints Reported Among Children Who Received
Combined ~ive Measles - Rubella (RA 27/3) Virus Vaccine, Lot U62345/C-F023 (Study #512)

Clinical

Complaint

0-4

Mal aise
Anorexia
Upper Respiratory
Gast r ointestinal
Persons

Illness
Tllaess

with Complaint:

Persons with No Compla int:

Tota l Vaccinees (55 Children)
Davs Post Vaccination
5-12
13-18
19-28
29-42
1

2

1

(1.8%)

(3.6)

(1.8)

1
(1.8)

1
(1.8)

2

J

(3.6)

(S.S)

3
(5 . 5)

2
(3. 6)

J
(5.5)

(5.5)

3

6

(5. S)
52
(94 . S)

(10. 9)
49
(89. 1)

4
(7.3)

3

6
(10.9)
49
(89.1)

2

No. with
Complaint

Initially
Serone11:atives (17 Children)
Davs Post Vaccination
No. with
0-4
5-12
13-18
19-28
29-42 Complaint

2

0

1

0

8

2

(). 6)

(11.8)

1
(1.8)

6

3

2

14

(5 .5)
52
(94. 5)

(J. 6)

41

(9 4 . 1)

(94. l)

SJ
(96. 4)

1
(5. 9)

1
(5.9)

2
J

1

1

1

(5.9)

(5. 9)

(5.9)

l

1

(5,9)
l&

(5. 9)
16

1
(5. 9)

16
(94.l)

2

2

(11. B)
15

(11.8)

(88.2)

(88. 2)

JS

5
12

8/11/78

MEMO
To
From
Subject

File

Location

T. Schofield

Location

Statistical

Analysis

Date

- Study #512

No significant
differences
exist in seroconversion
rates for
measles and rubella
or clinical
reaction
rates among three
lots of combined measles-rubella
(RA 27/3) virus vaccine .
Multivariate
analysis
of variance was performed on post-titer
values for children who were initiall
y seronegative
to both
me asles and rubella
by the HI test . The log transformation
was used , While sample sizes were small, a significant
difference
exists between the measles HI titers
for children
who received
Lot #62343/C-F021 and children
who received Lot #62345/C-F023 .
No other differences
could be determined . Geometric mean titers
were :

Measles

Rubella

Lot l/62343/C-F021

(n=lS)

17 . 4

308 . 0

Lot ll62344/C-F022

(n=l8)

40 . 0

376 . 3

Lot //62345 /C-F023 (n=17)

69.9

289 . 3

T. S .

8/ 14/78

Reference

No. 4

Program:

Study #514 - To measure antibody and clinical
responses
to
three consecutive
lots of combined measles-rubella
virus
vaccine.

Vaccine;

Combined live

measles-rubella

virus

vaccine,

lyophilized

Lot #62343/C-F021
Lot #62344/C-F022
Lot #62345/C-F023
Responsible

Clinical

Investigator:

Robert E. Weibel, M.D.
Director,
Division of Preventive
Medicine
Joseph Stokes, Jr. Research Institute
Children's
Hospital
of Philadelphia
34th Street and Civic Center Boulevard
Philadelphia,
Pennsylvania
19104
Study Locations:
Pediatric
Medical Associates,
Havertown, Pennsylvania
Lansdale Medical Group, Lansdale,
Pennsylvania
Geisinger Medical Center, Danville,
Pennsylvania
G. F. Schultheis,
Jr ., M.D. and W.W. Holm, M.D.,
King of Prussia,
Pennsylvania
G. A. Starkweather,
M.D., Havertown, Pennsylvania
Children's
Clinic of Chester and Vicinity,
Chester,
Penns ylvania
Date Study Initiated:

September

9, 1977

Date Study Completed:

May 13, 1978

Study Procedure:
One hundred sixty-seven
children,
13 months to 12 years
of age, were included in the study.
Each received
a
0 .5 ml subcutaneous
dose of combined live measles-rubella
virus vaccinâ‚¬.
Blood samples were obtained on day of vaccination
and 6 weeks after vaccination.
Each child was
followed 6 weeks for clinical
complaints.

(Dr. Weibel)

Clinical

Protocol~

Stud y #514

Combined Live Me asles-Rubella

(RA 27/3)

Program :

Â· Combined live

virus

Purpose:

To measure antibody
lots of vaccine.

Vaccine :

Combined live

measles-ru

bella

and c linical

measles-rubella

Virus

va c cine

responses
virus

Vaccin e

to thre e cons e cutiv e

vaccine , l y ophiliz

ed,

Lot no . 62343/C - F021
Lot no . 62344/C-F022
Lot no. 62345/r.-Fn23
Vacc ine dose is 0 . 5 ml given

subcutaneously

.

The vaccine is supplied
in single dose vials.
Each vial should be
reconstituted
with 0.7 ml of sterile,
pyro gen-free
distilled
water
which is supplied in prefilled
syringes.
CAUTION: The vaccine should not be given to persons with known
sensitivity
to neomycin, chicken , eggs or feathers.
Persons wit h
leukemia or other immunologic disorder
and persons receiving
immunosuppressive
drugs should not be vaccinated.
Also, the vaccine
should not be given to persons with a febrile
respiratory
illness
or otner ac t ive febrile
infection.
Keep dried

vaccine

stored

Keep dried

vaccine

at 4Â°C in t r ansport .

Keep reconstituted
after rehydration.
Procedure:

at -20Â°c

vaccine

until

on ice .

used .

Di scard

unused vaccine

4 hours

The study population
will consist
of up to 150 children
with a
negative history
for vaccination
and illness
caused by measles and
rubella viruses.
The child r en should range from 1 to 6 years of
age .
Informed written
consent will
of each child who participates
Each child will receive
the three vaccine lots.

be obtained from a parent
in the study.

a 0.5 ml subcutaneous

Bleeding samples (10-15 ml) will
diately
before and 6 weeks after

injection

or guardian
of one of

be obtained from each child
vaccina t ion.

imme-

Page 2
Clinical
Protocol - Study #514
Combined Live Measles-Rubella
(RA 27 /3) Virus

Vaccine

Each child will be followed cl i nically
for local and systemic
complaints
occ urring within 6 weeks after vaccination.
Observations should include special
notation
for rash, nodes, a r thralgia,
arthritis,
fever, malaise and anorexia.
All complaints
should be
recorded on the case report form .

Procedure:
(continued)

Schedule:
Time

Action

Day 0
Vac.cinate

Serology:
Clinical

- All Persons

Bleed 10-15 ml
0.5 ml , subcutaneously

Days 0-42

Clinical
follow - up for local
and systemic complaints

Week 6

Bleed 10-15 ml

Levels of circulating
measles and rubella
determined by hemagglut i nation - inhibition
Forms:

Adverse
Reactions:

Unused Vaccine:

antibodies
test.

will

be

Attached.
Any serious or alarming reaction,
including
death due to any cause
during the investigation,
whether related
or not related
to the
test material,
must be reported
immediately to Merck & Co., I nc.,
through Dr . Maurice R. Hilleman, telephone
(215) 699 - 5311, Ext.
5532, or in his absence, Dr. Arlene A. McLean, telephone
(215) 699-5311,
Ext. 6383.
All unused v a ccine should be ret urned immediately
to Merck Sharp &
Dahme Research Laboratories,
West Point, Pennsylvania
19486.

M. R. Hilleman,

Ph.D .

SYMPTOM RECORD
RUBELLA STUDY NO. ________

_
CASE NO, ___

N,
(L.Ast)

(First)

D Rectal
DAY

DATE

D Oral

INSTRUCTIONS

0

ON REVERSE

Ill

SIDE

t-

C(

"'
0 0
z a:

zC(

1Â·

.J
C,

1/)

Ill
w <'
I: z > z
w w
:t u
.J
w z w C, C( .J w t
z z a: ::, a: 0 a: ~
0 ::, 0 0 C( l 0 0
>
z a:
0
w

>

(ChÂ«lc One)

.

"'
0

Temperature

H

:t
t-

"'

"' "'

01 01 01 03 05

Â°'

_ _ _ _ _

(MIOClle)

C(

w
:t

w â€¢ Descr ibe

t

0

i

t-

w

0.
0.
t- !. Ill
"'
C(
z ~a: I:
ll.
0., C( 0C( "'
Ill
z a: 0
1/)

C(

IJJ

COMMENTS

a:
a: :,"' :t w w 0C( I w "'
a: a: w u > 0"'
C(
C(
C(
"'
IJJ
0 z a: 0 0 :t C( ll. .J

,,.

01 01

"' "'

11 12 14 61 24 25

1

2
3
4

5
6

7

8
9
10
11

12
13

--

14

,

..

17
18
19

20

21
22

23
24
25

26
27
28
29

30

31
32
33

34
35
36
37

38
39
40

,.

- ..

l

PLEASE RETURN FOR FOLLOW-UP VISIT ON : ____

BE SURE TO BRING THIS RECORD ALONG WITH YOU.
TIIUt

l"ilU7(DOMI

______

_ _

THE JOSEPH

STOKES,

THE CHILDREN'S

JR . RESEAR CH INSTITUTE

HOSPITAL

UNIVERS

ITY

34TH

OF

& CIVIC

CENTER

PHILADELPHIA,
ROBERT
DIV I 610N

E . W EIBEL.,
OF

M.0.,

PREVENTIVE

OF PHILADELPHI

A

PENNSYLVANIA
BLVD .

PA. 111104

DIRECTOR

(2115 )

MEDICINE

(21 15) EV 7-l:!1109

November

10, 1977

Arlene A. McLean, Ph. D .
Director, Biologics Evaluation & Analysis
Merck Sharp & Dohme Research Laboratories
West Point, Pennsylvania
19486
RE: Clinical Protocol - Study #514
Combined Live Measles-Rubella

Vaccine

Dear Arlene:
(b)(6)

At the conclusion of the first thirty voccinees
at Pediatric Associates
it was noted by Dr . Al Carlson that the lot number on the lost viol C-F022 did
not correspond with the lot required on the work sheet . After a thorough review
of the situation it con not be determined when the lot of vaccine not corresponding
to the record was given . This infor matio n must be considered in the evaluation of
al l clinical and serologic records from these vaccinees .
The fol lowi ng steps hove been token to prevent the recurrence

of this situation :

l . In addi tion to the col or code for eoch lot , as now used, the required
vaccine lot will be placed on the study reg ist ration shee t in the
re qui red col or of the Iot .
2 . Each lot wil I be placed in a separate color coded box rathe r than
in a single box with color coded areas as now used .
These changes have been instituted

to insure the accuracy

Sincerely,

Robert E . Weibe l , M . D .
REW:ceb
cc:

Alfred Carlson, M . D .
Ka ren Compbel I, R. N .

of the records .

EV 7â€¢11000

Table
Serological
Combined Live Measles - Rubella
No.
No.

Age

Vacc.

Serol.
Tested

1

Findings
Among Children Who Received
(RA 27/3) Virus Vaccine, Lot #62343/C-F021

Initially
Measles - Rubella
Conversions/Total
Measles
Rubella

Seronegative
to:
Measles Only Rubella Only
Conversions/
Conversions/
Total
Total

(Study

Initially
Measles

#514)

Seropositive

to:

and Rubella

(Months)
13

14
15
16
17
18
19
20
21
23

l
8

0

8
16
8
2
3
0

17

8
2
3
1
1
1
1

7/8
13/13*
8/8
2/2
2/2

8/8
13/13
8/8
2/2
2/2

3/3
1/1

1
1

1/1
1/1

I

1/1

1/1

3
1

1/1

1/1

(Years)
2

3
1

3

Total
Mean Age:

44
1.4 Years

47

2/2

1/1
34/35
(97 .1 %)

35/35
(100%)

7/7
(100%)

Overall

Conversion

Measles

41/42
(97.6%)
* One sample

pair

tested

2/2
(100%)

0

Rates

Rubella
37/37
(100%)

by serum neutralization.

8/11/78

Table
Serological
Combined Live Measles - Rubella

Age
(Months)
14
15
16

No.
Vacc.
5

No.
Serol.
Tested
5
16
4

18
19
21

16
6
5
5
1
2

(Years)
2
4
8
12

2
1
1
1

Total
Mean Age:

45
39
1.8 Years

17

4

5
1
1

Findings Among Children Who Received
(RA 27/3) Virus Vaccine, Lot #62344/C-F022

Initially
Measles-Rubella
Conversions/Total
Measles
Rubella
5/5
12/12
2/2
2/2
4/4
1/1
1/1

2

Seronegative
to:
Measles Only Rubella Only
Conversions/
Conversions/
Total
Total

5/5
12/12
2/2
2/2
4/4
1/1
1/1

3/4
2/2
1/2
1/1

(Study #514)

Initially
Measles

Seropositiv

e to:

and Rubella

.

1/1

1
0
1
1

1/1
1/1
27/27
(100%)

27 /27
(100%)
Overall

2/2
(100 %)

8/10
(80.0%)
Conversion

Measles
35/37
(94.6 %)

0

Rates

Rubella
29/29
(100 %)
6/27 /78

Table
Serological
Combined Live Measles-Rubella

Age
(Months)
13
14
15
16
17
18
21
(Years)
2
4
Total
Mean Age:

No.
Vacc.
1
7

No.
Serol.
Teste d
1

Findings Among Children Who Received
(RA 27/3) Virus VaccineJ Lot ll62345/C - F023 (Study #514)

Initially
Measles-Rubella
Conversions/Total
Measles
Rubella
1/1
5/5
11/11
9/9
3/3
1/1
1/1

Seronegative
to:
Measles Only Rubella Only
Conversions/
Conversions/
Total
Total

13

6
13

14
4
2
1

14
4
2
1

1/1
5/5
11/11
9/9
3/3
1/1
1/1

2
1

1
1

1/1
1/1

1/1
1/1

33/33
(100%)

33/33
(100%)

45
43
1.4 Years

3

Overall

1/1
2/2
4/4
1/1
1/1

1/1

9/9
(100%)

1/1
(100%)

Measles

Seropositive

to:

and Rubella

.

Conversion

Measles
42/42
(100%)

Initially

0

Rates

Rubella
34/34

(100%)
6/27 /78

Table 4
Serological
Findings Among Children Who Received
Combined Live Measles - Ruhella (RA 27 /3) Virus Vaccine, Lot It Unknown (Study

Age

No.
Vacc.

No.
Sero l .
Tested

Ini t ially
Measles-Rubella
Conversions/Total
Measles
Rubella

Seronegative
to:
Measles Only Rubella Onlv
Conversions/
Conversions/
Total
Total

Initially
Measles

f/514)

Seropositive

to:

and Rubella

(Months)
14
15
17
18

2
5
18
1
1

2
5
18

(Years)
2

l

13

7

lO
Total
Mean Age:

1
1

1
1

1/2
5/5
16/17*
1/1
1/1

2/2
5/5
17 /17
1/l
1/1

1
1
1

1/1
1/1

1/1
1/1

26/28
(92. 9%)

28/28
(100%)

30
30
1.7 Years

1/1

1/1

Overall

1/1

Conversion

Measles
27/29
(93 .1%)

* One sample pair

tested

1/1
(100%)

(100%)

0

Rates

Rubella
29/29
(100 %)

by serum neutralization.

8/11/78

Table 5
Distribution
of Post - Vaccination
Measles and Rubella, Who Received
Post - Titer
Distribution
Measles

<S

(HI)

s

10
20
40
80
160
)320

-

Total
Geometric
Mean Titer:
Rubella

(HI)

* One titer

Antibody Titers Among Children
Combined Live Measles-Rubella

Lot l/62343/C -F021

Who Were Initially
Seronegative
to
(RA 27/3) Virus Vaccin e (Study #514)

Number of Children
Lot f/62344/C-F022
Lot #6234 5/C-F02 3

Lot 0 Unknown

1

2
1
1
2

1

12
9
6
6

10
6
5
4

4
12
9
7

3

34

27

33

27

>79.S*

)78.0

)114 .3

250.9*

1

2
5
8
5

64
128
256
~512

1
5
12
17

16

7
25

1
4
2
21

Total
Geometric
Mean Titer:

35

27

33

28

__231.2
.1

>366.7

>415 .0

2371.1

determined by serum neutralization
in calculation
of G.M.T.

2
9

not in c luded
8/11/78

Table
Haxi1DUmTemper atures
Combined Liv e Measles-Rub el la
Haxilllum
( "F

Temperature
Oral)
( 99

99 - 100.9

Q-4

30
(66.7%)
13

(28. 9)
101 - 102. 9
103 - 104.0

6

Reported Among Children Who Received
Viru s Vaccine, Lot f62343 / C-F 021 (Study #514)

(RA 27/3)

Total Vaccinees (47 Children)
Davs Pos t Vacc ination
5- 12
U - 18
19-2 8
29-42

No . "1th
Max. Temn.

JO
(66 . 7)

28
(63 . 6)

22
(50.0)

12

(33. 3)
22
(48 . 9)

n

14
(31.8)

15

14

(2 8 . 9)

(34 .1)

1
(15.6)

2
(4. 4)

l
(2.J)

(11.4)

1
(2 . 3)

2
(4 .5 )

4

3

3

2

15

s

0-4

lnitiallv
Ser one2atives
(38 Chil dr en)
Davs Post Vac cin ati on
No. with
5- 12
1.3-18
19- 28
29-42 Hax. Teino .

27
(75 .0)

(36 . 1)

8
(22. 2)

5
(13 . 9)

15

25
(69.4)

27
(75 .0)

20
(55 .6 )

17

9

(4 7. 2)

(25 .0)

7
(19.4)

(25 .O}

2
(5.6 )

1
( 2.8)

(13 . 9)

1
(2.8)

2
(5.6)

3

2

2

2

13

2
(4 . 4)

l
(2.2)

Not Taken

2

2

Case I
(b)(6 )

Max. Temp.

~

Clini cal Complaint

102.2

35-38

102.0
103 . 0
103.4
102.0
103.0
102 . 0

9-11

10
29-3 1
13- 14
3-6
41- 4 2

104.0
103 . 0
102 . 0
103.2

7-10
32- 36
8-12
25- 35

103.0

0-4

Upper Respirato r y Illness,
Gastrointestinal
Illness,
Nonspecific
Rash, Teething
Upper Respi rat ory Illness,
Otitis,
Anor ex i a
None
UppeÂ·r Respiratory
Ill ness , Nonspecific
Rash
Teething
Uppe r Respi r atory Ulness
Upper Resp iratory
I ll ne9s, Irritability,
Anorexia,
Myalgia
Heasle9 - Like Rash
Lower Respiratory
Illne9s , Gastr ointesti nal Illness
Upper Respiratory
Illness,
Lymphadenopat hy
Ir r it ab le, Vi ral Infection,
Non- Spec ifi c Rash ,
Anorexia
Non- Specific Ra9h, Anorexia

2

(2 .8)

1
(2 .8 )

2

2

1

2

9
5

ll
9
13

Serology
Measles
Rubella
(5

80

<8

>512

(5

<5

160
80

<e
(8

)512
>512

(5

80

<8

<5
<5

<S

(8

256
256

40

(8

>512

<5

40

(8

>512

(5
(5

)3 20
)320

<8
(8

) 512
- 256

<5

)320

8

64
8/1J/7P.

Table

7

MRximumTemperatures Reported Among Children Who Received
C0111binedLive Heasles -Ruhell a (RA 27/J ) Vir:us Vaccine, Lot 162J44/C - F022 (Study 1514)
Maximum Temperature
( Â° F Oral)
( 99
99 - 100.9
101 - 102.9

0-4

Case I
(b) (6)w

0-4

Initiallv
Serone<>atives (32 Childr en )
Days Post VacC'lnation
No. vH h
5-12
13-18
19-28
29-42 Max. Temi,.

21
(48. 8%)

28
(65 .1)

25
(59.5)

22
(52.4)

9

( 30. 2)

21
(48. 8)

21
(48 . 8)

14
(32 .6)

12
(28. 6)

18
(42.9)

20

1
(2.3)

8
(18. 6)
1
(2.3)

1
(2. 3)

2

2
(4 .8)

10

6

(4 .8)

4

(20.0)
1
(3.3)

2

2

103 - 104 .6
Not Taken

Total Vaccinees (45 Children)
Davs Post Vaccination
No. vith
S- 12
lJ-18
19-2 8
29--42 Hax. Terno.
13

2

Hax. Tem11,

J

17
(56.7)

10
(33 . 3)

21
(70.0 )

18
(fi2. 1)

15
(Sl. 7)

7

13

l)

(43 .3)

9
(3 0 . 0)

R

(43. 3)

12
(41.4)

14

(27.6)

2
(6.9)

7

(7 . 1)

102.7

Days
5-9

103 . 0
104 . 6

18-19
22-25

103.0

18-23

103.0
l02. 2

10 - 11
10

102.0
102.0

4- 6
3-10

3

3

2

2

2

Clinical
Coni11laint
Upper Respiratory
Illness,
Ophthalmopathy ,
Gas trointestinal
I llness
Upper Respirat ory I llness
Upper Respiratory
Illness,
Gast r oint esti nal
Illness
Upper Re9piratory
Illness,
Gastr ointes tinal
Illness,
Nonspeci f ic RAsh, Anor exia
Upper Respiratory
Ill ness
Upper Respiratory
Illness , Gastrointest
ina l
Illness , lrrl t ab ili ty , Anore xia
Upper Respirat ory I llne s ~, Myalgla
I rritability

2
(6.9)
l

2

(3.4)

2

J

2

J

Ser ology
Measles
Ruhella
<5 160
J2 )5 12

<5

160

8 ..?_
512

<5

40

(8

(5
<5

I.O
GO

(8 >512
>512 )5 l2

(5
<S

<5

128

) 320

<8

)512

>512
)5 12
6/27/78

Table

8

Haxlmu111
Tenperature!'I Reported Alllon~Children Who Rec.elved
C0111binedLive Heasles - Ruhella (RA 27/3) Virus Vaccine, Lot i'62)45/C-P02)
Haxf.mu111
Teaiperature
(Â° F Oral)
(9 9
99 - 100 .9
101 - 102.9

0-4
26
(59 .1%}
16
(36,4)

14
(31.8)
17

()8. 6)

l

5

(2.3)

(11.4)
4
(9.1)

103 - 104.8
105.0
Fever -

Total Vacdnees (45 Childre n)
Davs Post Vaccina tion
No. vith
5-12
13-18
29-42 Max. Temo.
19-28
25
(56.8)
16
(36, 4)
2
(4. 5)

21
("7.7}

19
(43. 2)
2
(4. 5)

Case I
(b) (6)

13
13
13

4

1

l
(2.3)
3

1

2

1

1

1

1

1

1

Max. Te1112.
102.2

~

102.0
105.0
104.2

5-11

5-7
10-11

104 .8

4-9

104.0

8-14

102.4
104.0
102.0

5-1

1

No Temperature

Not Taken .

24
(54.5)
15
(34 . 1)
4
(9.1)

39

1
7-11

0-4
22
(66.7)

(Study 1514)

Initially
SeronPOatives ()3 Child ren )
DavR Post Vacclnatlo n
tfo. vi th
13-18
19-28
29-42 Hax. T".!"...e..:__
5-12
11

(33. 3)

19
(57. 6)

17
(51 . 5)

18
(54.5)

10

13
(39, 4)

10
(JO .3)
4
02.1)

10

11

l)

11

(3) .3)

()9.4)

(33 .3)
2
(6.1)

2
(6.1)
4
(12.1 )
1
(3 .0)
2

Clinical Comelaint
Upper Respiratory
Illness,
Gastrointesti
nal
Illness,
Anorexia
None
UpperÂ· Respiratory
Illness,
0tltis,
Anorex~a
Upper Respiratory
Illness,
Gastrointestinal
Illness,
Headache
Upper Respiratory
Illness,
Otith,
Irritable,
Anorexia
Upper Respiratory
11lness, Gasttointes t inal
Illness,
Anorexia
None
Upper Respiratory
[lln~ss,
Anorexia
Gasttointestinal
Illne""â€¢
Heasl~!!-T ,ike Rash

1
(3.0)

8

4
1

1

2

1

Serolo11;y
Measles
Rubella
(5
160 <8 )512
<5
<S

40
160
160

(8
(8

<S )320

<8

256

(5

>320

<8

)512

<5

80
160
80

8

<8

256
>512

(8

>512

(5

<5
<5

32

>512
- 256
)512

6/27 /78

Table

9

Haxtnru111Te.111peratures Reported Among Children Who Received
COlll~ined Live Measles-Rubella
(RA 27/3) Virus Vacc ine, Lot I Unlcno= (Study 1514)
Kaxillum Te111perature
("F Oral)
<99

99 - 100.9

0-4

Total Vaccinees (JO Children)
Days Post Vaccination
5-12
13-18
19-28
29-42

20
(66.7%)

18
(60 . 0)

22
(73.3)

10
(33. 3)

6
(20.0)
4
(13.3)

1

1

(J.3)

101 - 102.9
103 - 104. 0

19
(63.3)

16
(53.3)

11

7

9

(30.0)

10
(33. 3)

9

(23.3)

3
(10.0)

7

(3. 3)

1
(3.3)

1
(3. 3)

3

2

(6. 7)

Case I
{b) {6}

Max. Tene.
103.4

102. 1
104.0
103.0
103.0
102.0

No. w1th
Hax. Temp.

0-4

Initially
SeroneRatives
(28 Children)
Days Poat Vaccination
No . wlth
5-12
13-18
19-28
29-42 Hax. Temp .
17

(60. 7)

16
(57.1)

10
(35. 7)

6

7

9

(21.4)

(25 .0)

(32.1)

4
(14. 3)

1

1

(3 .6)

18

2
(7 .1)

Clinical
COllll!laint
21-22
Upper Respirat ory Illness,
Otitis , Gastrointestinal
Illness,
Anorexia
16-17
Upper Respiratory
Illness
6-10 â€¢ Heaslea-Like
Rash
32-)6
Bronchitis,
Gastrointestinal
Illness
7-12
Gastroin testinal
Illness,
Measles-Like
Rash
10-11
Gastrointestinal
Illness,
Anorexia

~

20
(71.4)

(64.3)

15
(53.6)

JO

9
(32.1)

8

3
(10. 7)

7

(3 .6)

1
(3.6)

1
(3.6)

3

SerolORY
Heaslea
Rubella
<5 160
<II >512
(5

10

(5

40

(8
(8

128
~512

<5

40
80

(8
(8

)512

(5

256
6/27/78

Table 10
Clinical
Complaints Reported Among Children Who Rece ived
Combined Live Measles - Rube lla (RA 27 / 3) Virus Vaccine, Lot 662J4J / C-P021 (Study /1514)
It:

Clinical
Complaint
Injection
Site:

0- 4
2
( 4. 3%)

Soreness
Erythema and Soreness
Systemic:
Lymphadenopat hy

1
1
l

(2.2)
Measles - Like Rash
Ir ritabilit

y

Anorexia
Disturbed

Illness

Gastrointestinal
Nonspe cific

Illness

Rash

)

'
1

l

(2 . 7)
l

1

(2. 7)
3

(6. 7)
7
(15.6)
2
(4 .4)

19
(41. 3)

l
1

2
l

l
(2.2)
2
(4 ,J)
1
(2 . 2)
22
(47.8)
2
(4. 3)

I ni tially
Serone2 a tiv es (Jij Children)
Davs Post Vacc inati on
No . with
0-4 J 5-12
13-18
19- 28
29-42 Compla i nt
2
2
(5.4 )

2

(2.2)
6
(13.0)

1
(2.2)

Other*
Viral

1
(2.2)
2
(4. 3)
5

Otit is
Ophthalm .opathy

1

(10.9)
13
(28.3)

Hyalgia
Upper Respiratory

1

5

2
(4 .3)

No. wi_th
Complaint
2

(10.9)
9
(19. 6)
Sleep

Fatigue

Total Vac cin e es (47 Children)
Davs Post Vacc ination
5-12 j 13-18
19- 28 . 29-42

2
(4 .4)
8
(17 .8 )
2
(4 .4)

1
(2 . 2)

10

5

22

(13. 5)
8
(21. 6)

3
4

I

1

(2. 2)
20
(43.5)

(2.2)
16
(35.6)

18

1
35

(40 .0)

l

(2.2)

2

2
(4 .4)
7
(15 . 6)

9
(20.0)

19

4
(8.9)

5
(11.1)

9

l

J

(2. 2)
2

2

7
(15. 2)

6
(13 ,0)

(8 . 7)

4

4
(8. 7)
2
(4.3)

3
(6.5)

(2.2)

1

Infection

16
(43. 2)

4

3

(6.5)
(4 .J)

2
(5 . 4)

3

J
(8 .1)
12
(J2. 4)

5
(13. 5)

2
(5.4)
6
(16. 2)

1

2

(2.7)
1
(2.7)
1
(2. 7)
19
(51.4)
2
(5 .4)

(5.4)

2
(4 .3)

Persons

with Complaint:

Persons

with No Complaint:

Ne2ative

Surveillance

*Includes

nose bleed,

bruise

27
(58 . 7)
19
(41. 3)
1

29
(63.0)
17
(37. O)
1

from venipun c ture,

8

5

18

(13.5)
2
(5.4)

3
3

1
(2.7)
17
(45.9)
3
(8 . 1)

(35.1)
1
(2. 7)

2
(5.4)

2
(5.4)
7
(18. 9)
4
(10.8)

1
(2.7)
7

5

3

(18. 9)

(13 . 5)

(8 .1)

3
(8.1)

2
(5.4)

(2. 7)

1

13

2
(5.4)

(4. 4)

Teething

1
(2.7)

1

1

(2 .7 )
14
(37.8)

28

4

3
7
(18. 9)

15

5
(13. 5)

7

1
(2. 7)

3

l

1

(2. 7)

1

3

5

(2.2)

(6.7)

(11.1)

25
(54.J)
21
(45.7)
l

23
(51.1)

23 j
(51.1) ,

40

22

22

6

(48.9)
2

(48.9) .
2

8

l

23
(62. 2)
14
(37 .6)
l

2
(5 . 4)

1
(2 . 7)

3
(8 .1)

24
(64. 9)

20
(54.1)
17
(45.9)
l

19
(51.4)

13

(35.1)
l

18

(48.6)
1

5

8

(13. 5)
17
(45. 9)
20
(54 .1)

32

1

1

5

and ul c ers on tongue .
8/ 11/78

Table

11

Clinical
Complaints Reported Among Children l,lho Rece ived
Combined Live Mea s l es -Rubella
(RA 27/J) Virus Vacci ne, Lo t D62144/C-F022 (Study
Total Vaccinees (45 Children)
Days Post Vaccination
Cl i n i ca l Complain t

0-4

5-12

Lymphadeno pa thy

13-18

19-28

29-42

1

No. with
Compl a int

lnitiallv
Ser oneRatives ()2 Childre n )
Days Post Vacc l nati on
No. wl th
0-4
5- 12
1)-]8
19-28
29-42 COlll_I)laint

1

1

(2.3%)
Measles - Like Rash
Headache

1

(2 .J)
Ir ritability

,1

(2.J)
Anorexia
Fati gue

3

2

(6. 7)

7)

(2. 3)
4
(9.3 )

3

l,

(7 . 0)

(9 .3 )

Upper Respiratory

Illness

l

Gastrointestinal
Nonspecific

Il lness
Rash

3

.o)

20
(46.5)

17
()9 . 5)
1
(2 .3}
4
(9.))
12
(27 . 9)
7
(16. 3)

Otitis
Ophthalmopathy

l

(2.3)
2
(4. 7)

(1

2
(4 .7)
5
(11. 6)
4
(9.3)

1
(2 .3)

1

2

(4. 7)

4

(2 .3)

(4 . 7)

2

Hyalgia

16
(37. 2)
1
(2 .3)
2
(4. 7)
7

(16.3}

3

1
(2. J)
2
(4. 7)

1
(2.3)
18
( 41. 9)

1
(2.3)
10
(2).3)

7

9

(20. 9)

Teething
Persons
Persons

with Complain t:
with

No Complaint:

J
(7. 0)

25
(58.1)
18

30
(69 .8)

(41.9)

(30 . 2)
2

13

NeRative

Surv eil lan c e:

2

* In cludes

soreness

of venipuncture

at site

23
(53.5)
20
(46.5)
2

1
(2.3)
14
(32.6}
2
(4. 7)
l

(2.3 )
7
(16 .3)
5
(11.6}
1
(2.3}

21
(48 . 8)
22

(51.2)
2

3

J

2

14

5

32

1

1

(3 .J)

(3 .3)

3
(10 . 0)
2
(6.7)
1
().3)

2
(6.7)

11
(36. 7)

10
(33.3)
1
(3 .3)
3
(10 . 0)

J

6
21
13

2
(6.7)
J
(10.0)

2
(6 . 7)

7

(23.J)

l

3

() . 3}

(10.0)

2
2
3
(10 .0)
1
() .J)

J
(10 .0 )

8

(7 .O}

20
(46.5)
23
(53.5)

35

2

2

8

9

2

l

1

() .3)

(3.3)

11

13
(43 .3)

(36. 7)
1
(J .3)
2
(6 . 7)
4
(13. 3}
4
(13 .3)

1
(3.3)

1
(J . 3)

7
(23. 3)
6
(20.0)

3
10
(33.3}

21

2.

3

(6. 7)
1
(3 .3)
3
(10 .0}
2
(6. 7)

1

5
13

8

0

2
1
(2.J)

2
(6. 7)

(6. 7)

2

(16.3)

1
(2.3)
2
(4. 7)

3
(7 . 0)

(7.0)

2
(6. 7)

l,

3

Varicella
Othe r *

l

( ) . 1)

(7.0)
3
(7 . O)
2
(l,.

1514)

1
(3 .3)
1

2

l

(3. 3)

(6, 7)

(3.3)

15
(50.0)
15
(50.0)

19
(63 . 3)

15
(50.0)
15
(50.0)

2

11

(36. 7)
2

2

1

1
(3 .3)
15
(50.0)
15
(50.0)
2

2

5

(6. 7)
12
(40. O)

23

18

7

(60 .0)
2

2

an d ul c er s on tonRue.

6/2 7 /7P.

Table

12

Clinical
Complai nts Reported Among Children Who Recei ved
Combined Live Measles -Rube ll a (RA 27 /J) Virus Vacci ne , 1,ot ll62)45/C -F 023 (Study

Clinical
Injection

Compl aint

Site:

0- 4

To t a l Vacc ine es (4 5 Chi ldren)
Days Pos t Vacc i na t ion
5- 12
13-18
19-28
29 - 42

1
(2.3 %)
1

Soreness
Systemic :
Measl es - Li ke Rash

l

l

4
(9 . 1)

1
(2.3)

Beadacne

'1
(2 . 3)

2
(4 . 5}

1
(2.3)

Irritability

1
(2.3)

2
(4.5 }

1
(2.3)

Anorexia

6
(13.6)

Fatigue

11

J

6

(6.8)

(13 . 6)

2

0titis
0phthalmopathy
Gastrointestinal
Rash

Teething
Persons

with Complaint;

Persons

with No Complaint:

25
( 56. 8)

7

(15 .9 )

(27.3)

4
(9. 1)

(11.4)

1
(2.3)

(2.J)

22
{50 . O)
22
{50.0 )
l

5

32
(72. 7)
12
(2 7 .3)
l

1
(2 .3 )

l

6
3

(2.3)
7
( 1 5 . 9)

5
(11.4)

10
(2 2. 7 )

23

3
(6.8)

3
(6.8}

11

2
(4 .5)

3
(6. 8)
2
(4 .5)

27
{61.4)
17
(38. 6}
l

25
(56.8)
19
(43.2)
1

41

26
(59.1)
18
(40. 9)
1

1
(3 . 0)
1
(3.0)
2
( 6.1)

17

2
(4 .5)

1

2
(6.1)

9
(20. 5)

2
(4. S)

J

(6.8)
1

3

l
(3.0 )

1
(3.0 )

2

38

4

(6 . 8)
12

3

(9.1)

(6.1)
9

19
( 4 3. 2)

(9.1)

1

4

24
(54. 5)

1

1

1
(2.))

20
(45. 5)

(2 . 3)
1
(2 . 3)

Illness

Surveillance

14
(31.8)

Initially
Ser onegatives
(3) r.hildren)
Days Post Vacc i nat i on
No. with
5-1 2
lJ- 18
19-28
29-42
Compla in t

1
(J .O)
l

5
(15. 2)

1

1
(2.3)

Upper Respira t ory Illne s s

Negative

2
(4 .5}

(25 . 0)

Myalgia.

0-4

4

1
(2.3)

Nonspe c ific

No. with
Compla int

2
(6.1)

4
(12 .1)

2
1
(3 . O)

)

6
(18 . 2 )

lJ

l
1
(3.0)

10

19

(30.3)

(57.6)

14
(4 2. 4)

l

l

(J.O)

18
(54.5)

3

2

2

(9 . l}

(6.1)

(6.1)

1
{3.0)

13
(3 9. 4)

29

1
(3.0}

5

1

1

(3. 0)

(3.0)

5
(15.2)

(27.3)

4
(12 . 1)

3
(9,1)

7
(21 . 2)

15

2
(6.1)

3
(9.1)

2
(6 . 1)

2
(6.1)

3
(9. 1)

8

2
(6.1)

2

4

(fi .1 )

9

1
(3 .0)

16
(4 8 .5)

l

(27.3)

3

1
(3.0)

5

J

11514)

25
(75 . 8 )

17

8

(51. 5)

(2 4 . 2 }

19
(57. 6)
14
( 42 .4)

1

21
(6J,6)
12
(36 .4)

19
(57.6)
14
(42.4)

31
2

6/ 27/78

Table

13

Clinical
Complain ts Reported Among Children Who Recei ved
Combined Live Measles-Rubella
(RA 27/J) Virus Vaccine, Lot If Unknown (Study
Total Vaccinees (JO Children)
Davs Post Vaccination
Clinical
C0111plaint
Injection
Site:

0-4

Measles-Like

13-18

19-28

29 - 42

2
(6.7%)

2

1
1

1
1

Erythema
Soreness
Systemic:
Lymphadenopathy

5-12

.

1

Headache

2
(6.7)

1
{] . 3)
2

Illness

(6 .7)

2
(6. 7)

1
(3 . 3)

(10.0)

18
{60.0)

Lower Respiratory

5-12

13-18

]

1

2

L
L

14
(46 . 7)

1

1

1

1
(3. 6)

4

4
(14.J)

l

2

1
(3 .6)

l

2
(6. 7)

4

2
(7.1)

2
(7.1)

1
(]. 6)

1
(J.6)

2
(7.1)

4

2
(6. 7)

5
(16. 7)

5
(i6. 7)

9

1
(3 .6)

2
(7.1)

2
(7 .1)

4
(14. 3)

4
(14.J)

8

1
(3.3)

1
{3.3)

1

1
(3 .6)

1
(3 . 6)

1

13
(43.J)

19
(63.3)

26

12
(42. 9)

18

24

(64 . 3)

1
(3 . 3)

1

11
(36. 7)

1
J
(3. 3)

2
(6.7)

2
(6. 7)

]

6 â€¢
(20.0)

3
(10.0)

1
(3 .3)

(3. 3)

(10.0)

Nonspecific

Rash

1
(3 .J)

Bell's

18
(64. 3)

13
(46.4)

11
(39.3)

1
(3.6)

1

Persons
Persons

with CO!Dplaint:
with No Complaint:

3
5
(16. 7)

1

Palsy

Teething

5
(16. 7)

14

3
(10.0)

5

1
(3.3)
2
(6.7)
21
(70. 0)
9
(30.0)

20
(66.7)
10
(33.3)

4

(7.1)

1
(3 .6)

(3.3)

ina l Illness

No. with
Complaint

1
(3.3)

0titis

Gastrointest

29- 42

(J. 3)

Illness

Ophthalmopathy

L9-28

2

1

Fatigue
Upper Respiratory

0-4

(28 Children)

(7 .1)

4
(13. ))

Anorexia

Initially
Serone~atives
Davs Post Vacc ination

{]. ])

Rash

Irritability

No. with
Complaint

11514 )

(10.7)

(17. 9)

1

1
(3 .6 )

1
(3. 6)

]

(7 .1)

s

1

]

)

1
(3.3)

7

(10.0)

13
(43.3)
17
(56.7)

17
(56.7)

22

28

(73 . 3)

13

2

2
(7 . I)
3
(10 . 7)

{]. f\)

(10. 0)

(43. J)

1
(3 . 6)

8
(26. 7)

2

2
(7 . 1)
21
(75 .0)
7
(25.0)

3
{10. 7)
18
(64.3)

10
(35.7)

13

(t,6 . 4)
15
(5].6}

1

1
3

5
(17. 9)

5

13

(17. 9)
]

5

(10. 7)

1
(3. 6)
3
(10. 7)

(J. 6)

16
(57.1)
12
I (f.2.9)

20
(71. G)
/l
(28. 6)

1
1

7
26
2

6/27 /78

MEMO
To

From
Subject

File

Location

T. Schofield

Location

Statistical

Analysis

Date

- Study If514

Significant
differences
in seroconversion
rates for measles
and rubella
and clinical
reaction
rates among vaccinees
receiving
three lots of combined measles-rubella
(RA 27/3) vaccine were
investigated.
Lots of vaccine were :
Lot #62343/C-F021
Lot #62344/C-F022
Lot #62345/C-F023

No significant
these rates.

differences

exist

among the three

lots

for any of

The groups (lots) were investigated
for statistical
differences
in post-vaccination
titer
among vaccinees
who were initially
seronegative
to both measles and rubella
by the HI test . Multivariate
analysis
of variance
was run in conjunction
with the
Kruskal-Wallis
k-sample test on the individual
components .
No significant
differences
could be determined among the three
lots of vaccine.

T.S .

8/14/78

